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 Glycosaminoglycans (GAGs) are a family of complex mixture of linear 
polysaccharides that are present in both vertebrates and invertebrates. This polysaccharide 
plays important roles in physiological and pathological conditions, including cancer. In this 
study, GAGs were isolated from two different fish (whelks and cockles) belonging to mollusc 
invertebrates. The crude GAGs isolated from each shellfish demonstrated variable selective 
anti-cancer activities against many cancer cell lines including breast (MDANQ01 and 
MDA468), leukemia (MOLT-4 and K562) and ovarian (HeLa) cancer. None of the 
commercial GAGs exhibited any anti-cancer activities against all the cancer cells studied. 
Previous studies conducted on the isolation of GAGs from molluscs reported mainly its anti-
coagulant and anti-inflammatory activities; thus neglecting its record of anti-cancer activity. 
 All purified whelk fractions (A – D & F) obtained failed to show any anti-cancer 
activity; with the exception of fraction E, which showed equal levels of selective anti-cancer 
activity against breast cancer cells. Mechanism of cell death caused by the three novel GAGs 
on cancers cells were investigated via cell cycle analysis and apoptosis detection assay. Cell 
cycle analysis revealed significant perturbations in the cancer cell cycle showing cell cycle 
arrests at different stages. Similarly, there were significant apoptosis inductions induced by 
the three novel GAGs on each of the cell lines investigated. 
 Structural elucidations of the two fish GAGs, using chemical, enzymatic, 
Polyacrylamide, Superose 12 size exclusion chromatography , gel filtration and SAX-HPLC 
methods of analysis, revealed the presence of both chondroitin sulfate (CS)/dermatan sulfate 
(DS)-like and HS-like GAGs. Discrepancies in the structural elucidations of the novel GAG 
mixtures and the commercial GAGs may be partly responsible for the anti-cancer activity of 
the novel polysaccharides, as changes in exogenous GAGs structural composition, especially 


































1.0 General introduction  
Glycosaminoglycans (GAGs) are a family of linear, complex, polydisperse 
polysaccharides extracted and purified from different animal tissues (Cassaro and Dietrich, 
1977; Heinegard and Sommarin, 1987; Pejler et al, 1987a). They are very heterogeneous 
polysaccharides in terms of relative molecular mass, charge density, physico-chemical 
properties, biological and pharmacological activities (Jackson et al, 1991). GAGs are 
ubiquitous in nature, occurring in a wide variety of organisms, including both vertebrates and 
invertebrates. They are linked typically to a protein core in order to form proteoglycans. 
These anionic polysacharides elicit many biological functions, largely through their 
interaction with proteins (Cesaretti et al, 2004). Major GAGs in vertebrates and invertebrates 
include heparin, heparan sulfate (HS), chondroitin sulfate/dermatan sulfate (CS/DS), acharan 
sulfate (AS), and hyaluronic acid (HA) and keratin sulfate (KS).  
All GAGs chains except KS comprise alternating units of an amino sugar, either N-
acetyl-D-glucosamine (GlcNAc) or N-acetyl-D-galactosamine (GalNAc) and a hexuronic 
acid (HexA), either glucuronic acid (GlcA) or iduronic acid (IdoA). Keratan sulfate contains 
GAGs chains comprising of galactose attached to acetyl-D-glucosamine (Afratis et al., 2012: 
Yamada et al, 2011).  HS and heparin are the most widely studied of these polysaccharides 
due to their involvement in many important biological processes. They have been shown to 
play important roles in the control of stem cell growth and differentiation (Patel et al, 2014 
and Desai 2013). Moreover, they are involved in a number of important biological activities, 
such as developmental processes, angiogenesis, blood coagulation, cell adhesion and tumour 
metastasis (Sasisekharan et al, 2006: Wei et al, 2005: Vives et al, 1999: Lindahl et al, 1998: 




HS is also vital in regulation of embryonic development, as well as in 
pathophysiological conditions, such as inflammation, wound healing, angiogenesis and 
cancer (Tamm et al 2012: Lo et al, 2011: Sasisekharan et al, 2006). These activities are 
facilitated by the ability of HS proteoglycans (HSPG) to interact and regulate proteins, such 
as enzymes, cytokines, growth factors, and extracellular matrix (ECM) bimolecules (Wei et 
al, 2005: Vives et al, 1999). The divergent structure of HS allows it to bind to and regulate 
the activity of various growth factors, like fibroblast growth factors 1, 2, 4 etc (FGF-1, FGF-
2, FGF-4 etc), chemokines, morphogens and enzymes at the cell surface and in the ECM: 
hence influencing cell adhesion, motility, growth and differentiation (Lo et al, 2011: 
Sasisekharan et al, 2006: Vives et al, 1999). The ability of HS to modulate the activities of 
many so-called heparin-binding growth factors, serve to co-ordinate the interaction of FGF 
with their tyrosine kinase receptors (FGFRs); moreover, this appears to play a critical role in 
receptor dimerization and activation (Iozzo and San Antonio 2001: Dickson et al 2000: Vives 
et al, 1999: Ernst et al, 1995). The modulatory effect of HS is critical to angiogenesis that 
occurs in pathological conditions, including tumour growth and progression; this has been 
implicated in the vascularisation of all solid tumours (Iozzo and San Antonio, 2001). 
Biological activities of HS depend broadly on the interaction between polysaccharides 
and proteins, which appears to be mediated by distinct saccharides sequences within HS 
chains. Moreover, the expression of different sequences within the HS chains demonstrates 
various levels of specificity, selectivity and molecular organisation. Modulation of tumour 
growth occurs through the interaction with angiogenic growth factors, like FGF-10, or with 
negative regulators of angiogenesis like anti-angiogenic antithrombin III (Iozzo and San 
Antonio, 2001: Ernst et al, 1995). 
The modulatory effects of HS on the growth factors and chemokines involved in tumour 
angiogenesis have been suggested to be mediated through one of the following mechanisms: 
4 
 
 The voluntary binding of the growth factors to soluble ECM associated or cell-surface 
HS results in the fine control of the bioavailability of growth factors; for example, binding of 
tumour growth-factor beta (TGF-β) to betaglycan, a cell-associated PG, and decorin, which is 
present in the ECM, and also for fibroblast growth-factor-2 (FGF-2) that binds basement 
membrane perlecan in addition to cell-membrane syndecans (Mellor et al, 2007 and 
Massague 1992). 
 The binding of HS to growth factors protects them from proteolytic degradation and 
acid inactivation (Samuel et al, 2000: Szabo 1991 and Saksela et al, 1988). 
 HS modulates the access of FGF growth factors to specific signaling receptors by 
different mechanisms that may involve independent interaction of HS with an aspect of the 
transmembrane tyrosine kinase glycoprotein component of the FGFR complex (Kan et al, 
1993). 
 HS may also trigger an intracellular transduction signal by interacting directly with 
growth-factor receptors with no growth factors being present (Rusnati et al, 1993). 
Indeed, Rusnati and others have reported that heparin/HS can activate FGFRs in the absence 
of the growth-factor. This observation goes against the traditionally accepted proposal of a 
ternary complex involving GAGs, growth factors, and tyrosine kinase (TK) receptors 
(Rusnati et al, 1993). The introduction of this model led to an extensive study involving many 
research groups and there is still much debate on actual mechanisms by which GAGs mediate 
the activation of the FGF’s. Regardless of this debate some general properties of the 
signalling complex can be surmised and these are outlined below: 
 Heparin/HS-related molecules can be useful tools to modulate the biological activity 
of heparin-binding angiogenic growth factors and cognate TK receptors (Mellor et al, 2007). 
5 
 
 Heparin/HS-related molecules can be designed with various structures that are able to 
affect differently the biological activities of angiogenic growth (Mellor et al, 2007). 
The ideas expressed above show some promise, therefore, there is need for the development 
of inhibitors of the activation of growth factors by GAGs and the subsequent development of 
new anti-cancer treatments aimed at the inhibition of tumour-cell proliferation. 
The ability of low molecular weight heparin fragments administered systemically to 
reduce the angiogenic activity of FGF2 and vascular endothelial growth-factor (VEGF) 
validate this hypothesis (Ghandi and Mancera, 2010; Norrby 2000: Norrby and Ostergaard 
1997 and 1996). Consequently, many HS/heparin fragments and mimics have been shown to 
have potential as inhibitors of tumour angiogenesis. In addition to the role played by HS in 
regulation of tumour angiogenesis, we shouldn’t forget the potential roles for HS in directly 
regulating the growth of cancers through interactions at the tumour cell surface. The 
structural complexity of tumour-cell HS (both at the cell surface and extruded into the ECM) 
has been shown to play vital roles in tumour development. It enables them to modulate 
directly several aspects of tumour-cell phenotype, including growth kinetics, invasiveness 
and metastatic potential (Sasisekharan et al, 2002). Hence, a given tumour-derived HS-GAG 
or HSPG can be protumorigenic or antitumorigenic, depending on whether it is anchored at 
the cell surface or present in the ECM as soluble-free GAGs or/and depending on the HS-
GAG sequence ( Gomes et al., 2013: Liu et al, 2002 and Sasisekharan et al, 2002). 
Targeting tumour angiogenesis by interfering with the interaction of HS with 
angiogenic growth factors is a well-established model for the development of HS mimetic 
therapeutics. However, we shouldn’t forget the ability of HS to modulate the growth and 
development of tumours via other mechanisms. This could certainly lead to the determination 
of, as yet unknown, HS structures and interactions that could pave way toward the 
development of novel cancer therapeutics. 
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 The study describe in this thesis employs GAGs derived from shellfish in a novel 
approach that targets directly the growth of cancer cells, rather than the vasculature and 
angiogenic processes within the tumour. The anti-cancer activity of these shellfish-derived 
GAGs is a unique finding, with none of the commercially derived GAGs from mammalian 
sources demonstrating any anticancer activity. 
The GAGs derived from these shellfish have not been characterised in terms of their 






















1.1  Glycosaminoglycans 
GAG’s are natural heteropolysaccharides, belonging to the family of polyanionic 
polysaccharides. These highly negatively-charged polysaccharides are ubiquitous in nature, 
occurring in a wide variety of organisms and tissues attached typically to a protein core to 
form molecules known as proteoglycans (PGs). They are composed of repeating 
disaccharides units comprising either sulfated or non-sulfated disaccharides. Their properties 
have been shown to vary considerably depending on the tissue or cell type from which they 
are extracted. (Andrade et al, 2013: Vijayabaskar and Somasundaram 2012: Afratis et al, 
2011: Heinegard and Sommarin 1987; Pejler et al, 1987: Cassaro and Dietrich 1977). 
GAGs elicit numerous biological functions, largely through their interaction with proteins, 
including growth factors.  
          GAGs are found located within the cell mebrane and in the extra-cellular matrix 
(ECM). They act by binding selectively to a variety of proteins and pathogens and are crucial 
to many disease processes, such as inflammation, neurodegeneration, angiogenesis, 
cardiovascular disorders, cancer and infectious diseases (Ghandi and Mancera et al, 2010: 
Mark et al 2002). 
The GAG family has several archetypal members including heparan sulfate (HS), heparin, 
chondroitin sulfate/ dermatan sulfate CS/DS, keratan sulfate (KS) and acharan sulfate (AS). 
There is also the non-sulfated GAGs consists of hyaluronic acid HA (Figure 1.1). HA lack a 
covalently protein core and are generally synthesised at the intracellular surface of the plasma 
membrane. HA GAGs has been reported to be a key player in tissue homeostasis, cancer 
progression, inflammatory conditions, myocardial infarction and angiogenesis (Afratis et al., 
2012: Slevin et al., 2002). HS and heparin are the most widely studied members of the 
GAG’s family, because of their involvement in many biological activities including 
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angiogenesis, cell proliferation, wound healing, inflammation etc (Afratis et al., 2012: Vives 



















Fig. 1.1: Schematic structures of GAGs. 
Heparin/HS and HA are glycosaminoglycans; chondroitin sulfate (CS) and dermatan sulfate (DS) are 





   COO- 
              Heparan sulfate 
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1.2      GAG’s structure and functions 
GAGs comprise a linear chain of 10–200 disaccharide units of repeating N-acetyl-D-
glucosamine/galactosamine, which is linked to uronic acid (iduronic or glucuronic acid) 
(Tumova et al, 2000: Lindahl et al, 1998). The disaccharide repeat unit can be modified to 
include N- and O-sulfation and also epimerisation of β-D-glucuronic acid to α-L-iduronic 
acid (Conrad, 1998). In addition, the five different modifications for disaccharides give rise to 
2
5
 = 32 combinations. Thus, this modification makes the complexity of the GAG much 
greater than that of proteins, which are made up of 20 amino acids. With these 32 building 
blocks, a GAG octasaccharide could have in excess of a million possible sequences; thereby 
making HS-GAGs not only the most acidic, but also the most information-dense biopolymers 
found in nature (Conrad, 1998).  
The physical form of GAGs and the specific interactions between them and other 
ECM components are controlled frequently by the sequence of disaccharide residues that they 
are comprised of. Usually, GAGs interact with transient components of the ECM, either at 
the cell surface, in solution or sequestered in the matrix. For instance, FGF-2 induced 
endothelial-cell proliferation requires trimolecular interactions between FGF-2, FGF -TK 
receptors (FGFR) and HS (Jaye et al., 1992: Kiefer et al, 1991: Klagsbrun and Baird, 1991: 
Yayon et al, 1991). This interaction activates TK activity of the intracellular domain of the 







1.3 Heparin/HS structures and functions 
Heparin/HS, usually isolated from animal tissue including vertebrates and 
invertebrates, is an important and chemically-distinct polysaccharide of considerable 
biological relevance. As explained above they are polydisperse, highly sulfated, linear 
polysaccharides, consisting of a repeat unit of uronic acid in either of its glucuronic or 
iduronic form attached to D-glucosamine residues (Figure 1.1) ( Koo et al., 2008: Volpi et al, 
2005: Islam and Linhardt, 2003). This group of GAGs have a very complex structure yet they 
are the most widely studied members of the GAG family. The structural complexity of 
Heparin/HS can be considered at both PG and GAG levels; 
 At the PG level, different numbers of polysaccharide chain (possibly with different 
disaccharide sequences) can be attached to the various serine residues present in the protein 
core (Koo et al, 2008).  
 At the GAG level, some of HS/Heparin structural complexity results from their 
polydispersity. 
GAG especially heparin has a molecular weight ranging from 5-40kDa (degree of 
polymerisation (dp) 10-80) with an average molecular weight of 13 kDa. Heparin/ HS 
structure has been partially characterised by studying their biosynthesis (Kjellen et al, 1992). 
Twelve sulfation profiles for HS/heparin disaccharides have been reported and these have 
equally been resolved and characterised by various separation techniques including chemical, 
enzymatic, and spectroscopic techniques (Malavaki et al., 2011: Sasisekharan et al., 2006: 
Linhardt, 1991).  
Problems arise in the structural analysis of HS/Heparin GAGs since they are extensivley 
modified by O- and N-sulfation in addition to isomerisation of the iduronic acid making them 
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the most structurally diverse members of the glycosaminoglycan family. The amino group 
may be either sulfated or acetylated and each disaccharide unit may have up to three of the 
hydroxyl groups sulfated (2-O-S, 3-O-S and 6-O-S). Glucuronic acid rich polymers are 
sometimes classed as HS while the iduronic acid rich polymers are also sometimes refers to 
as heparin. Heparin contain a pentasaccharide region (GlcNAc/NS(6S)-GlcA-GlcNS(3S,6S)-
IdoA(2S)-GlcNS(6S) that bind to antithrombin III and this makes it the most widely used 
carbohydrate based therapeutic because the binding allows it to inhibit blood coagulation 
(Loganathan et al,1990: Marcum and Rosenberg,1989a: Linhardt et al,1988b: Atha et 
al,1985: Lindahl et al, 1984). Relating structure to biological activities, such as that described 
for heparin, is critical in our understanding of the role sulfation patterns and epimerisation 
play in the natural function of heparin/HS chains.  
Sulfation patterns of HS/heparin play a very crucial role in their interactions with growth 
factors, proteins and cytokines, and therefore may affect their biological roles. HS/heparin 
have been implicated in numerous biological processes at the cell–tissue–organ interface ( 
Malavaki et al., 2011: Conrad 1998), which are triggered mainly by their interactions with a 
wide range of proteins, such as cofactors of the coagulation cascade, extracellular-matrix 
components and a variety of cytokines and growth factors (Vives et al 1999: Permimom and 
Belfield, 2000), angiogenesis (Sasisekharan and Venkataraman, 2000), viral invasion (Shukla 
et al, 1999 and Chen et al, 1997), and anticoagulation (Petitou et al, 1999).  
The HS/heparin also exerts its modulatory effects on key biological processes by binding 
to growth factors, cytokines, morphogens, enzymes and other signaling molecules (Taipale 
and Keski-Oja, 1997). They can regulate the activity of signaling molecules by modulating 
their diffusion, receptor on and off rates, and effective concentration at the cell surface and 
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the ECM, However, these processes become especially important at the cell–tissue–organ 
interface.  
Previous studies have added an extra dimension to this cell-surface event by indicating 
that HS mediates dimerization, either of FGF-2 of FGF receptor or of both, which may be a 
requirement for signal transduction (Ornitz et al, 1996: Pantoliano et al, 1994: Springer et al, 
1994: Mascarelli et al, 1993: Ornitz et al,1992). The binding of HS chains to FGF-2 and 
FGFR occurs through N- sulfated glucosamine (GlcNS) and 2-O-sulfated iduronic acid 
(Ido2S) units or 6-O- sulfated glucosamine (Glc6S). Once the FGFs bind to their receptors, 
FGFR complexes dimerise, in conjuction with HS/heparin moiety, leading to the activation of 
tyrosine kinase through autophosphorylation. Ultimately, these events facilitate the binding of 
second messenger proteins which in turn trigger many other intracellular signalling 
(Gallagher 2001:  Dickson et al 2000).  
The various roles played by these polysaccharides are becoming clearer as researchers 
continue studying them.  
 
1.4 CS structure and functions 
Chondroitin and dermatan sulfate make up a second GAG family, also known as 
galactosaminoglycans. These polysaccharide chains are, again as in HSPG’s, normally found 
covalently bound to a protein core forming high molecular weight units, with a large number 
of GAG chains attached (Ernst et al, 1995). The basic structural unit of this class of GAG is a 
disaccharide in which a uronic acid (D-glucuronic and L-iduronic acid) is attached (β1→3) to 
N-acetyl galactosamine (Figure 1.1). CS is the most abundant GAG in the body skeletal 
muscle and soft tissue.  
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There are various sulfation patterns of CS and among the most studied sulfated CS 
GAGs are the two common isomers CS-A (O-sulfo group attached at position 4 of galactosyl 
residue) and CS-C (O-sulfo group attached at position 6 of galactosyl residue) see Figure 1.2. 
Similarly, disulfated CS are also classified as CS-D (O- sulfo group attached at position 2 of 
glucuronic acid and position 6 of galactosyl residue) or CS-E (O- sulfo group attached at 
position 4 and 6 of galactosyl residue). The other CS isoform formerly designsted as CS-B is 
called DS which is characterised by the presence of IdoA moiety in his disaccharide chains. 
Similar to HS/heparin, the various sulfation patterns of CS GAGs enable specific interaction 
with many molecules, including growth factors, cytokines, chemokines, adhesion molecules 
and lipoproteins (Asimakopoulou et al., 2008).  
The size of CS chains varies greatly, with an average of about 40 repeating 
disaccharides units for the cartilage proteoglycans, corresponding to a molecular weight of 
approximately 20,000 (Iozzo, 1985). Their sulfo group content also varies depending on the 
number(s) attached to both or either of the galactosyl and uronic acid residues (Iozzo, 1985). 
Once again they all show a considerable degree of microheterogeneity within the polymer 
chain in a manner very similar to HS. The disaccharide unit present in CS/DS may be non-
sulfated, mono-sulfated or disulfated and both iduronic and glucuronic acids may be present 
in a given polymer chain.  
DS (CS-B) is a polydisperse; microheterogenous sulfated copolymer of D-Gal-NAc 
and primarily L- iduronic acid (L-IdoA), with O-Sulfate groups most commonly attached to 
position 4 of the galactosyl residue and position 2 of the L- Iduronic acid residues (Linhardt 
and Hileman, 1995). Many DS core proteins such as decorin and biglycan have been 
identified (Kresse et al, 1993: Coster, 1991). Decorin and biglycans have been reported to 
play vital roles in many biological activities including organisation of collagen fibrils, 
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regulation of the extravascular activities of thrombin, act as anticoagulants by inhibiting 
thrombin and lipid metabolism (Pangrazzi and Gianese, 1987). ). CS-B or DS is abundant in 
skin and is also found in heart valves, tendons and arterial walls. It is made up of linear 
repeating units containing D-galactosamine and either L-iduronic acid. Its molecular weight 
ranges from 15,000 to 40,000 daltons. 
 Moreover, CS-A is commonly found in humans in cartilage, bone, cornea, skin and 
the arterial wall. The molecular weight of CS-A ranges from 5,000 to 50,000 daltons and 
contains about 15 to 150 basic units of D-galactosamine and D-glucuronic acid (Wastenson, 
197).  CS-C, is primarily found in fish and shark cartilage, but also in humans, is also made 







































Figure 1.2: Structure of different types of CS 
(A) Chondroitin-6-Sulfate; (B) DS; (C) Chondroitin-4-Sulfate 
 
 




1.5 Glycosaminoglycans isolated from shellfish 
          Many researchers, including Dietrich and co-workers, reported the isolation of GAGs 
similar to heparin with comparable anti-thrombin activities from mollusc’s invertebrates. 
Similarly, heparin-like substance with relative ability to bind antithrombin III (ATIII) has 
been isolated from the marine clams, anomalocardia brasiliana (Pejler et al, 1987: Dietrich et 
al, 1985). Another GAG similar to heparin GAG, with an AT-binding region comparable to 
that of mammalian heparin has also been purified from another clam species, Mercenaria 
mercenaria (Jordan and Marcum, 1986). Additionally, heparin, (a highly sulfated 
polysaccharide, commonly isolated from mast cell or mucosa and also used as an 
anticoagulant in the clinic) (Bjork and Lindahl, 1982) has been reported to have some other 
biological activities, such as; anti-viral activity, bind to a variety of growth factors, inhibit 
complement activation, and regulate angiogenic activity (Weiler et al, 1992; Jackson et al, 
1991; Casu 1985; Folkman et al, 1983). 
 
1.6 Biosynthesis of GAGs 
HS and CS are synthesised in the Golgi, whereby the individual GAG chains are O-
linked to a core protein, forming a large polysaccharide-protein conjugate known as 
proteoglycan (PG) (Sasisekharan et al, 2006: Silbert and Sugumaran, 2002: Sugahara and 
Kitagawa, 2002). However, KS can be either N-linked or O-linked to the core protein of the 
PG (Funderburgh 2002). HA is not synthesised in the Golgi from the core protein but rather 
by an integral plasma membrane synthase, which secretes the nascent chain immediately 
(Itano and Kimata, 2002). All GAGs, with the exception of HA, are biosynthesised as 
proteoglycans and the linkage region is the same in all, except for keratan sulfate. This 
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linkage region consists of the tetrasaccharide; glucuronic acid (GlcA), galactose (Gal), Gal, 
and xylose (Xyl)-linked to the hydroxyl group of serine in the polypeptide core (Sugahara 
and Kitagawa, 2000). Biosynthesis of all GAGs, except HA  is initiated from a core protein, 
rich in serine-glycine repeats, which create the platform for the attachment of one or more 
GAG chains via the linkage region (Kimura et al, 1984). Contrarily, HA GAGs lack a 
covalently bound protein core and is synthesised at the intracellular surface of the plasma 
membrane (Afratis et al., 2012) 
 Biosynthesis of GAG is a complex non-template-driven process that involves many 
enzymes that assemble the GAG polymer and then sulfate them at specific positions. GAGs 
are synthesised as homopolymers, which are modified subsequently by N-deacetylation and 
N-sulfation. This is followed by numerous modifications, including sulfation, epimerisation 
and desulfation; all of which are performed in a spatiotemporal manner, producing mature 
and functional GAG chains that exert biological functions dependent on their specific 
structure. This is common to both types of GAG chain and is formed through the stepwise 
addition of each monosaccharide residue by the respective specific glycosyltransferase 
(Grimshaw,1997).                                                                                                                           
 After the attachment of the linker, the first modification to the chain determines 
whether the chain matures into a CS or HS. This modification involves the transfer of a 
GlcNAc (HS) or a GalNAc (CS) monosaccharide. The enzyme GlcNAcT-I transfers GlcNAc 
to the tetrasaccharide linker, initiating HS biosynthesis (Rohrmann et al, 1985). This enzyme 
is different from the glycosyltransferase GlcNAcT-II that is involved in the elongation of the 
HS GAG chains. In the case of CS, the initiating GalNAc residue is transferred to the linker 
region by the enzyme GalNAcT. It is not very clear whether the activity of this enzyme 
differs from the GalNAc transferase activity of chondroitin synthase, which is involved in the 
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chain-elongation process. In all cases real chain-building ensues after the transfer of GlcNAc 
(HS) or GalNAc (CS) to the linker.  
In the case of HS chains, a multidomain glycosyl-transferase successively adds 
GlcNAc and GlcA; thus, initiating the chain-elongation process. This multidomain enzyme is 
encoded by EXT1 and EXT2 of the EXT family of genes. Although EXT1 and EXT2 possess 
the ability to transfer both GlcNAc and GlcA, it has been established that these enzymes form 
a single oligomeric unit, which is required for complete in vivo chain-elongation activity. 
Similarly, in the case of CS, chondroitin synthase, also a known multidomain enzyme, 
transfers GalNAc and GlcA successively for chain elongation (Sashisekhare et al, 2006). 
Molecular cloning has been achieved for four of the glycosyl transferases responsible for the 
biosynthesis of the linkage region tetrasaccharide (Uyama et al, 2007: Kitagawa et al, 1998). 
 Firstly, xylosyl transferase (XylT) transfers a Xyl residue from UDP-Xyl to specific 
serine residues in core proteins in the endoplasmic reticulum and the cis-Golgi compartments 
(Figure 1. 3) (Uyama et al, 2007). Secondly, Two XylTs, XylT-1 and XylT-2, were cloned, 
and their amino acid sequences found to be significantly homologous. In contrast enzymatic 
activities were only shown by XylT-1, not by XylT-2. Following the transfer of a Xyl 
residue, two Gal residues are transferred to the Xyl residue by two kinds of galactosyl 
transferases (GalTs), GalT-I and GalT-II, in the cis- 1-O-Ser, in the medial- and trans-Golgi 






















Figure 1.3; Schema of the biosynthetic assembly of the GAG backbones by various  
          glycosyltransferases. 
A number of glycosyltransferases are required for the synthesis of the backbones of GAG’s.e.g XylT, Xyl 
transferase; GalT-I, Gal transferase-I; GalT-II, Gal transferase-II, GlcAT-I, GlcA transferase-I; GalNAcT-I, 
GalNAc transferase-I; CS GlcAT-II, CS GlcA transferase-II;GalNAcT-II, GalNAc transferase-II; CS 
polymerase, GlcA/GalNAc transferase; GlcNAcT-I, GlcNAc transferase-I; GlcNAcT-II,GlcNAc transferase-II; 
HS polymerase, GlcA/GlcNAc transferase; ChSy-1, chondroitin synthase-1; ChSy-2, chondroitin synthase-2; 
and ChPF, chondroitin polymerising factor. 
 
 
 The biosynthesis of the linkage region is completed by the actions of GlcAT-I; 
transferring a GlcA residue to the linkage trisaccharide, Galβ1→3Galβ1→4Xylβ. Moreover, 
one study highlights that the expression level of GlcAT-I correlates well with the amount of 
Heparan sulfate/Heparin 
 Chondroitin sulfate/Dermatan sulfate 
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GAGs; thereby suggesting that GlcAT-I regulates the overall expression of GAGs (Uyama et 
al, 2007). The resulting GAG chain backbone undergoes extensive sulfation modifications, 
during chain elongation, thus making GAG chains some of the most negatively-charged 
families of biopolymers in mammalian cells. 
 
1.7 Biosynthetic modification of HS-GAG chain (HS chain elongation) 
The nascent HS chain is first modified by N-deacetylase, N-sulfotransferase (NDST), 
which is a multidomain enzyme that cleaves the N-acetyl group from the GlcNAc 
monosaccharides and transfers a sulfate group to the N-position. This is followed by the 
action of the C-5 uronyl epimerase, which converts GlcA to IdoA (Figure 1.4) in selected 
positions. 2-O-sulfation of the uronic acid by the 2-O sulfotransferase (2-OST) can follow the 
epimerisation process. The 2-OST acts on IdoA- as well as GlcA-containing HS chains; 
however, the IdoA containing chains are the catalytically preferred substrates (Pinhal et al, 
2001: Rong et al, 2001). The final set of modification enzymes are the 6-O (6-OST) and 3-O 
(3-OST) sulfotransferases, which sulfate the 6-O and 3-O positions of the GlcNAc moiety, 
respectively. Many of the above biosynthetic enzymes have distinct isoforms that are 
selectively expressed in different tissues (Kusche-Gullberg and Kjellen 2003). Four different 
isoforms of NDST, three different 6-OSTs, and six different 3-OSTs have been characterised 
in humans and mice (Kusche-Gullberg and Kjellen 2003), they all have different specificities 








Figure 1.4 HS chain elongation 
The chains are synthesised on the core protein by the sequential action of individual glycosyl transferases. A 
common tetrasaccharide linkage region is formed, followed by the addition of alternating GlcA and GlcNAc 
residues, producing in turn the precursor chain. This chain is then enzymatically modified by deacetylation and 
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1.8  Biosynthetic modifications of CS/DS GAG chains (CS/DS chin elongation) 
CS/DS sulfated GAGs [(CS] are covalently attached to their respective core proteins 
through the GAG–protein linkage region, GlcAβ1→3Galβ1→3Galβ1→4Xylβ1→O-Ser 
(Figure 1.3). The biosynthesis of CS can be broadly divided into that of chondroitin and DS. 
CS is comprised of predominantly the GlcA epimer, whereas dermatan is predominantly 
comprised of IdoA. Thus, the CS C-5 uronyl epimerase is more prominent in the biosynthesis 
of DS. The first GalNAc transfer to the linkage region by the alleged GalNAc transferase-I 
leads to the synthesis of the repeating disaccharide region [(→4GlcAβ1→3GalNAcβ1-)n] of 
CS/DS through alternate additions of β-GalNAc and β-GlcA by the concerted actions of the 
putative GalNAc transferase-II and GlcA transferase-II enzymes, which are specific to CS 
backbone synthesis (Figure 1.5). 
The three main sulfation events of the CS chains are 4-O and/or 6-O-sulfation of 
GalNAc and 2-O-sulfation of uronic acid. There are four different isoforms of the CS 
GalNAc 4-OST (C4ST-1, C4ST-2, C4ST-3, and D4ST-1) and three different isoforms of the 





Figure 1.5; Pathways of CS/DS chain elongation. 
C4ST, chondroitin 4- O -sulfotransferase; C6ST, chondroitin 6- O -sulfotransferase; D4ST, dermatan 4- O -
sulfotransferase; CS/DS2ST, uronyl 2- O -sulfotransferase; Gal-NAc4S-6ST, GalNAc 4-sulphate 6- O -
sulfotransferase; O unit, GlcA b 1-3GalNAc; iO unit, IdoA a 1-3GalNAc; A unit, GlcA b 1-3GalNAc(4S); iA 
unit, IdoA a 1-3GalNAc(4S); iB unit, IdoA(2S) a 1-3GalNAc(4S); C unit, GlcA b 1-3GalNAc(6S); D unit, 




1.9 Analysis of GAGs and their oligosaccharide fragments 
There are various ways to study the biological function of GAGs structures in order to 
understand the structure-activity relationships (SAR). Traditionally, the determinations of 
GAG’s structures are usually derived from the following steps: 
Direct extraction and purification of HS populations from tissues or culture cells arising 
from different organs.  
Partial chemical and enzymatic modifications of GAGs to produce oligosaccharides of 
defined modifications and size (Yates et al, 2004). The structure of these fragments can 
be confirmed using disaccharide compositional analysis as well as sequencing methods.  
Chemically synthesised GAGs oligosaccharides (Grootenhuis et al, 1995) may shed light 
on specific HS structure activity relationships. Synthesis of GAGs structures is a very 
long and specialized process. However, solid-phase synthesis and combinatorial 
chemistry has greatly advanced this field in recent years (Vohra et al, 2008: Seeberger 
and Werz, 2005: Seeberger and Haaze, 2000) 
 
1.10 Traditional methods for extraction and purification of GAGs from Tissue 
 Samples and Cultured Cells 
In general, extraction of GAGs is initiated by the action of proteolytic enzyme 
(e.g.Alcalase) on the core protein of PGs. This enzyme degrades the core protein into short 
peptides, thereby releasing the corresponding GAGs chain. Dialysis with high concentrations 
of harsh organic solvents such as 8 M urea and addition of trichloroacetic acid (Lyon and 
Gallagher, 1991) or guandinium chloride are also employed (Yanagishita et al, 1987). These 
chemicals are chaotrophic agents that are capable of disrupting the three-dimensional (3D) 
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structures of proteins, DNA and RNA. Urea and other chaotrophic agents usually disrupt the 
3D structure of proteins by interfering with the stabilizing inter-molecular interactions which 
mediate non-covalent forces such as hydrogen bonds, van der Waals forces and hydrophobic 
effects (Puvirajesinghe and Turnbull, 2012). The disadvantages of these methods include: 
they are lengthy; they can involve multiple sample transfers; they can contain harsh 
chemicals; and they may alter pH and cause de-N-sulfation (Inoue and Nagasawa, 1976). 
Other methods include β-elimination, which involves alkaline borohydride treatment, which 
also acts to disrupt the serine-xyloside linkage that attaches GAG chains to the core protein 
backbone; all these methods result in the release of intact GAGs from protein cores (Stenstad 
et al, 1993). 
Another method that can be used for GAGs purification, from cultured cells, involves 
the use of a non-ionic detergent solution, such as 1% Triton X-100 0.5 M KCl, which can 
then be subjected to density centrifugation using caesium chloride gradients. This separates 
the molecules according to their density (Jalkanen et al, 1988). Electrophoretic techniques 
can be used for separation of proteoglycans. This technique can be used either separately or 
in combination with SAX-chromatography, depending on the degree of purification required 
or type of HSPG to be purified. 
 
1.11 Chemical and enzymatic depolymerisation of GAGs used in structural analysis 
The polydisperse nature and large size of GAG chains means that it impossible to 
determine the structure of individual GAG chains. Structure activity relationships between 
GAG chains and proteins must therefore be determined by reducing the size of the chains into 
more manageable oligosaccharides. The most common method of determining differences in 
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GAGs derived from a variety of sources is the analysis of disaccharides composition, which 
is commonly achieved by depolymerisation of the GAGs chain by chemical or enzymatic 
treatment. Site-specific enzymes are used to degrade the polysaccharides for structural and 
analytical purposes (Murata and Yokoyama, 1987: Linhardt 1986). Depolymerisation of the 
polysaccharides can results in the creation of smaller saccharides chains, known as 
oligosaccharides by partial degradation enzymatic or chemical treatment.  
They can also be degraded further by a combination of site-specific enzymes in order 
to yield disaccharides, subsequent analysis by SAX-HPLC can give the total disaccharide 
composition of the GAG chains.  While similar disaccharides may be present in different 
tissues, the proportion of each varies considerably thereby allowing the identification of 
structural differences between tissues. Furthermore, the domain structures of GAGs can be 
analysed to understand the relative distributions of nonsulfated and sulfated domains from 
different cells and tissues (Esko and Lindhart, 2001). The structures found in different 
domains can be analysed further using oligosaccharide mapping, which provides a 
‘fingerprint’ of the domain structures (Turnbull and Gallagher, 1991: Turnbull 1990: 
Turnbull and Gallagher, 1988). The development of GAG sequencing technology has been 
used to provide more detailed information on the structure of individual oligosaccharides 
involved in important biological interactions (Turnbull et al, 1999). GAG oligosaccharides 
structures have been studied extensively by using one or more of the following methods and 
have provided a wealth of information on the relationships between the fine structures of 
GAG chains. 
Originally, depolymerisation of HS/heparin was achieved using nitrous acid 
hydrolysis. Nitrous acid cleaves in between the hexosamine residues and the hexuronate 
residues, where the amino group is either N-sulfated or unsubstituted. This result in the 
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conversion of the D-glucosamine at the reducing end of the structure into a 2, 5- anhydro-D-
mannose residue and the hexuronate residues remain intact (Burdon and Van Knippenberg, 
1985). This reaction has been studied extensively and is proven to be pH-dependent. Direct 
deamination of N-sulfated glucosamine residues is possible at a low pH condition (< 2.5). 
However, N-unsubstituted residues are deaminated more rapidly at an optimum pH 4 
(Shively and Conrad, 1976). 
This method cannot be used to fully characterise the GAG oligosaccharides directly as 
the depolymerisation process does not generate a suitable specific chromophore, in other 
words, chemical digestion and separation of such fragments can be followed only at low 
sensitivity by spectroscopic detection (Powell et al, 2004). Increased detection sensitivity is 
achieved by combining nitrous acid degradation with reducing end labelling methods, such as 
radiolabelling, or fluorescent tags. The labelling reaction of the reducing end of nitrous acid 
treated fragments is aided by the fact that the 2, 5- anhydro-D-mannose residue produced at 
the reducing end is highly reactive (Puvirajesinghe and Turnbull, 2012). Furthermore, this 
method is limited by its ability to cause reduced yield due to ring contraction of uronic acid 
residues or p-elimination of the glucuronic acid (Guo and Conrad, 1989). 
 
1.12 Use of separations techniques for structural analysis 
GAGs can be analysed in many different ways, the choice of techniques depending on 
factors such as the source and quantity of materials, the type of data required and the 
preparation and/or treatment of GAGs prior to the analysis process. NMR spectroscopy and 
mass spectrometry are useful techniques for such analysis and have been able to provide 
direct sequence information (Kitagawa et al, 1995). However, both techniques require 
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specialized instruments, which are not routinely available and NMR in particular requires 
relatively large quantities of materials (millimolar to micromolar quantities). These 
drawbacks leave chromatographic techniques as the most common and easiest methods used 
to examine GAGs structure (Puvirajesinghe and Turnbull, 2012). 
 
1.13 Strong anion-exchange chromatography (SAX-HPLC) 
To date, chromatography remains the most reliable technique for the routine 
separation of GAGs and the common ones generally in use are gel chromatography and high-
performance liquid chromatography (HPLC). Oligosaccharide products can be purified and 
separated according to their molecular weight and other properties such as charge and 
hydrodynamic volume (Puvirajesinghe and Turnbull, 2012). Several methods, such as 
radioactivity measurement, UV detection at 232 nm, fluorescence detection, can be used for 




H in samples prepared 
by biosynthetic radiolabelling (e.g., cultured cells) or where oligosaccharides (digested using 
nitrous acid) are labelled at their reducing-ends with 
3
H–borohydride and UV detection at 
232 nm can also be used to detect the disaccharide products. Another UV wavelength 
commonly used is 215 nm, which detects acetyl bonds, although this is less sensitive than 
detection at 232 nm. Fluorescence detection is another reliable and extremely sensitive 
method that can be used to detect fluorescently-tagged oligosaccharides. Strong anion-
exchange chromatography (SAX-HPLC) techniques are used for the separation of structures 
according to their negative charge content. A common column is the Pro-Pac PA1, which is 
made of quaternary ammonium functional groups attached to nonporous core particles by 
agglomerated MicroBead™ resin.  SAX-chromatography can be used in combination with 
PAGE separation, for the purification of GAGs oligosaccharides (Vives et al, 2001). 
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1.14 Polyacrylamide Gel Electrophoresis (PAGE)  
Electrophoresis is primarily an analytical technique for charged molecules. It is a technique 
that separate GAG oligosaccharides based on their mass to charge ratio (m/z). Although, 
PAGE analysis is one of the common biochemical techniques used for the separation of 
protein and DNA, it has also been used to separate GAG samples in a similar manner for its 
use in the analysis of DNA and protein (Wong et al 2006). However, PAGE analysis of GAG 
oligosaccharides was initially complicated because of the demand for high resolution due to 
the polydispersity and structural heterogeneity of GAG samples: this drawback has now been 
resolved by the introduction of discontinuous gel electrophoresis, together with the 
development of specialised stacking gels and buffer (Rice et al 1989). 
 The use of fluorescent tags to label digestion products at their free reducing-ends via 
reductive amination reaction has also been determined and this has led to a technique known 
as flourophore-assisted carbohydrate electrophoresis (FACE). The enzymes-digested 
products can be stoichiometrically coupled to a fluorescent tag and separated using high 
percentage gels. Picomolar concentrations can be viewed using a transilluminator 
(Puvirajesinghe and Turnbull, 2012). 
 
1.15 GAG’s degrading enzymes 
Overall GAG’s degrading enzymes are an extremely important tool in relating GAG 
structure/sulfation pattern to biological activities therefore an understanding of the 
specificities of these enzymes is crucial to interpreting the data generated by the action of 
these enzymes on GAG chains. The most widely used enzymes are a family of structurally 




Heparinases are enzymes lyases that can eliminatively cleave heparin or HS into 
disaccharide and oligosaccharide products: they are also involved in the release of heparin- 
bound growth factors from the ECM (Kim et al, 2000). Six different heparinase enzymes 
have been isolated from four different bacteria namely: Flavobacterium heparinum, Bacillus 
sp., Bacteroides heparinolyticus, and an unclassified soil bacterium (Yoshida et al, 2002). At 
least 29 other bacteria expressing heparinase activity as determined by a qualitative plate 
assay has been isolated. (Yoshida et al, 2002: Steyn et al,1992: Salyers et al, 1977). 
Fractionation of crude heparinase afforded three different heparinases usually called lyases I, 
II and III, each of which have a different substrate specificities (Figure 1.6) (Desai, 1993). 
The individual heparinase enzymes cleave unique glycosidic linkages, allowing Heparin and 
HS to be degraded to specific types of oligosaccharide fragments which vary in length and 
sulfation pattern (Linhardt et al, 1990). 
 Isoelectric focusing (PI) showed that Bacillus species heparinase (PI = 6.6) has an 
overall negative charge at its optimal pH of 7.5 while all three F. heparinurn heparinases (PI 
= 8.5- 10.1) are positively charged at their pH optima of 7-7.5. For enzymes that degrade a 
polyanionic substrate, this appears to be an important difference that may imply different 
mechanisms for heparinases from Bacillus sp. and from F. Heparinum (Lohse and Linhardt, 
1992). However, the temperature optimum for Bacillus sp. heparinase is 50°C but 90% of the 
activity is lost after 3h at 45°C (Bellamy and Horikoshi, 1992). Moreover, for short digest 
sodium phosphate buffer has been reported to give higher activity than sulfonate-based 
buffers (MOPS, TES, and HEPES), but the latter seem to increase stability of heparinase’s I, 
II, and III (Lohse and Linhardt, 1992). It appears in general that the optimal conditions for 
heparinases are different depending on the durations of the assay but there is some 
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controversy about this finding which could be critical in determining the completeness of 
GAG digestions.  
There is very important substrate specificity associated with heparin lyases, which has 
been defined as a disaccharide containing a cleavable linkage. Heparinase I cleaves the 
linkages HNS (6X)-I-2S [GlcNS (6S) (1 → 4) IdoA2S],  heparinase II the linkages HNY,6X- G/I2x 
[GlcNS (6S) (1 → 4) IdoA (GlA) 2S], and heparinase III the linkages HNAc-I and HNY,6X-G 
[GlcNAc(1 → 4) IdoA] and [GlcNS (6S) 1 → 4) GlcA)], in which H is glucosamine, I is 
iduronic acid, G is glucuronic acid,Y is sulfated or acetylated (CH3CO or SO3) and X is 
sulfated or unsubstituted (H or S03). 
  
Figure 1.6: Primary glycosidic linkages cleaved by Heparin lyases. 
 Abbreviations: X, H or SO3−; Y, CH3CO or SO3−. Heparin lyase II cleaves at either glucuronic or iduronic 
acid residues. 
 
The enzymatic action of individual heparinases leads to the generation of 
oligosaccharides with specific structural features. Degradation of HS with all the three 
heparinases reduces HS chains to their disaccharide components, an essential property in 
structural characterisation. These disaccharide units comprises of ∆
4,5
-uronic acid attached to 
N-acetylglucosamine at the reducing terminus and with varying degrees of sulfation (Lohse 
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and Linhardt, 1992). Both D-glucuronic acid and L-iduronic acid give the same ∆
4, 5
-uronic 
acid after enzyme treatment (Lohse and Linhardt, 1992). The main disaccharides found in 
HS/heparin and their traditional abbreviations are; Δ-UA-GlcNAc (IVA); Δ-UA-GlcNS 
(IVS); Δ-UA-GlcNAc (6S) (IIA); Δ-UA(2S)-GlcNAc (IIIA); Δ-UA-GlcNS (6S) (IIS); Δ-UA 
(2S)-GlcNS (IIIS); Δ-UA(2S)-GlcNAc (6S) (IA);Δ-UA (2S)-GlcNS (6S) (IS). 
 
1.17 Heparinase I from F. heparinum (EC 4.2.2.7)                                                         
Heparinase I has also been shown to cleaves heparin at both the GlcNS (6S) (1 → 4) IdoA 
(2S) and GlcNS (3S,6S) (1 → 4) IdoA (2S) linkages (Xiao et al 2011). The GlcNS(3S6S) (1 
→ 4) IdoA(2S) linkage, found primarily within the antithrombin III binding site, is more 
susceptible to heparinase I than the major heparin disaccharide repeating unit GlcNS(6S) (1 
→ 4) IdoA(2S). The complete depolymerisation of heparin by heparinase I has been reported 







 Figure 1.7: Unsaturated disaccharide derived from HS by enzyme catalysed            
elimination. 
 
1.18 Heparinase II from f. heparinum 
Heparinase II is also active on both heparin and HS, with the HS activity being 
approximately twice as high as the heparin activity (Lohse and Linhardt 1992: Linhardt et al, 
1990: Nader et al, 1990). The distribution of products for heparinase I1 degradation of 
heparin is not as well characterised as for heparinase I and appears to reflect the composition 
of the substrate. Heparinase II degradation of heparin yields predominantly the trisulfated 
disaccharide structure with other minor detectable disaccharides being produced; this fits 
with the highly sulfated nature of the heparin polymers. Moffat and others have reported a 
broad substrate specifity of this enzyme. A characteristic that is contrary to the general 
property of enzyme reported previously (Desai et al., 1993a: Moffat et al, 1991a). 
 Furthermore, this enzyme has been demonstrated as capable of cleaving both of the 
isomeric forms of uronic acids (IdoA and GlcA) even though the epimerised C5 hydrogen is 
being abstracted in the reaction (Desai et al, 1993). This is unusual for enzymatic reactions 
which are normally stereospecific due to the defined structure of the enzyme catalytic site. 
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The susceptible linkages are HNY,6X-U2X where the uronic acid can be IdoUA or GlcUA, the 
X group can be sulfated or unsubstituted, and Y can be either sulfated or acetylated but not 
free.  
 
1.19 Heparinase III from f. Heparinurn (E.C 4.2.2.8) 
Heparinase III is less active on standard heparin or heparin-like segments of HS, i.e. 
highly sulfated polymers and specifically degrades mono- or non-sulfated sequences within 
HS chains. None of the standard methods of oligosaccharides analysis of GAGs such as, 
SAX-HPLC (Linhardt et al., 1990), capillary zone electrophoresis (CZE) electropherograms 
(Ampofo et al., 1991), gradient PAGE (Desai et al., 1993a) yielded any appreciable 
disaccharide degredation products when heparin was incubated with heparinase III. The 
degradation products from heparinase III degradation of HS are poorly non- and mono- 
sulfated disaccharides, indicating a preference for the enzyme to degrade less modified 
regions of the polymer.  
Previous studies conducted by Rice and colleagues have also highlighted that 
heparinase III is more active towards larger oligosaccharides than the smaller ones. It has also 
been shown to be active towards oligosaccharides with N, 6-disulfated (NS6S) or N-
acetylated hexosamine (Linhardt et al, 1990: Rice and Linhardt, 1989). These findings have 
resulted in speculation that N-sulfation and 6-O-sulfation do not inhibit cleavage by this 
enzyme. This was confirmed by the existence of 6-O-sulfated and N-sulfated products 




1.20  Chondroitinases                                                                                    
 Chondroitinase enzymes are once again extremely important tools for the structural 
characterisation of GAGs and have been isolated and characterised from bacteria of the 
genera Arthrobacter, Flavobacterium, Aeromonas, Bacillus, Bacteroides, Proteus and an 
unclassified strain possibly Aurebacterium (Earnst et al, 1995: Yamagata et al, 1968). 
Chondroitinase-ABC (EC 4. 2. 2. 4) is a general purpose enzyme that cleaves all glycosidic 
linkages in the three members of the CS group and also with hyaluronan. It is been classified 
as a remarkable enzyme because of its ability to cleave linkages with iduronic acid as well as 
linkages with its isomer, glucuronic acid (Linhardt et al 2006).  
In addition, chondroitinase activity has been detected in several other microorganisms 
(Linhardt et al., 1986: Salyers et al., 1977). It is an extremely important tool used to 
completely degrade CS/DS to their disaccharide components, which can be quantified by 
SAX-HPLC, CE, FACE, PAGE, etc. It acts on chondroitin 4-sulfate, chondroitin 6 sulfate, 
and DS, and acts slowly on hyaluronate (Figure 1.8). Inability of the chondroitinases to show 
any activity towards heparin or HS, which are entirely 1      4 linked indicates, that the 1      3 









Figure 1.8: Glycosidic linkages cleaved by chondroitin lyases. 
Abbreviation: Ac, CH3CO. 
 
Chondroitinase-B lyase (EC 4.2.2.19) is specific for DS degradation and the resulting 
oligosaccharides as resolved by SAX-HPLC has been reported by Linhardt and others to 
yield ΔUA-GalNAc (0S); ΔUA-GalNAc6S (6S); ΔUA-GalNAc4S (4S); ΔUA2S-GalNAc4S 
disaccharides accounted for 50 to 65% of the 232 nm absorbance while the remaining 35 to 
50% absorbance most likely originated from unidentified oligosaccharides (Linhardt et al, 
1991). However, degradation of oversulfated DS GAG chains isomers additionally yielded 
the trisulfated disaccharide, ΔUA (2S)-GalNAc (4S, 6S) (Figure 1.9) (Murata and Yokoyama, 
1987). Purification of the crude enzyme by column chromatography over hydroxyl apatite led 
to discovery of chondroitinase-AC lyase (4.2.2.5) which only eliminates the amino sugar 
attached to glucuronic acid and to chondroitinase-B lyase which eliminates amino sugars 
attached to iduronic acid (Gu 1995). Separation of the hydrolysis products by SAX-HPLC 
Chondroitin ABC lyase       Chondroitin ABC lyase 
Chondroitin ABC lyase 
Chondroitin sulfate E 
Oversulfated chondroitin 
Chondroitin sulfate D 
Unsulfated chondroitin    Chondroitin sulfate A 
Chondroitin ABC, B lyase chondroitin ABC, AC lyase 
Chondroitin ABC, AC lyase  Chondroitin ABC, AC lyase 
 
Chondroitin sulfate B    chondroitin sulfate C 
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after treatment of GAGs with AC/ B lyases provides useful analytical information on their 
structure. They are also powerful tools used to generate CS/DS oligosaccharides and for 






Figure 1.9: Unsaturated disaccharides derived from CS by enzyme catalysed             
         elimination. 
Abbreviation: R = SO3
-













1.21 Glycosaminoglycans and cancer 
Recent studies have demonstrated the significant roles played by GAGs and 
proteoglycans in tumourigenesis and tumour progression (Yip et al, 2008 and Conte et al, 
2007). For example, in breast cancer, changes in GAG and PG expression on the cell surface 
and in the ECM allow tumour cells to proliferate, gain the ability to invade surrounding 
tissues, metastasize to distant organs and induce angiogenesis (Guo et al, 2007 and Polyak, 
2007). 
HS are present on the surface of every eukaryotic cell, inclusive of both tumour cells 
and the surrounding cells. This polymer has also been shown to be vital for tumour survival 
(Liu et al., 2002). This includes the endothelial-cell compartment that is very close to a 
growing tumour; indeed HS has been linked with the ability to modulate the process of 
tumour angiogenesis (Gandhi and Mancera, 2010 and Ram et al, 2002). HS chains on the 
tumour-cell surface have been proven to be important in many aspects of tumour phenotype 
and development, including cellular transformation, tumour growth, invasion and metastasis 
(Liu et al, 2002 and Sanderson et al, 2001). In vivo studies in mice highlight that changes in 
the fine structure of tumour cell surface HS have marked effects on tumour cell growth 
kinetics and metastasis formation (Liu et al, 2002). Some HS sequences expressed on the 
tumour cell surface appear pro-tumourogenic, whereas others are anti-tumourogenic (Gandhi 
and Mancera, 2010). Recent advances in structural elucidations of HS have led to the 
discovery of its anti-tumourogenic capability both in vivo and in vitro (Gandhi and Mancera, 
2008). HS structure-activity relationship studies, such as this have opened up many new 
exciting avenues for the generation of polysaccharide-based anti-cancer therapeutics  
( Linhardt 2013:Ram et al, 2002). 
Changes in HS structure on the tumour cell surface seem to mediate their effects by 
regulating differential growth-factor signaling, cell adhesion, proliferation and migration (Liu 
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et al, 2002 a). Moreover, alterations in the level of expression of the protein core of HSPGs as 
well as HS structural differences and/or density on HSPGs, can potentially make cancer cells 
highly versatile in the modulation of their behaviour (Esko and Lindhal, 2001: Tumbull et al, 
2001). 
The structural complexity of HS arises from the differential modification of individual 
disaccharide units within an oligosaccharide chain (Esko and Lindhal, 2001: Tumbull et al 
2001) which result ultimately in great structural diversity. One of the consequences of the 
great structural diversity of HS structure is that these molecules are able to bind and interact 
with a wide variety of proteins, such as growth factors, chemokines, morphogens, enzymes 
and other signaling molecules, that are important for tumour development, such as FGFs. 
Cells can perform subtle changes to the biosynthesis of HS chains and hence have the 
ability to change how the cells interact with these molecular effectors that bind HS. This 
allows the tumour cell HS-GAGs (both at the cell surface and extruded into the ECM) to 
modulate directly several aspects of tumour-cell phenotype, including growth kinetics, 
invasiveness and metastatic potential (Varki and Varki, 2002). One of the consequences of  
tumour-derived HS or HSPG is that, it can be pro-tumourogenic or anti-tumourogenic 
depending on whether it is anchored at the cell surface or present in the ECM as soluble-free 
GAGs (Liu et al 2002), as well as depending on the HS-GAG sequence. 
Recently, it has been demonstrated that cancer cells alter their cell-surface HS profile 
during the process of transformation, including differential expression of particular 
proteoglycan protein core sequences, in addition to changing the HS fine structure of given 
proteoglycans (Blackhall et al 2001). Other studies have revealed that HS chains are involved 
in the initial oncogenic transformation of a normal cell to a tumour-cell (Xiang et al, 2001: 
Filmus 2001). Changes in both the expression level and the oligosaccharide sequence 
characteristics of cell-surface HSPGs have been shown to correlate with transformation in 
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several malignancies (Ram et al, 2002). For example, the HSPG syndecans is required to 
maintain the differentiated morphology and localisation of epithelial cells. Syndecan-1 
expression is down regulated in various malignant tumours, including uterine carcinoma and 
multiple myeloma (Ram et al, 2002). Its expression decreases as in situ carcinoma progresses 
to invasive carcinoma (Sanderson 2001). This decrease in expression may be linked to 
phenotype changes in these cancers. Specific HS structural changes have been noted during 
malignant transformation of colon cancer cells from adenoma to carcinoma (Jayson 1998). 
Likewise, glypican-1, another cell-surface HSPG that closely control cell growth and 
division, has been shown to act as a negative regulator of cell proliferation for certain tumour 
types ((Ram et al, 2002). Glypicans have also been shown to modify cellular responses to 
bone morphogenetic proteins and insulin-like growth-factor-2 -factors that are important in 
cellular division and differentiation (Ram et al, 2002). An association has also been made 
between specific mutations in HS-related biosynthetic genes and inherited syndromes that 
increase cancer risk, implicating these molecules in tumourigenesis (DeBaun et al, 2001). 
Simpson–Golabi–Behmel syndrome (SGBS) is a complex congenital overgrowth syndrome 
with features that include macroglossia, macrosomia, and renal and skeletal abnormalities, as 
well as an increased risk of certain malignancies. Most cases of SGBS seem to arise as a 
result of either deletions or point mutations within the gene that encodes glypican-3 (GPC3) 
at Xq (Mundhenke 2002). GPC3 expression is also down regulated in a number of cancers, 
including breast and ovarian carcinomas, and mesotheliomas (Mundhenke 2002). 
Tumour cell surface HS also binds growth factors, cytokines and structural proteins 
that are involved in modulating autocrine and paracrine signaling loops that are important for 
tumour growth and progression (Mundhenke 2002) .The diverse structural characteristics of 
HS enable them to act either as inhibitors or potentiators of these signalling loops, depending 
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on their sequence context (Liu et al, 2002). Recent studies have highlighted that, in vitro, 
tumour cell surface HS can promote growth-factor signaling and tumour-cell proliferation. 
Tumour cells are reported to influence actively the affinity of their HSPGs for FGF-2, 
as well as for other growth factors, by modulating the overall density and sulfation pattern of 
their HSPGs. Modified HS and CS, have been studied as potential cancer therapeutics. In an 
attempt to generate a potentially therapeutic mimetic of syndecan-1, Pumphrey and 
colleagues discovered that carbodiimide-modified glycosaminoglycans reduced breast cancer 
and myeloma cell viability by inducing apoptosis (Pumphrey et al, 2002). Moreover, 
modified CS abolished breast tumour growth in nude mice. HS mimetics with anti-cancer 
properties such as KI-111 [2-(4-fluoro-3-nitro-benzoyl) benzoic acetic anhydride] inhibited 
tumour-cell adhesion, migration, growth, and invasion in vitro (Ishida et al., 2004).  
In contrast, other KI related compounds inhibited cancer invasion and migration but 
promoted tumour cell adhesion (Ishida et al, 2004: Simizu et al, 2004). 
HS has also been shown to be involved in the promotion and inhibition of tumour 
angiogenesis with many approaches aimed at blocking the interactions between HS and 
angiogenic growth factors (Sanderson. 2001). 
 
 
1.22 Tumour angiogenesis 
Angiogenesis is a natural process that involves both the growth of new blood vessels 
from pre -existing vessels and also closely regulated sequence of events starting with the 
degradation of the basement membrane by activated endothelial cells (Hussain et al 2009). 
Tumours cannot grow as a mass above few mm in size unless a new blood supply is induced. 
The various stages involved in tumour angiogenesis are illustrated in Figure 1. 10. 
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Angiogenesis is controlled by a balance between proangiogenic factor [including 
FGFs: acidic (FGF-1) and basic (FGF-2), Vascular endothelial growth (VEGF), Tumour 
necrosis factor-alpha (TNF-alpha), Follistatin Granulocyte colony-stimulating factors (G-
CSF), Hepatocyte growth-factor (HGF)] and anti-angiogenic factors [including anti-
angiogenic antithrombin III, CD 59 complement fragment, heparin hexasaccharide fragment, 
human chorionic gonadotropin (hCG)]. The angiogenic switch represents the overall 
activities of the angiogenic stimulators and inhibitors which may either shift the balance 
towards inhibition or stimulation (Presta et al, 2003). Tumour neovascularization and angio-
proliferative diseases result in uncontrolled endothelial-cell proliferation.                                                                                                                                           
HSPG’s participates in the modulation of the neovascularization that happens in 
different physiological and pathological conditions. This modulation occurs through 
interaction with angiogenic growth factors (Presta et al, 2003), which is due, in part, to their 
capacity to bind to and modulate the activity of angiogenic growth factors. However 
contrasting effects can be obtained depending on the types of HSPGs and/or on the 
experimental conditions adopted e.g, purified perlecan enhances angiogenesis induced by 
FGF-2 while other purified HSPGs are ineffective (Aziever et al, 1994). Glypicans support 
the binding of FGF-1 and FGF-2 to human tyrosine kinase FGF receptor-1 (FGFR-1) in a cell 
free system and replaces heparin in supporting FGF-2 induced cellular proliferation of HS-
negative cells expressing FGFR-1 (Bonneh-Barkay et al, 1997). Soluble heparin/HS inhibit 
the binding of FGF-2 to FGFRs and HSPGs present on the surface of endothelial cells 
(Coltrini et al, 1994). Thus, this observation suggest that negative effects on angiogenesis 
may be exerted by the binding of angiogenic growth factors to soluble HSPGs or GAGs 
rather than to cell-associated HSPGs. 
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HSPGs may also modulate angiogenesis also by protecting angiogenic growth factors 
from heat (Gospodarowicz and Cheng, 1986) and proteolytic degradation (Coltrini et al, 
1994) and by affecting their radius of diffusion (Flaumenhaft et al, 1989). Finally, HSPGs 
present in the ECM may act as a reservoir for angiogenic growth factors that will reach 
higher local concentrations and will sustain the long-term stimulation of endothelial cells 
(Presta et al, 1989). A common theme among growth factors interacting with TK receptors is 
the involvement of ligand-induced receptor dimerization in receptor activation (Ullrich and 
Schlessinger, 1990).  
Crystal structures of HS/FGF/FGFR ternary complexes revealed markedly different 
geometrics (Pellegrini et al, 2000). A single molecule of heparin/HS may bind several 
molecules of FGF-2 (Coltrini et al, 1993) suggesting that GAGs induce oligomerization of 
angiogenic growth factors. Heparin has been reported to induce dimerization of FGF-2 in cell 
free system (Coltrini et al, 1993). It has also been demonstrated that the dimerization and 
activation of FGFR catalysed by heparin-dependent oligomerization of FGF is required to 
induce a mitogenic response (Spivak-Kroizman et al, 1994). FGF-2 molecules has been 
recently demonstrated to self-associate through specific interactions in a sequential pattern, 
resulting to the formation of bioactive FGF-2 dimmers, and that Heparin can serve as a 
platform to stabilize the inter-molecular FGF-2 interactions, thus favouring receptor 
dimerization (Kwan et al, 2001). The capacity of various angiogenic factors to bind 
heparin/HS indicates that molecules that are able to interfere with this interaction may act as 
angiogenesis inhibitors; for example, the ability of low molecular weight heparin fragments 
to be administered systemically in order to reduce the angiogenic activity of FGF-2 and 
VEGF (Norrby 2000; Norrby and Ostergaard, 1997). 
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The biological activity of angiogenic growth factors on endothelial cells is controlled 
by a complex interplay among free and cell-associated heparin/HS GAG chains. In this 
scenario, natural and synthetic heparin related angiostatic compounds play their 
pharmacological action (Presta et al, 2003). This observation indicates that distinct structural 
requirements are necessary for the interaction of heparin/HS with different growth factors. 
Even though these specific binding sequences may be masked in heparin due to its high 
degree of sulfation, the high heterogeneity in HS structure allows a more refined tailoring of 
selective binding regions that may influence the biological activity and bioavailability of 
















1.23 Fibroblast growth factors (FGFs) and their receptors (FGFRs) in human breast 
 cancer 
The pleiotropic effects of FGFs are mediated through four highly conserved receptor 
tyrosine kinases (RTKs), known as FGF receptor 1-4 (FGFR1-4). The extracellular domain of 
these receptors contains three immunoglobulin-like (Ig) domains (D1, D2 and D3) (Turner 
and Gross 2010), which bind to specific members of the FGF family of growth factors. 
The second and third Ig domains are the most important for FGF ligand binding and 
specificity; whereas the first Ig domain, absent in certain isoforms, is presumed to have an 
auto inhibitory function (Turner and Gross, 2010). Alternative splicing of the carboxyl half of 
the third Ig domain yields either the IIIb or the IIIc isoforms of FGFR1-3 (Turner and Gross, 
2010: Eswarakumar et al, 2005).These various isoforms of FGFRs exhibit tissue-specific 
expression and respond to different spectrum of the 18 mammalian FGFs known to date 
(Beenken and Mohammadi, 2009). 
Many researchers have linked overexpression of FGFs to human breast cancer and this 
finding has been substantiated by other in vitro studies which equally revealed multitudes of 
properties that suggest their involvement in breast cancer induction, progression and 
metastasis (Dickson et al 2000).  
FGFR2-IIIb, expressed usually in epithelial cells, can be activated by FGFs of 
mesenchymal origin e.g. FGF-7 and FGF-10, whereas FGFR2-IIIc e.g FGF-1 and 
 FGFR 2IIIc expressed on mesenchymal tissues responds to ligands secreted by epithelial 
cells (Rusnati et al, 1994). 
Studies have highlighted the critical role of aberrant FGFR2 signaling in cancer, including 
overexpression of FGFR2 and its ligands, mutations and amplifications of the receptor, and 
receptor isoforms switching (Turner and Gross, 2010: Eswarakumar et al, 2005). Single 
nucleotide polymorphisms (SNPs) of FGFR2 correlate with increased risk of breast cancer 
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development, presumably due to elevated FGFR2 expression. Missense, potentially 
activating, mutations of FGFR2 have been reported in multiple cancer types, including 
endometrial, ovarian, breast, lung, and gastric cancer (Turner and Gross, 2010).  
Furthermore, the FGFR2 gene is amplified in a subset of gastric and breast cancers 
(Turner and Gross, 2010). The co-expression of FGFR-2IIIb and FGF7, in pancreatic and 
gastric cancers, as well as lung adenocarcinomas, is associated with poor prognosis (Turner 
and Gross, 2010), which may likely due to aberrant receptor activation through the formation 
of autocrine activation loop. However, decreased expression of FGFR-2IIIb has been 
reported in several cancer types during tumour progression and phenotypic change. (Turner 
and Gross, 2010), possibly reflecting the physiological role of FGFR2 in regulating tissue 
homeostasis. 
A number of FGF family members and their receptors have been detected in both 
normal and malignant breast tissue through the application of reverse transcription 
polymerase chain reaction procedures (Matsuike et al, 2001). Increased expression of 
FGFR2-IIIb has been described in breast, colorectal, cervical, pancreatic and prostate 
cancers; however, it may also act as a tumour suppressor (Turner and Gross, 2010). Hence, 
interactions between GAG mediated growth-factor binding to these TK receptors has the 
potential to modify the growth and metastatic potential of tumours, which may enable new 









1.24 The cell cycle 
 
Figure 1.11: The cell cycle showing the two major events that takes place within the cell. 
 
Control of the cell cycle is an extremely complex process that networks with 
numerous regulatory proteins, which control the events leading ultimately to proliferation, 
cell growth, organism development, regulation of DNA damage repair and diseases, such as 
cancer. The cell cycle can be divided into two major sections as illustrated in the diagram 
above (Figure 1.11). These are: Interphase, the non-dividing but metabolically active period 
of the cell cycle including Gap I (G1), DNA Synthesis (S), Gap (G2) and the Mitosis phase, 







comprising prophase, metaphase, anaphase, and talophase. (Peng 1998: Rickert 1996 and 
Roy 1994). G1 and G2 phases of the cycle represent the gaps between the two major events 
that occur in the cell i.e. synthesis and mitosis.  
The G1 phase is the first gap in the cycle in which the cell is preparing for synthesis of 
DNA (replication) and is also a growing stage for the cell. S-phase is the first major events in 
the cell cycle in which the cell starts synthesising new DNA. During the S-phase the new 
daughter strands of DNA for each chromosome is synthesised and as a result of this DNA 
replication, each chromosome gains a second chromatid, hence, duplication of genomic 
information takes place (Johnson and Walker, 1999).  
The G2 phase is the second gap in the cell cycle that occurs before the cell progress to 
mitosis and follows the DNA synthesis phase. During the G2 period of growth, materials are 
prepared for the next mitotic division. At this stage, the cell regulatory proteins check the 
entire cascade involved at the S-phase before the cell cross to this phase and if everything 
iscorrect, then the cell can progress to the next phase which is mitosis. The mitotic phase is 
where the actual cell division takes place through a cascade of events, as presented in the 
diagram below (Figure 1.12). Successful completion of mitosis leads to an onset of interphase 
and the cell begins a period of growth which spans through the first phase, called G1 and 
continues through the S and G2 phase. However, new cells generated from this series of 
events could either start a new cycle or remain in a state of quiescence known as G0. G0 is a 
gap between mitosis and interphase. At this stage, the cell is inactive and no physiological 










Figure 1.12: The four stages of mitosis 
 The cell cycle is a continuous event in both normal and cancer cells, including breast cancer. All the 
cell cycle events are strictly controlled by the regulatory proteins in order to control growth and development. 
However, there is uncontrolled and increased proliferation in cancer cells, especially breast cancer cells. This is 
probably a result of the impairments of some of the regulatory proteins that control or check abnormal 





1.25 Cell Cycle regulation 
 
 
Figure 1.13: The cell cycle and its regulation by cyclins, CDKs, and CDKIs. 
The cell cycle is divided into four distinct phases (G1, S, G2, and M). The progression of a cell through the cell 
cycle is promoted by CDKs, which are positively and negatively regulated by cyclins and CDKIs, respectively. 
As shown, cyclin D isoforms (cyclin D1–D3) interact with CDK4 and CDK6 to drive the progression of a cell 
through G1. The association of cyclin E with CDK2 is active at the G1-S transition and directs entry into S-
phase. S-phase progression is directed by the cyclin A/CDK2 complex, and the complex of cyclin A with Cdc2 
(also known as cdk1) is important in G2. Cdc2/cyclin B is necessary for the entry into mitosis. The INK4 (for 








, bind and inhibit cyclin 







, negatively regulate cyclin E/CDK2 and cyclin A/CDK2 complexes. 
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 The cell cycle is regulated strictly at selected checkpoints that are controlled by group 
of modulators known as cyclin and cyclin-dependent kinases (CDKs), cyclin-dependent 
inhibitors (CDKI) and retinoblastoma gene products (pRB). These modulators are the key 
regulatory factors that dictate the orderly progression of the cell cycle through the activation 
and deactivation processes (Johnson and Walker, 1999). A number of CDKs have been 
identified including CDKs A, B1, B2, C, D1, D2, D3, E and many more (Figure 1.13). All 
cyclins contain a cyclin box, an important domain used to bind and activate CDKs. Cyclins 
and CDKs are also involved in the regulation of cell transcription, DNA repair, 
differentiation, and apoptosis (Peng 1998: Rickert 1996 and Roy 1994). Phosphorylation of 
CDK subunits can both positively and negatively regulate kinase activity (Arellano 1997) and 
ubiquitin-mediated proteolysis plays another crucial role in cell cycle control by targeting 
cyclins and other regulators for destruction at key times during the cell cycle (King 1996 and 
Pagano 1997). Some CDK’s have been reported by LaBaer and co-workers to positively 
regulate the cell cycle by functioning as assembly factors for cyclin D/cdk complexes 
(LaBaer et al, 1997). CDK’s are regulated by several methods, one of which includes 
phosphorylation of threonine and tyrosine residue. CDK’s are very important to cell cycle 
control because its deactivation will prevent mitosis, which is the ultimate committal event in 
the cell cycle (Johnson and Walker, 1999).  
 
1.26 Role of Cell-cycle Regulatory molecules in Breast Cancer Development and  
    Progression 
The resulting DNA damage and the integrity of mitotic spindles caused by any 
intrinsic or extrinsic elements are assessed during transition between the four major phases of 
the cell cycle. Cell cycle progression is arranged by the relative activity of a family of serine 
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threonine kinases (Figure 1.14). The cyclins encode co-regulatory subunits of a holoenzyme 
that phosphorylates and inactivates a number of substrates including pRb (Hilakivi-Clarke et 
al, 2004). Cyclin D1 has been reported to be one of the commonly over expressed genes in 
breast cancer (Arnold and Papanikolaou, 2005: Sutherland and Musgrove, 2004). Oestrogen 
receptor (ER)-positive breast cancers has also been shown to produce cyclin D1 amplification 
and over expression more commonly than ER-negative cancers, and it is in the ER-positive 
subgroup that the most consistent association between cyclin D1 amplification and poor 
outcome has been found (Sutherland and Musgrove, 2004). Sutherland and others have 
suggested that the ability of cyclin D1 to modulate transcription may be important in 
mammary oncogenesis (reviewed in Arnold and Papanikolaou, 2005: Sutherland and 
Musgrove, 2004) 
 
1.27 Cyclin D1  
Cyclin D1 encodes the labile regulatory subunit of the cyclin CDK4/6 holoenzyme. 
Phosphorylation of the pRb protein is thought to change the confirmation of pRb which, in 
turn, alters further upon phosphorylation by cyclin E/CDK2 complexes. It is considered that 
the phosphorylation of the pRb protein by the cyclin D1/CDK4/6 holoenzymes is required for 
transition through the G1 /S-phase of the cell cycle. The cyclin D1 gene has been reported by 
Zwijsen and his co-workers to physically associate with the ER and induce ER signaling in a 
CDK-independent manner (Zwijsen et al, 1997).                                                                                                                                   
 Immuno-neutralizing experiments performed by Lukas et al have revealed that cyclin 
D1 is required for oestrogen-induced cellular proliferation (Lukas et al, 1996). It has also 
been shown to enhance ER signaling through functioning as a coactivator-like protein, 
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analogous to the p160 steroid receptor coactivator (SRC) of the ER, in cultured cells. 
Research has revealed that up to 30- 50% overexpression of Cyclin D1 is present in primary 
breast cancers, partly due to amplification of the cyclin D1 gene, CCND1; hence, cyclin D1 is 
one of the most commonly overexpressed oncogenes in breast cancer (Arnold and 
Papanikolaou, 2005: Sutherland and Musgrove, 2004). This overexpression effect of Cyclin 
D1 is more pronounced in ER-positive breast cancers than ER-negative cancers, and it is in 
the ER-positive subgroup that the most consistent association between cyclin D1 
amplification and poor outcome has been reported (Sutherland and Musgrove, 2004).  
 In addition, Cyclin D1 has been proven to be overexpressed in ductal hyperplasia and 
ductal carcinoma in situ as well as invasive cancers and these findings suggest that it may 
play a role in the evolution of breast cancer. In contrast to general opinion based on this 
finding that cyclin D1 overexpression might be expected to be associated with high 
proliferation rates, over expression of cyclin D1 in breast cancer is characteristic of slow-
growing, more differentiated cancers (Sutherland and Musgrove, 2004).  
Moreover, in a panel of breast cancer cell lines, CDK4 activity was not strictly related 
to cyclin D1 expression, suggesting that functions of cyclin D1 other than its ability to 
activate CDK4 and promote cell proliferation might contribute to its activity as a mammary 
oncogene ( Fu et al, 2004: Sutherland and Musgrove, 2004). Amplification of the cyclin D1 
gene, CCND1, is observed in just a few of cyclin D1 overexpressing breast cancers. 
Furthermore, Cyclin D1 has been implicated in the oncogenic actions of Ras and Neu/erbB2 
Murine mammary tumours induced by oncogene display increased expression of cyclin D1, 
while cyclin D1 expression is necessary for Ras or erbB2-mediated mammary tumourigenesis 
(Sutherland and Musgrove, 2004). However, the relationship between cyclin 
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D1overexpression and erbB2 amplification in human breast cancer is yet to be elucidated 
(Arnoldand Papanikolaou, 2005).  
   
1.28 Cyclin E1  
Cyclin E1 is reportedly overexpressed frequently in breast cancers, particularly ER-negative 
breast cancers. This observation is attributed to the presence of a number of low molecular 
weight isoforms, which appear to contribute to poor clinical outcomes (Sutherland and 
Musgrove, 2004). The low molecular weight isoforms display enhanced binding to CDK2 to 
produce a complex that is relatively resistant to inhibition by p21 and p27 (Wingate et al, 
2005). Moreover, cyclin E1 overexpression is of greater prognostic significance when p27 
expression is reduced and CDK2 activation increased (Caldon et al, 2010). The association 
between cyclin E1 overexpression and markers of proliferation together with the above 
mentioned role as suggested by Caldon and co-workers that the CDK dependent functions of 
cyclin E1 may be critical to its role in mammary oncogenesis (Caldon et al, 2010). 
                                                                                                                             
1.29 p27 and p21   
These two genes are tumour suppressor genes and many studies have confirmed this 
(Musgrove 2004). The role of p21 and its abundance as a modulator of outcome in primary 
breast cancer is still unclear. Expression is generally undetectable in normal breast epithelial 
cells and very variable in breast cancers, with conflicting data on the prognostic implications 
of p21 expression from a limited number of small patient groups (Tsihlias et al, 1999). 
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The use of p27 as a prognostic marker has been more widely investigated. Normal human 
mammary duct epithelial cells exhibit nuclear immunoreactivity for p27, while breast cancers 
often exhibit reduced p27 expression and/or mislocalisation of p27 to the cytosol (Alkarain et 
al, 2004). In general, reduced nuclear p27 expression is associated with high tumour grade 
and ER negativity, and in a small majority of studies, represents an independent prognostic 
indicator upon multivariate analysis (Alkarain et al, 2004). However, loss of heterozygosity 
at band 13 of chromosome 12, which harbours the p27 gene, has been reported in breast 
cancers, although, somatic mutations in this gene are rare (Alkarain et al, 2004), and the 
predominant mechanism for loss of protein expression appears to be linked to increased 
protein turnover. Newman and Spataro have reported that ErbB2 overexpression associates 
with low p27 levels in breast cancer patients overall (Newman et al, 2001) or in the 
lymphnode negative subset (Spataro et al, 2003). Hence, activation of signaling pathways 
downstream of this receptor may promote p27 degradation. However, RTK signaling can also 
lead to restriction of p27 to the cytosol. Additionally, in cancers with either low or high p27 
expression, the presence of cytosolic p27 was associated with worse overall survival rate 
(Alkarain et al, 2004). 
 
1.30 Therapeutic target in breast cancer                                                                                
 There are two major therapeutic approaches that are useful in the treatment of breast 
cancer; namely: the modulation of the cell cycle and direct inactivation of checkpoint 





1.31 Modulation of the cell cycle  
 Alteration to any of the major phases of the cell cycle may lead to carcinogenesis, 
which is a major concern in the field of cancer research. Subsequently, the cell cycle has 
become the bedrock of the major therapeutic interventions research, providing numerous 
opportunities to target checkpoint controls in order to develop new therapeutic strategies for 
combatting this disease.                                           
These include induction of checkpoint arrest leading to cytostasis and, ultimately, apoptosis; 
arrest of proliferating cells in defined stages of the cell cycle, which may in turn sensitize 
them to treatment with other therapeutic agents, such as radiation; and targeting therapies 
towards specific regulatory components of the cell cycle (Caldon et al, 2010). Those drugs 
that have diverse mechanisms of action and ex-chromosome breakage can cause cell cycle 
arrest at both the G1/S and G2/M checkpoints (Lowe et al, 1993).  
 The most common and reliable chemotherapeutic approach is the induction of DNA 
damage, followed dogmatically by induction of apoptosis. Some chromosome breakers and 
DNA cross links agents such as cisplatin and Mustard have been reported to cause cell cycle 
arrest at both G1/S and G2/M checkpoints (Lowe et al 1993). G1 arrest caused by these 
agents is mediated by p53, which in turn induces an increase in p21, resulting in inhibition of 
cyclin/CDK2 and cyclin/CDK4 complexes and hypophosphorylation of Rb (Robert and 
Thompson, 1979). Up-regulation of p21 also results in sequestration of PCNA, which 
contributes to arrest at G1/S. The G2/M checkpoint induced by DNA damage can occur by 
either p53-dependent or independent mechanisms (Paules et al, 1995: Agawal et al, 1995). 
Both p21 and phosphorylation of CDK1 is required for passage of cell from G2 phase into M-
phase and can participate in the DNA damage G2/M checkpoint. Tumour cells in which p53 
are inactive can bypass the G1/S checkpoint and exhibit increased sensitivity to DNA-
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damaging agents such as cisplatin (Fan et al, 1997) as a result of failure to arrest and repair 
their damaged DNA.  
Another intervention is also made possible by the use of microtubular inhibitors such 
as taxol and vinca alkyloids. These act principally by distrupting the normal tubular 
polymerisation/depolymerisation and mitotic spindle formation (Gorbsky 1997). Hence, the 
cells are forced either to initiate a p53-dependent arrest at the mitotic spindle assembly 
checkpoint (Cross et al., 1995), a radiosensitive phase of the cell cycle, or continue to 
progress through M-phase and become aneuploid and arrest in G1 (Argawa, 1995). 
 Arrest in G2/M induced by these drugs (taxol and vinca alkaloids) is associated with 
stabilization of cyclin B complexes (Poon et al, 1997). Tumour cells treated with microtubule 
inhibitors can undergo apoptosis from both G1 and G2 arrest (Wood et al, 1995). Microtubule 
inhibitors have also proven effective in the clinic as radiosensitizers (Liebmann et al, 1994). 
Combined chemotherapy/radiotherapy with taxol, which blocks cells at the mitotic spindle 
assembly checkpoint, can enhance the sensitivity of radiation-resistant tumours to 
radiotherapy (Liebmann et al, 1994: Tischler et al, 1992). 
 G1 checkpoint arrest can also be triggered by depletion of ribonucleotide pools, 
caused by nucleoside analogs such as hydroxyurea and gemcitibine. G1 arrest at a point may 
be totally distinct from that associated with DNA damage (Linke et al, 1996).This latter G1 
checkpoint is mediated by p53 and also requires up-regulation of p21 (Wharl et al,1997). In 
checkpoint-defective cells, such as those with inactive p53, bypass of the G1/S checkpoint 
produces DNA strand breaks, resulting in cell death (Chang et al, 1998). Both gemcitibine 
and hydroxyurea have also been effectively used as radio sensitizers for a variety of tumour 
types (Shewach and Lawrence, 1996). Anti-metabolites such as methotrexate and 5-
fluorouracil have been reported to inhibit thymidylate synthase and DNA synthesis and 
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induce a p53-dependent S-phase arrest (Matsui et al, 1996). However in tumour cells, in 
which p53 is inactive, DNA damage induced by these drugs goes undetected and cells 
progress to G2 and subsequently undergo apoptosis (Lowe et al, 1993).  
These drugs are also used clinically as radiosensitizers as a result of their ability to 
arrest cells in the radiosensitive phase of the cell cycle (Robertson et al, 1996). 
Topoisomerase inhibitors have been reported to also cause DNA damage, resulting in 
increased levels of cyclin A and S-phase arrest or inactivation of cyclin B/CDK2 complexes 
and G2/M arrest (Kaufmann et al, 1999). Moreover, the prominent role of p53/p21-mediated 
activity for many of the above-named drugs in addition to the activity of topoisomerase 
inhibitors can also be mediated by the Rb/p16 pathway. In some cell types, drugs such as 
camptothecin and etoposide produce an increase in p16, which inhibits phosphorylation of Rb 
resulting in a G1 cell cycle arrest (Shapiro, 1998).Therefore, in addition to p53; their activity 
may also be dependent on the presence of a functional Rb protein. Tumour cells that lack 
functional Rb can bypass this checkpoint and progress through the cell cycle, becoming 
genetically unstable and acquiring additional genetic alterations including changes in ploidy. 
 
1.32 Direct inactivation of checkpoint controls                                                                      
Some successful or potentially successful therapeutic strategies involve the use of agents that 
target cell cycle regulatory molecules. As mentioned previously, the activity of cyclin-kinase 
complexes is regulated by phosphorylation and several CDK inhibitors have been identified, 
which exhibit specificity for the ATP-binding pocket of these and block their phosphorylation 
CDKs (Walker et al, 1998). Chemical inhibitors of CDKs such as olomoucine and its analog 
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roscovitine exhibit specificity for CDK1 and CDK2 (Vesely, 1994). These inhibitors can 
induce both G1 and G2 arrest as well as apoptosis (Walker, 1998).  
As mentioned above, in response to DNA-damaging agents, some tumour cells can 
arrest in G2 in a p53-independent manner. This G2/M checkpoint arrest occurs as a result of 
phosphorylation and inactivation of CDK1. Staurosporine and its second-generation analog 
7-hydroxystaurosporine (UCN-01) inhibit the phosphorylation of CDK1, resulting in the 
activation of this M-phase regulator and abrogating the G2/M arrest (Wang et al,1996). Use 
of UCN-01 has been most successful in combination with DNA-damaging agents such as 
cisplatin (Bunch and Eastman, 1996) and camptothecin (Shao et al,1997) in p53- deficient 
cells that can bypass the G1 checkpoint and would otherwise arrest in G2. As a consequence 
of UCN-01 treatment, tumour cells that have sustained DNA damage progress through the 
cell cycle beyond the G2/M checkpoint and undergo apoptosis (Wang et al, 1995). Similar 
strategies with several agents (such as caffeine) that abrogate the G2 checkpoint by activating 
CDK1 have been shown to preferentially sensitize p53-deficient cells to other genotoxic 
agents such as radiation and etoposide (Yao et al, 1996). 
 Active cyclin D-kinase complexes, which serve to phosphorylate Rb and release E2F, 
can also be inhibited by small peptides derived from p16 (Fahraeus et al, 1998). A 20-amino-
acid peptide of p16 can bind CDK4; inhibit activation of cyclin D-CDK4 activity, and block 
cell cycle progression through G1. As predicted, this cell cycle arrest requires a functional Rb 
protein (Fahraeus et al, 1998). Similarly, double-stranded DNA with high affinity for E2F can 
act as a molecular decoy, compete for E2F binding to DNA, and inhibit the ability of E2F to 




Targeting of breast cancer by anti-angiogenic drugs available to date have been shown 
to be a failure and regulators of the cell cycle in conjunction with radiotherapy and surgery 
are still the mainstay in the treatment of the disease. However, during the next 20 years more 
targeted therapy is likely to become the preferred method of treatment. It is hoped that the 
results shown in this study could lead to a new class of targeted cancer therapeutics aimed 

















1.33 Cell death                                                                                                                              
 Natural death is an integral part of cell development and this was also described by 
Cotter and Curtin as a natural event that can be related to an integral part of toad development 
(Cotter and Curtin, 2003). Natural death has been described newly in many ways after this 
observation. There are two major mechanisms by which cells undergo natural death: necrosis 
or apoptosis. 
 
1.34 Necrosis                                                                                                                                        
 Necrosis, otherwise known as cell murder, is described as the death of cells through 
external damage (extrinsic factors), usually caused by destruction of the plasma membrane or 
the biochemical pathways that support the cells integrity. The necrotic cell is characterised by 
swollen morphology and plasma membrane lyses, which releases cytoplasmic components 
(necrotic debris) into the surrounding tissue spaces, attracts inflammatory cells and ultimately 
leads to the tissue destruction characteristic of inflammation. The death of a single cell by this 
mechanism might be resolved in some tissues, but a large number of cells dying by necrosis 
usually results in inflammation, subsequent repair and scarring; leading to compromise and 
permanent alteration of tissue architecture.  
 Necrosis can occur in a matter of seconds (Collins et al, 1997) and also can cause loss 
of cell-membrane integrity followed by swelling of both cytoplasm and mitochondria; 
ultimately resulting to cell and many of its internal organelles lyses’ (Leist and Jäättelä, 
2001). The products of necrotic cells are usually phagocytosed by macrophages, and this 
process provokes an inflammatory response in vivo. Necrosis-like programmed cell death 
describes programmed cell death that does not involve chromatin condensation and has 
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varying degrees of other apoptotic features. In some cases caspase-1 and caspase-8 have been 
implicated in this type of programmed cell death (Leist and Jäättelä, 2001). Some of the 
factors that lead to necrosis are detailed in the following sections. 
 
1.35 Pathophysiology and physiological factors leading to necrosis 
 Cell and tissue death is a common phenomenon that usually arises suddenly as a result 
of some extreme conditions (high temperature, heat shock etc): a process that leads to 
unregulated process of both membranes and cytosol destruction. This finding led to the 
concept that when cell destruction is followed by rapid disruptions of the plasma membrane, 
cytoplasmic structures, and the nucleus, death is passive and unregulated. However, necrotic 
cell death could also be regulated by some specific physiological conditions such as bacterial 
infections, viral infection, bacterial toxins etc. (Warny et al, 2000: Dong et al, 1997). 
 Necrosis can also be triggered by components of the immune system, such as 
complement (Shimizu et al, 2000), activated natural killer cells (Blom et al, 1999), and 
peritoneal macrophages (Arantes et al, 2000).The pathogen-induced necrotic programs in 
cells of immunological barriers (e.g. intestine mucosa) may reduce invasion of pathogens 
through the surfaces affected by inflammation (Ehlers et al, 1999). 
 Necrotic cell death can also result from pathological conditions that are characterised 
by inadequate secretion of cytokines, nitric oxide (NO) and reactive oxygen species (ROS). A 
classic example of necrotic conditions is ischemia that leads to a drastic depletion of oxygen, 
glucose, and other trophic factors and evokes massive necrotic death of endothelial cells and 




1.36 Apoptosis                                                                                                                        
 Apoptosis is a form of cell death that usually occurs when cell is exposed to 
unfavourable conditions such as heat, hypoxia, and radiation, cytotoxic anti cancer drugs, 
toxicants or any physical damage (Elmore 2007). It is usually initiated in order to prevent 
inflammation associated with necrotic process by a careful removal of damaged cells from 
injury sites (Fin et al, 2005). Initiation of apoptosis triggers a series of events that culminate 
in the cell’s destruction. This process is usually called "programmed cell death" as it is an 
innate response of the cell that protects the remainder of the organism from a potentially 









Figure 1.14: The processes involved in apoptosis 
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 Apoptosis also describes a common mechanism by which cell undergoes natural 
death. It involves cascades of preprogrammed arranged events, including morphological and 
biochemical changes, which qualifies it as an example of programmed cell death (Wyllie et 
al, 1980). During the initial phases of apoptosis, cells shrink and their nuclei condense, after 
which they disintegrate into well-enclosed apoptotic bodies (Figure 1.14). The common 
features of apoptosis include cell shrinkage, plasma membrane blebbing, cell detachment, 
externalization of phosphatidylserine, nuclear condensation and ultimately DNA 
 fragmentation (Brauchle et al., 2014: Majno and Joris, 1995).  
Apoptosis is a normal occurrence during development and aging and as a homeostatic 
mechanism to maintain cell populations in tissues: it also occurs as a defence mechanism, 
such as in immune reactions or when cells are damaged by disease or noxious agents 
(Norbury and Hickson, 2001). However, many stimuli and conditions including physiological 
and pathological are among other factors that triggers apoptosis; yet not all cells will 
necessarily die in response to the same stimulus. At low doses, irradiation or some cytotoxic 
drugs used for cancer chemotherapy results in DNA damage in some cells, ultimately, 
leading to apoptotic death through a p53-dependent pathway (Elmore, 2007). Some cells 
express Fas (Fatty acid synthetase) or TNF (Tumour necrosis factor) receptors that can lead 
to apoptosis via ligand binding and protein cross-linking. Other cells have a default death 
pathway that must be blocked by a survival factor such as a hormone or growth-factor 
(Elmore, 2007).   
 Apoptosis and necrosis can occur independently, sequentially and simultaneously, but 
there is need to make a clear distinction between the two processes  
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(Zeiss 2003: Hirsch 1997 ); the type of stimuli and/or the degree of stimuli play a critical role 
in this process. Interestingly, low doses of some environmental perturbations such as heat, 
radiation, hypoxia and cytotoxic anti-cancer drugs can induce apoptosis but these same 
stimuli can result in necrosis at higher doses. In addition, apoptosis is a coordinated and often 
energy-dependent process that involves the activation of a group of cysteine proteases called 
“caspases” and a complex cascade of events that link the initiating stimuli to the final demise 
of the cell (Elmore, 2007: Fin et al 2005). Apoptosis can also be seen as a stage-dependent 






Figure 1.15: Stages of apoptosis 
(A) Full blown apoptotic Figure (early apoptosis); (B) Different forms of chromatin aggregation 







1.37 Morphology of Apoptosis 
 There are various morphological changes that occur during apoptosis and some of 
these changes were characterised by nuclear and cytoplasmic condensation, and cellular 
fragmentation into membrane-bound fragments. Early apoptosis is usually characterised by 
cell dehydration followed by changes in cell size and shape, resulting into smaller, dense 
cytoplasmic and more tightly packed organelles cells (Fink and Cookson 2005). The 
membrane bound fragments or apoptotic bodies (Figure1.16C) are consequently engulfed by 
microphages, parenchyma cells, or neoplastic cells and are desolved within the 
phagolysosomes (Figure 1.16D). This process allows cell deletion with little tissue disruption 
and no inflammation.  
 The process of apoptosis and removal of apoptotic cells are practically free of 
inflammatory reaction. Lockshin and William suggested this process of tissue deletion 
without inflammation allows reutilization of cellular components (Lockshin and William, 
1965). The morphological characteristics of apoptosis were purported to result from a general 
mechanism of controlled cell deletion, which plays a complementary role to mitosis and 
cytokinesis in maintaining stable cell populations within tissues. The concept of apoptosis 
furthered the hypothesis that living cells are programmed genetically to contain components 
of a metabolic cascade that, when activated, can lead to cellular death (Lockshin and Zakeri, 
2001).  
Various morphological changes that occur during apoptosis can be measured by 
scatter light analysis (flow cytometry) and some of these changes are characterised by some 
of the features described above. In short, the cells traversing through the focus of a laser 
beam in a flow cytometer scatters the laser light. Analysis of the degree of scattered light 
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gives indepth information about the morpholical changes that characterise the onset of 
apoptosis (Darzynkiewicz et al 1992).  
 Hacker also described the various morphological changes that occur in apoptosis by 
light and electron microscopy (Hacker, 2000). Cells view under the electron microscope 
shows cell shrinkage and pyknosis as the major morphological changes that characterised 
early stage of apoptosis (Kerr et al., 1972). On histologic examination with haematoxylin and 
eosin stain, apoptosis involves single cells or small clusters of cells. The apoptotic cell 
appears as a round or oval mass with dark eosinophilic cytoplasm and dense purple nuclear 
chromatin fragments (Figure 1.16 A). Electron microscopy also shows other subcellular 
changes that occur during early chromatin condensation and some of these changes involve 
aggregation of electron-dense nuclear material under the nuclear membrane although there 
can also be uniformly dense nuclei (Figures 1.16 B). This process leads to extensive plasma 
membrane blebbing followed by karyorrhexis and separation of cell fragments into apoptotic 
bodies during a process called “budding.” The organelle integrity is still maintained and all of 
this is enclosed within an intact plasma membrane. Macrophages that engulf and digest 
apoptotic cells are called “tingible body macrophages” and are found frequently within the 
reactive germinal centers of lymphoid follicles or occasionally within the thymic cortex. The 
tingible bodies are the bits of nuclear debris from the apoptotic cells. The anti inflammatory 
activity associated with both apoptosis process and removal of apoptotic bodies is due to the 
following reasons: (1) apoptotic cells do not release their cellular constituents into the 
surrounding interstitial tissue; (2) they are quickly phagocytosed by surrounding cells thus 
likely preventing secondary necrosis; and (3) the engulfing cells do not produce anti-






Figure 1.16: Morphology of apoptosis. 
(A) Normally shaped nuclei (B) Chromatin clumping in apoptotic nuclei (C) Different features of 








1.38 Biochemical features of apoptosis                                                                   
 Apoptotic cells have been described previously as exhibiting several biochemical 
modifications, such as protein cleavage, protein cross-linking, DNA breakdown, and 
phagocytic recognition that together result in the distinctive structural pathology (Hengartner 
2000). There are various biochemical features that ensue once apoptosis programme has been 
initiated and some of these biochemical features are discussed below; 
 
1.39 Activation of caspases 
Activation of caspases is one of the biochemical features of programme cell death. This 
process is trigerred by some of the external stimuli that causes apoptosis. Caspases are 
usually expressed widely in an inactive proenzyme form in most cells: activation of this 
proenzymes lead to casdade of events including activation of other procaspases, initiation of a 
protease cascade, aggregation and autoactivation of other procaspases. This cascade of events 
amplifies the apoptotic signaling pathway; thus leading to rapid cell death (Figure 1.17). 
Caspases have proteolytic activity and are able to cleave proteins at aspartic acid residues, 
although different caspases have different specificities involving recognition of neighbouring 
amino acids. Once caspases are activated, there appears to be an irreversible commitment 
towards cell death (Elmore 2007).  
 Ten major caspases have been identified and categorised broadly into initiators 
(caspase-2,-8,-9,-10) (Cysteinyl aspartic acid-protease-2-8-9-10), effectors or executioners 
(caspase-3,-6,-7) (Cysteinyl aspartic acid-protease-3-6-7) and inflammatory caspases 
(caspase-1,-4,-5) (Cysteinyl aspartic acid-protease-1-4-5) (Cohen, 1997; Rai et al, 2005). 
Other caspases such as caspase-11 (Cysteinyl aspartic acid-protease-11), have been shown to 
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regulate apoptosis and cytokine maturation during septic shock and caspase-12 (Cysteinyl 
aspartic acid-protease). This mediates endoplasmic-specific apoptosis and cytotoxicity by 
amyloid-β has been reported (Kang et al, 2002: Koenig et al, 2001: Nakagawa et al, 2000: Hu 
et al, 1998). Extensive protein cross-linking is another characteristic of apoptotic cells, which 


















1.40 DNA fragmentation 
 DNA fragmentation is one of the earliest recognizable changes that characterised 
irreversible commitment to programmed cell death (Wyllie 1980). This process is initiated by 




dependent endonucleases, resulting in DNA 
fragments of 180 to 200 base pairs (Bortner et al, 1995).  Oberhammer and co workers have 
reported that formation of the larger DNA fragments is unconnected to oligonucleosome 
formation (Oberhammer et al., 1993). Similarly, cleavage of DNA into these larger fragments 
is sufficient to allow chromatin condensation and subsequent apoptosis, without 
oligonucleosome formation. DNA fragmentation can be clearly seen when the sample are run 
on agarose gel electrophoresis and stained with ethidium bromide:  a characteristic ladder 
pattern is evident when viewed under UV light (Allen et al 1997).  
 
1.41 Phosphatidylserine (PS) Translocation 
Translocation of PS is another biochemical changes that takes place during early 
apoptosis (Allen et al 1997). Bratton and co-workers described this biochemical feature of 
apoptosis as the expression of cell-surface markers that result in the early phagocytic 
recognition of apoptotic cells by adjacent cells, permitting quick phagocytosis with little 
compromise to the surrounding tissue. This is achieved by the movement of the normal 
inward-facing phosphatidylserine of the cell’s lipid bilayer to expression on the outer layers 
of the plasma membrane (Bratton et al, 1997). Although externalization of phosphatidylserine 
is a popular identified ligand for phagocytes on the surface of the apoptotic cell, however, 
recent studies have shown that other proteins like annexin1and calreticulin are also exposed 
on the cell surface during apoptotic cell clearance. 
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Annexin V, an anticoagulant with other biological effects, is a member of a family of 
proteins which exhibits Ca
2+
-dependent binding to negatively charged phospholipids (Allen 
et al 1997). Annexin V binds strongly and specifically to phosphatidylserine residues and can 
be used for the detection of apoptosis (Allen et al 1997). Externalisation of PS occurs in early 
apoptosis when membrane integrity is still intact: this process make flow cytometric analysis  
using fluorescein isothiocyanate- (FITC) labeled annexin V a useful quantitative measure of 
early apoptosis;  this method has also been used with the DNA intercalating dye PI.  During 
apoptosis the cells become reactive with annexin V after the onset of chromatin condensation 
but prior to the loss of the plasma membrane (Arur et al, 2003). Annexin V binding has been 
shown to reveal a much higher level of cells committed to apoptosis than PI staining, 
However, PI staining enter necrotic cells while apoptotic cells are excluded (Allen et al 
1997). Calreticulin is a protein that interacts with LDL (low density lipoprotein)- receptor-
related protein on the engulfing cell and is suggested to cooperate with phosphatidylserine as 
a recognition signal (Gardai et al, 2005). The adhesive glycoprotein, thrombospondin-1, can 
be expressed on the outer surface of activated microvascular endothelial cells and, in 
conjunction with CD36 (Cluster of differentiation 36), caspase-3-like proteases and other 
proteins, induce receptor-mediated apoptosis (Jimenez et al, 2000). 
 
 
1.42 Mechanisms of apoptosis                                                                                                      
The mechanisms of apoptosis have been described as a complex and sophisticated processes 
involving energy-dependent cascade of molecular events (Figure 1.18). There are two major 
mechanisms by which cells commit suicide by apoptosis, namely the extrinsic or death-
receptor pathway and the intrinsic or mitochondrial pathway (Figure 1.18). However, Igney 
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and Krammer have recently shown that the two pathways are linked and that molecules in 
one pathway can influence the other (Igney and Krammer, 2002). There is also an additional 
pathway known as perforin/granzyme which involves T-cell mediated cytotoxicity and 
perforin-granzyme-dependent killing of the cell. The perforin/granzyme pathway can induce 
apoptosis via either granzyme B or granzyme A (Elmore 2007).  
 The extrinsic, intrinsic, and granzyme B pathways converge on the same terminal 
otherwise known as execution pathway. This pathway is initiated by the cleavage of caspase-
3 and results in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-
linking of proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell 
receptors and finally uptake by phagocytic cells (Elmore 2007). The granzyme A pathway 
activates a parallel, caspase-independent cell death pathway via single stranded DNA damage 













1.43 Extrinsic Pathway (caspase -8 apoptosis)                                                                                                                
 The extrinsic signaling pathways that initiate apoptosis involve activation of caspace 
3- which is usually activated either by caspase -8 or -9. Activation of caspase -8 involves 
transmembrane receptor-mediated interactions which also include death receptors 
 (FasL/FasR,TNF-α/TNFR1, Apo3L/DR3 (Apo3 ligand/ Death-receptor 3), Apo2L/DR4 
(Apo2 ligand/ Death-receptor 4) , and Apo2L/DR5 (Apo2 ligand/ Death-receptor 5) that are 
members of the TNF receptor gene super family ( Weber et al 2010: Rubio-Moscardo et al, 
2005: Locksley et al, 2001: Suliman et al, 2001: Ashkenazi et al, 1998: Peter and 
Kramer,1998: Chicheportiche et al, 1997).   
 Ashkenazi and Dixit also reported that members of the TNF receptor family share 
similar cysteine-rich extracellular domains and have a cytoplasmic domain of about 80 amino 
acids called the “death domain” (Ashkenazi and Dixit, 1998). This plays a critical role in 
transmitting the death signal from the cell surface to the intracellular signaling pathways. The 
sequence of events that define the extrinsic phase of apoptosis are best characterised with the 
FasL/ FasR (Fatty acid synthetase ligand /Fatty acid synthetase receptor) and TNF-α /TNFR1 
(tumour necrosis factor-alpha /tumour necrosis factor receptor 1) models, which involve 
clustering of receptors and binding with the homologous trimeric ligand. Upon ligand 
binding, cytoplasmic adapter proteins are recruited which exhibit corresponding death 
domains that bind with the receptors.  
 The binding of Fas ligand to Fas receptor results in the binding of the adapter protein 
FADD (Fas-associated death domain) and the binding of TNF ligand to TNF receptor results 
in the binding of the adapter protein TRADD (TNF receptor-associated death domain) with 
recruitment of FADD and RIP (Receptor-interacting protein) (Wajant, 2002:  Hsu et al, 
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1995). FADD then associates with procaspase-8 via dimerization of the death effector 
domain, leading to the formation of a mitochondrial permeability transition (MPT). 
Subsequently, this causes auto-catalytic activation of procaspase-8 (Pro cysteinyl aspartic 
acid-protease 8) (Kischkel et al, 1995). Activation of caspase-8 automatically triggers the 
execution phase of apoptosis (Figure 1.18). 
 
1.44 Intrinsic Pathway (mitochondria apoptosis)                                                                                                                      
Mitochondria apoptosis appears to be much more common than caspase -8 dependent 
apoptosis in vivo and this apoptotic pathway is controlled by bcl-2 (B-cell lymphoma protein 
2) family of proteins (Cory and Adams, 2002).  BH3 protein belonging to bcl-2 protein 
family is the only protein that usually regulates the activation of the effectors Bax and Bak 
(Figure 1.18). Once Bax and Bak are activated, cytochrome c will be authomatically released 
from the mitochondria intermembrane space into the cytosol, where it binds to Apaf-1 
inducing its oligomerisation and thereby causing the activation of caspase-9 (Grepsi et al 
2010). Some stimuli like, radiation, toxins, hypoxia, hyperthermia, viral infections, free 
radicals have been reported to cause such changes in the inner mitochondria leading to an 
opening of the MPT pore, loss of the mitochondrial transmembrane potential and release of 
two main groups of normally sequestered pro-apoptotic proteins from the intermembrane 
space into the cytosol (Saelens et al., 2004). The clustering of procaspase-9 in this manner 
leads to caspase-9 activation. Smac/DIABLO and HtrA2/Omi (second mitochondrial 
activator of caspases/direct IAP binding protein with low PI) has been reported to promote 
apoptosis by inhibiting IAP (inhibitors of apoptosis proteins) activity (Schimmer 2004: Van 
Loo et al, 2002).  
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 The second group of pro-apoptotic proteins, AIF (Apoptosis Inducing Factor), 
endonuclease G and CAD (Caspase-Activated DNAse), are released from the mitochondria 
during apoptosis, but this is a late event that occurs after the cell has committed to die. AIF 
translocates to the nucleus and causes DNA fragmentation into ~50,300 kb pieces and 
condensation of peripheral nuclear chromatin (Joza et al, 2001). This early form of nuclear 
condensation is referred to as “stage I” condensation (Susin et al, 2000). Endonuclease G also 
translocates to the nucleus where it cleaves nuclear chromatin to produce oligonucleosomal 
DNA fragments (Li et al, 2001). AIF and endonuclease G both function in a caspase-
independent manner. CAD is subsequently released from the mitochondria and translocates to 
the nucleus where, after cleavage by caspase-3, it leads to oligonucleosomal DNA 
fragmentation and a more pronounced and advanced chromatin condensation (Enari et al, 
1998). This later and more pronounced chromatin condensation is referred to as “stage II” 
condensation (Susin et al, 2000).The control and regulation of these apoptotic mitochondrial 
events occurs through members of the Bcl-2 family of proteins. The anti-apoptotic members 
of the Bcl-2-family appear to block apoptosis by binding either BH3-only proteins or 
Bax/Bak (Grepsi et al 2010).    
 
1.45 Perforin/granzyme Pathway                                                                                                      
T-cell mediated cytotoxicity is a variant of type IV hypersensitivity where sensitized CD8
+ 
(Cluster of differentiation 8
+
) cells kill antigen-bearing cells. These cytotoxic T lymphocytes 
(CTLs) are able to kill target cells via the extrinsic pathway and the FasL/FasR interaction is 
the predominant method of CTL-induced apoptosis (Brunner et al, 2003). Conversely, they 
can also exert their cytotoxic effects on tumour cells and virus-infected cells through a new 
pathway that involves secretion of the transmembrane pore-forming molecule called perforin 
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with a subsequent exophytic release of cytoplasmic granules through the pore and into the 
target cell (Trapani and Smyth, 2002).  
 The serine proteases granzyme A and granzyme B are the most important component 
within the granules. Granzyme B will cleave proteins at aspartate residues and this leads to 
activation of procaspase-10 and can cleave factors like ICAD (inhibitor of caspase-activated 
DNase) (Sakahira et al, 1998). Barry and Bleackley and others have also shown that 
granzyme B can utilise the mitochondrial pathway for amplification of the death signal by 
specific cleavage of BID and induction of cytochrome c release (Barry and Bleackley, 2002; 
Russell and Ley, 2002). However, granzyme B can also directly activate caspase-3 by passing 
the upstream signaling pathways resulting into direct induction of the execution phase of 
apoptosis (Elmor, 2007). Goping and co-researchers has suggested that both the 
mitochondrial pathway and direct activation of caspase-3 are critical for granzyme B-induced 
killing (Goping et al, 2003). Recent research has shown that this method of granzyme B 
cytotoxicity is critical as a control mechanism for T-cell expansion of type 2 helper T (Th2) 
cells (Devadas et al., 2006). In addition, findings indicate that neither death receptors nor 
caspases are involved with the T-cell receptor-induced apoptosis of activated Th2 cells 
because blocking their ligands has no effect on apoptosis. On the other hand, Fas-Fas ligand 
interaction, adapter proteins with death domains and caspases are all involved in the 
apoptosis and regulation of cytotoxic Type 1 helper cells whereas granzyme B has no effect 
(Elmore 2007). 
 Granzyme A is also important in cytotoxic T-cell induced apoptosis and activates 
caspase-independent pathways. Once in the cell, granzyme A activates DNA nicking via 
DNAse NM23-H1, a tumour suppressor gene product (Fan et al, 2003). This DNAse has an 
important role in immune surveillance to prevent cancer through the induction of tumour-cell 
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apoptosis. Granzyme A protease cleaves SET (the nucleosome assembly protein that 
normally inhibits the NM23-H1 gene) complex thereby releasing inhibition of NM23-H1, 
resulting in apoptotic DNA degradation. In addition to inhibiting NM23-H1, the SET 
complex has important functions in chromatin structure and DNA repair. The proteins that 
make up this complex (SET, Ape1, pp32, and HMG2) appear to work together to protect 
chromatin and DNA structure (Lieberman and Fan, 2003). Therefore, inactivation of this 
complex by granzyme A most likely also contributes to apoptosis by blocking the 
maintenance of DNA and chromatin structure integrity. 
 
1.46 Execution Pathway                                                                                                        
Execution pathway is the final pathway of apoptosis and both extrinsic and intrinsic 
pathways end at the point. This phase of apoptosis is initiated by the activation of the 
execution caspases. Execution caspases activate cytoplasmic endonuclease, which degrades 
nuclear material, and proteases that degrade the nuclear and cytoskeletal proteins. Caspase-
3,caspase-6, and caspase-7 function as effector or “executioner” caspases, cleaving various 
substrates including cytokeratins, PARP (Poly (ADP-ribose) polymerase), the plasma 
membrane cytoskeletal protein alpha fodrin, the nuclear protein NuMA (Nuclear mitotic 
apparatus protein) etc., that ultimately cause the morphological and biochemical changes seen 
in apoptotic cells (Slee et al, 2001).  
 Caspase-3 is known to be the most important of the executioner caspases and is 
activated by any of the initiator caspases (caspase-8, caspase-9, or caspase-10). Caspase-3 
specifically activates the endonuclease CAD. In proliferating cells CAD is complexed with 
its inhibitor, ICAD (Inhibitor of CAD). In apoptotic cells, activated caspase-3 cleaves ICAD 
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to release CAD (Sakahira et al, 1998). CAD then degrades chromosomal DNA within the 
nuclei resulting to chromatin condensation. Caspase-3 also triggers cytoskeletal 
reorganisation and disintegration of the cell into apoptotic bodies.  
 Gelsolin, an actin binding protein, has been identified as one of the key substrates of 
activated caspase-3. Gelsolin will typically act as a nucleus for actin polymerisation and will 
also bind phosphatidyl inositol biphosphate, linking actin organisation and signal 
transduction. Caspase-3 will cleave gelsolin and the cleaved fragments of gelsolin, in turn, 
cleave actin filaments in a calcium independent manner. These result in disruption of the 
cytoskeleton, intracellular transport, cell division, and signal transduction (Kothakota et al, 
1997). Phagocytic uptake of apoptotic cells is the last component of apoptosis. Phospholipid 
asymmetry and externalization of phosphatidyl serine on the surface of apoptotic cells and 
their fragments is the hallmark of this phase. Although the mechanism of phosphatidyl serine 
translocation to the outer leaflet of the cell during apoptosis is not well understood, it has 
been associated with loss of aminophospholipid translocase activity and nonspecific flip-flop 
of phospholipids of various classes (Bratton et al, 1997). Ferraro-Peyret and others have 
shown that Fas, caspase-8, and caspase-3 are involved in the regulation of phosphatidyl 
serine externalization on oxidatively stressed erythrocytes, however caspase-independent 
phosphatidyl serine exposure occurs during apoptosis of primary T lymphocytes (Mandal et 
al., 2005: Ferraro-Peyret et al, 2002). The appearance of phosphatidyl serine on the outer 
leaflet of apoptotic cells then facilitates non-inflammatory phagocytic recognition, allowing 
for their early uptake and disposal (Fadok et al, 2001). This process of early and efficient 





1.47 Importance of Apoptosis 
Apoptosis plays significant roles in normal physiology relative to its counterpart, 
mitosis. Although it demonstrates a complementary but opposite role to mitosis and cell 
proliferation in the regulation of various cell populations. It is estimated that to maintain 
homeostasis in the adult human body, around 10 billion cells are made each day just to 
balance those dying by apoptosis (Renehan et al, 2001). This number can increase 
significantly when there is enhanced apoptosis during normal development and aging, or 
during disease. Apoptosis is also critically important during various developmental processes 
(Opferman and Korsmeyer, 2003: Nijhawan et al, 2000). 
Furthermore, apoptosis is significant in getting rid of the body pathogen-invaded 
cells; moreover, it is an important component of wound healing due to its involvement in the 
removal of inflammatory cells and the evolution of granulation tissue into scar tissue 
(Greenhalgh, 1998). Dysregulation of apoptosis during wound healing can lead to pathologic 
forms of healing, such as excessive scarring and fibrosis. Apoptosis is also required to 
eliminate activated or auto-aggressive immune cells either during maturation in the central 
lymphoid organs (bone marrow and thymus) or in peripheral tissues (Osborne, 1996). 
Moreover, apoptosis is central to remodelling in the adult, such as the follicular 
atresia of the postovulatory follicle and post-weaning mammary gland involution, just to 
mention a few (Lund et al, 1996: Tilly, 1991). Further, as organisms’ age, some cells begin to 
deteriorate at a faster rate and are eliminated via apoptosis. One theory is that oxidative stress 
plays a primary role in the pathophysiology of age-induced apoptosis via accumulated free-
radical damage to mitochondrial DNA (Ozawa, 1995: Harman, 1992). Apoptosis has to be 




1.48 Apoptosis and Necrosis: compare and contrast                                                         
Necrosis, a known toxic process whereby the cell is a passive victim and follows an energy-
independent mode of death, has been considered an alternative cell death to apoptosis. 
Although necrosis, as a form of cell death, has been a subject of debate since it refers to the 
degradative processes that occur after cell death, it is considered by some to be an 
inappropriate term to describe the mechanism of cell death (Elmore, 2007). Oncosis is 
therefore used to describe a process that leads to necrosis with karyolysis and cell swelling 
whereas apoptosis leads to cell death with cell shrinkage, pyknosis, and karyorrhexis (Majno 
and Joris, 1995; Levin et al., 1999).  
 Necrosis is also considered an uncontrolled and passive process that usually affects 
large fields of cells whereas apoptosis is controlled and energy-dependent and can affect 
individual or clusters of cells. Necrotic cell injury is mediated by two major mechanisms: 
interference with the energy supply of the cell; and direct damage to cell membranes. 
Whereas, apoptosis is mediated by two major mechanisms: extrinsic or death-receptor 
pathway; and the intrinsic or mitochondrial pathway (Figure 1.18). There is also an additional 
pathway, known as perforin/granzyme (Elmore, 2007). 
  Some of the major morphological changes that occur with necrosis include cell 
swelling; formation of cytoplasmic vacuoles; distended endoplasmic reticulum; formation of 
cytoplasmic blebs; condensed, swollen or ruptured mitochondria; disaggregation and 
detachment of ribosomes; disrupted organelle membranes; swollen and ruptured lysosomes; 
and eventually disruption of the cell membrane (Trump et al, 1997: Majno and Joris, 1995: 
Kerr et al, 1972). This loss of cell-membrane integrity results in the release of the 
cytoplasmic contents into the surrounding tissue, sending chemotatic signals with eventual 
recruitment of inflammatory cells (Figure 1.19).  
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 In contrast to necrotic cells, apoptotic cells do not release their cellular constituents 
into the surrounding interstitial tissue and are quickly phagocytosed by macrophages or 
adjacent normal cells, and there is ultimately no inflammatory reaction (Kurosaka et al, 2003: 
Savill and Fadok, 2000). Although the mechanisms and morphologies of apoptosis and 
necrosis differ, there is overlap between these two processes. Research has shown that 
necrosis and apoptosis represent morphologic expressions of a shared biochemical network 
described as the “apoptosis necrosis continuum” (Zeiss, 2003). For example, two factors that 
will convert an ongoing apoptotic process into a necrotic process include a decrease in the 
availability of caspases and intracellular ATP (Denecker et al, 2001: Leist et al, 1997). 
Whether a cell dies by necrosis or apoptosis depends in part on the nature of the cell death 
signal, the tissue type, the developmental stage of the tissue and the physiologic milieu 
(Zeiss, 2003: Fiers et al, 1999).  
 Therefore, distinguishing necrosis from apoptosis is regarded as a difficult task; 
especially with the use of conventional histology. This is because the two processes can occur 
simultaneously, depending on factors such as the intensity and duration of the stimulus, the 
extent of ATP depletion and the availability of caspases (Zeiss, 2003). It is also important to 
note that pyknosis and karyorrhexis are not exclusive to apoptosis and can be a part of the 
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1.49 Apoptosis and Cancer 
Abnormalities in cell death regulation can be a significant component of diseases such 
as cancer. Cancer formation is a possibility when there is dysfunctional regulation of the 
normal mechanisms of cell cycle, with either an over proliferation of cells and/or decreased 
removal of cells (King and Cidlowski, 1998). In fact, suppression of apoptosis during 
carcinogenesis is thought to play a central role in the development and progression of some 
cancers (Wong 2011: Kerr et al, 1994). There are a variety of molecular mechanisms that 
tumour cells use to suppress apoptosis and some of these molecular mechanisms are briefly 
discussed below: Tumour cells can acquire resistance to apoptosis by the expression of anti-
apoptotic proteins such as Bcl-2 (B-cell lymphoma protein 2) or by the down-regulation or 
mutation of pro-apoptotic proteins such as Bax (Bcl-2 associated X protein). The expression 
of both bcl-2 and bax is regulated by the p53 tumour suppressor gene (Miyashita, 1994). 
Vaux and co workers reported that certain forms of human B-cell lymphoma have 
overexpression of Bcl-2, and this is one of the first and strongest lines of evidence that failure 
of cell death contributes to cancer (Vaux et al, 1988).  
Another method of apoptosis suppression in cancer involves evasion of immune 
surveillance (Smyth et al, 2001). Certain immune cells (T cells and natural killer cells) 
normally destroy tumour cells via the perforin/granzyme B pathway or the death-receptor 
pathway. In order to evade immune destruction, some tumour cells will diminish the response 
of the death-receptor pathway to FasL produced by T cells. This has been proven to occur in 
a variety of ways including down-regulation of the Fas receptor on tumour cells. Other 
mechanisms include expression of non-functioning Fas receptor, secretion of high levels of a 
soluble form of the Fas receptor that will sequester the Fas ligand or expression of Fas ligand 
on the surface of tumour cells (Elnemr et al, 2001: Cheng et al, 1994). In addition, some 
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tumour cells are capable of a Fas ligand-mediated “counter attack” that results in apoptotic 
depletion of activated tumour infiltrating lymphocytes (Koyama et al, 2001). 
Alterations of various cell signaling pathways can result in dysregulation of apoptosis 
and lead to cancer; for example, the p53 tumour suppressor gene is a transcription factor that 
regulates the cell cycle. This is the most widely mutated gene in human tumourigenesis 
(Wang and Harris, 1997). The critical role of p53 is evident by the fact that it is mutated in 
over 50% of all human cancers. p53 can activate DNA repair proteins when DNA has 
sustained damage, can hold the cell cycle at the G1/S regulation point on DNA damage 
recognition, and can initiate apoptosis if the DNA damage proves to be irreparable 
(Pientenpol and Stewart, 2002) and dysregulation of this system can lead to tumourigenesis. 
For example, if the p53 gene is damaged (by chemical, radiation, viruses etc), tumour 
suppression is severely reduced or people who inherit only one functional copy of this gene 
will most likely develop Li–Fraumeni syndrome. This is characterised by the development of 
tumours in early adulthood (Gu et al, 2001: Varley et al, 1997). 
 Other cell signaling pathways that can also be involved in tumour development 
include, phosphatidyl inositol 3-kinase/AKT pathway. Up-regulation of the phosphatidyl 
inositol 3-kinase/AKT pathway in tumour cells renders them independent of survival signals. 
In addition to regulation of apoptosis, this pathway regulates other cellular processes, such as 
proliferation, growth, and cytoskeletal rearrangement (Vivanco and Sawyers, 2002). 
 
1.50 GAG’s and apoptosis 
GAGs have been shown to play a modulatory role in the apoptotic processes. For 
example, heparin has been shown to inhibit glomerular cell apoptosis in cell culture and 
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attenuates trophoblast apoptosis (Bose et al 2005: Ishikawa and Kitamura 1999). The GAG 
hyaluronan attenuates apoptosis induced by dexamethasone in malignant multiple myeloma 
cells (Vincent et al 2003).  Similarly, chondroitin CS and HS have also been reported to have 
attenuated apoptosis in fetal lung fibroblasts (Cartel and Post 2005).  
However, numerous data indicate the ability of GAGs to induce apoptosis. Hence, 
they may contribute to the natural processes of the body for the removal of tumour cells. 
Heparin in particular has been shown to induce apoptosis in human hepatoma cells (Karti et 
al 2003), human nasopharyngeal carcinoma cells (Li et al 2001) and peripheral blood 
neutrophils (Manaster et al 1996), possibly by interfering with transcription factor function 
(Berry et al 2004).  Likewise, derivatives of heparin and CS also induce apoptosis of 
myeloma and breast cancer cells in vitro (Pumphrey et al 2002).   
 
1.51 Overall aims of this study 
Comprehensive surveys of previous research into different classes of invertebrates, 
including molluscs, have demonstrated that GAG-like compounds, such as HS and/or 
heparin-like compounds, and CS and or DS, are present in many species (Medeiros et al, 
2000). However, commercial available preparations of GAGs compounds are mainly sourced 
from porcine and bovine intestinal or bovine lung tissue. A link between bovine spongiform 
encephalopathy and the similar prion-based Creutzfeldt-Jakob disease in humans 
(Schonberger, 1998), has limited the use of bovine GAGs in the clinic. Moreover, porcine 
GAGs also have problems associated with religious restrictions on its use (Volpi, 2005). 
Non-animal sources of GAGs with clinical useful activities are unavailable currently for 
pharmaceutical purposes. However, there is scant information on isolation/charactertisation 
of GAGs from molluscs such as whelk and cockles. There is even less information on the 
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potential biological activities of these mollusc derived polysaccharides and their potential use 
as new therapeutics for the treatment of human disease such as cancer.  
The primary aim of the work presented in this thesis is to isolate GAGs from whelks 
and cockles using a method similar to that described by Kim et al (1996), albeit with some 
slight modifications. Initial pilot studies revealed that novel GAG chains isolated from these 
two molluscs contain HS and CS/DS GAGs. The anticancer activities of these mullusc 
derived GAGs was assessed and commercial HS and CS/DS, from bovine sources, were used 
as comparative controls. 
The second aim of this project was to investigate the relationship between the 
structure of these mollusc derived GAGs and the observed anticancer activities. Studies have 
previously shown that modulation of HS GAGs structure on the surface of tumour cells could 
inhibit or promote tumour growth and metastasis (Liu et al, 2002). Understanding the fine 
structure and specific biological roles of GAGs has resulted in novel therapeutic approaches, 
including the development of HS/heparin-like compounds, which may act as inhibitors of 
tumour metastasis (Afratis et al, 2012). The anticancer activities of these HS/heparin related 
compounds have been shown to result primarily from their interaction, and inhibitory effects, 
on hundreds of different proteins, including FGFs, VEGF etc. The direct inhibition of tumour 
cell growth seen with our mollusc derived GAGs indicates a totally new mechanism for GAG 
related anticancer activity and the structural difference seen in these polysaccharides must be 
determind as a priority.  
The third aim of the presented work was to study the possible mechanism of action of 
the novel GAGs on cancer cells using cell cycle analysis and determination of apoptotic 
induction and to hopefully link with the GAG structural findings.  
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Overall the results obtained from this study will undoubtedly serve as the basis for the future 









































2.0 Experimental materials 
PD-10 pre-packed columns were purchased from Amersham Pharmacia Biotech. The 
TSK3000PW gel-filtration column and Pro-Pac PA-1 SAX-HPLC column (4.6 x 25cm) was 
purchased from Phenomenex (Macclesfield, UK) 
Cockles and whelks were purchased from Arndale fish market, Manchester, UK. Polcine HS 
and CS commercial GAGs were purchased from Celsus laboratories (Cincinnati, OH, USA). 
Heparin sodium salt was purchased from Sigma Aldrich, UK. ). Heparinase I 
(Flavobacterium heparinum; EC 4.2.2.7), heparinase II (F. heparinum; no EC number 
assigned) and heparinase III (F. heparinum; EC 4.2.2.8) were purchased from Grampian 
Enzymes (Orkney, UK). 
TEMED, Acrylamide/bisacrylamide 19:1 ratio, 40% solution, Ammonium 
persulphate, Cetylpiridium chloride, Ethylene diamineteracetic acid, chondroitinase-ABC 
from Proteus Vulgaris (0.83 units/mg), 99% Glycerol, Trizma base (Tris HCl), Cisplatinum 
(cis-Diammineplatinum(11)dichloride), 2-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), Acrylamide/bisacrylamide 19 :1 ratio, 40% solution, Foetal calf serum 
(FCS) – Biosera, Streptomycin and Penicillin, L-Glutamine, RPMI 1640 (Roswell Park 
Memorial Institute) – Biosera, DEAE-Sephacel, Propiodide (PI), (4',6-diamidino-2-
phenylindole (DAPI), Protease from Streptomyces griseus (Type XIV, ≥3.5 units/mg) and 
AZURE A dye were purchased from Sigma, UK. Acetone, Ethanol, eppendof tubes, 
 Micropipettes (10-1000 µl), Micropipettes (10-1000 µl) and other cell culture 
laboratory consumables were purchased from Fischer Scientific, UK. Dialysis tubing 
‘Visking’ was purchased from iBOTZ, USA. Sodium Chloride, Potassium acetate, Sodium 
bicarbonate, Trichloroacetic acid (TCA) and Sulphuric acid were purchased from Merck 
Millipore, UK. Bromophenol red and Glyceine (aminoacetic acid) were purchased from 
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Chemicals VWR BDH, UK. Anexin V-FITC stain was purchased from BIORAD, UK. 



























2.2       Preparation of GAGs  
Whelk (Buccinum undatum) and cockle (Cerastoderma edule) from the Irish Sea were 
sourced from local fish markets in Fleetwood, UK and were defatted using three 24h 
extractions with acetone and dried.  The fat-free dried cockles and whelks were crushed into a 
fine powder using an industrial blender. Approximately 40g of dried, defatted, pulverised 
powder was suspended in 400ml of 0.05 M sodium carbonate buffer (pH 9.2) and 20ml of the 
proteolytic enzyme Alcalase (Type XIV, ≥3.5 units/mg; 10 mg/ml) was added to the 
suspension in order to detach the carbohydrate chains from proteins. The suspension was 
shaken for 48 h at 200 rpm at 60 °C. The digestion mixture was cooled to 4 °C, and 
trichloroacetic acid added to a final concentration of 5% (to remove non degraded 
proteins/peptides and nucleic acids).  
The sample was mixed, allowed to stand for 10 min, and then centrifuged for 20 min 
at 8000 rpm. The supernatant was recovered by decanting and the precipitate discarded. 3 
volumes of 5% potassium acetate in ethanol were added to one volume of supernatant. After 
mixing, the suspension was stored overnight at 4 °C and then centrifuged for 30 min at 8,000 
rpm. The supernatant was discarded, and the precipitate was washed with absolute alcohol. 
The precipitate was dissolved in 400 ml of 0.2 M NaCl, centrifuged for 30 min at 8,000 rpm 
and the insoluble material discarded. GAGs were recovered from the supernatant by addition 
of 5 ml of a 5 % solution of cetylpyridinium chloride and the precipitate collected by 
centrifugation. 
The precipitate was dissolved in 100 ml of 2.5 M NaCl followed by the addition of 5 volumes 
of ethanol and the precipitate removed by centrifugation for 30 min at 10,000 rpm. The crude 
GAG precipitate was then dissolved in distilled water and dialysed as described below. 
99 
 
2.3 Desalting of crude GAGs 
Crude GAGs obtained from the extraction procedure were desalted using dialysis 
tubing pre- treated with 100mM EDTA. The dialysis tubes containing GAG extracts were 
dialysed against 100 volumes of distilled water for 72 hours under constant agitation with the 
distilled water changed at 24 hour intervals. After 72 hours, the desalted GAG extracts were 
freeze dried and stored at -20 
0
C for further use.  
 
2.4 Purification of crude GAGs by anion-exchange chromatography 
GAG samples (10mg) derived from the shellfish samples were dissolved in 10ml 
distilled water and manually injected onto a column (1.5x 5cm) of DEAE-sephacel 
equilibrated with 50 mM sodium phosphate buffer, pH 7.0. The column was eluted using a 
linear gradient of 0-3 M NaCl in 50mM phosphate buffer, pH 7.0 over a hundred minutes at 
flow rate of 1ml/min.  The elution was monitored spectrophotometrically at 210, 232 and 
254nm and 1ml fractions collected. Peak were pooled, freeze dried and finally desalted using 
PD 10 column 
 
2.5 Desalting of purified GAGs fractions 
The purified GAGs fractions were desalted on PD-10 column pre-calibrated with 
1mg/ml dextran (blue colour) and potassium dichromate (yellow colour) solution (the blue 
eluents were equivalent to GAGs, while the yellow eluents were equivalent to salt). The 
calibrated column was equilibrated with distilled water; the void volume and salt fractions 
were discarded while the GAGs fractions were pooled and stored at -20
0
C overnight before 
100 
 
being transferred to the freeze drier. The desalted GAGs samples were lyophilised and a dried 
and a pure white, fluffy GAG powder were obtained. 
 
2.6 Enzyme digestion of GAGs 
Samples of GAGs (1mg/ml) were treated with either heparinases or chondroitinase 




2.7 Chemical treatment (nitrous acid treatment)                                                                
Samples of GAGs were treated with nitrous acid according to the method described by Zhang 
et al., 2009. Powdered GAGs (100μg) were dissolved in distilled water (30μl) and 0.5M 
sulphuric acid (10 μl) and sodium nitrite (600μg) added. The combined reagents released 
gaseous nitrogen and formed nitrous acid. The reaction was halted after 15 minutes by adding 
an equal amount of 0.1M NaOH to neutralize excess nitrous acid. Treated samples were used 
for PAGE analysis, as described below. 
 
2.8 Polyacrylamide gel electrophoresis (PAGE analysis)                                                           
PAGE was conducted on Bio-Rad MiniProtean II systems. A resolving gel (15 ml of 40% 
acrylamide, 5 ml of 1.5 M Tris/HCl pH 8.5, 100 μl of APS, 60 μl of TEMED) were poured 
vertically, using a gel-pouring stand (Hoffer), between glass plates (16 cm x 32 cm) separated 
by 1.5 mm spacers. Butanol saturated with water (0.5 ml) was layered across the top of the 
gel and polymerisation, which began at the top of the gel, was completed within 20 min. The 
polymerised gel top layer was rinsed thoroughly with water to remove any excess gel and 
saturated butanol. Excess water was removed by filter paper.  
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The stacking gel (3 ml of 40% acrylamide, 5 ml of 0.5 M Tris/HCl pH 8.5, 100 μl of 
ammonium per sulphate (APS), 60 μl of TEMED and 12 ml of distilled water) was layered 
on top of the polymerised gel and a well comb was inserted. Samples were mixed with equal 
volume of loading buffer (20% glycerol) and applied to the wells using a micro syringe; a 
marker (20% v/v bromophenol blue) was applied to one of the wells. The gel was run at a 
constant voltage (200V) in a running buffer (25 mM Tris, 0.192 M glycine pH 8.3) until the 
tracking dye in the marker lane, reached the bottom of the gel. Gels were stained with 
aqueous 0.5 %Azure A under constant agitation for about 2 minutes and were destained by 
successive washes with distilled water and gels were scanned to preserve gels images. 
 
2.9 Superose-12 size exclusion chromatography 
Samples (at 10mg/ml) in a total volume of 20ul of water were applied to a Sepharose-
12 column, eluted in 0.2M ammonium hydrogen carbonate at a flow rate of 0.5ml/minute and 
0.5ml fractions collcted. Column Vo and Vt values were established by application of 
Bromophenol blue and sodium dichromate (1mg/ml).  
Vo fraction 15/16 
Vt fraction 34/35 







2.10 Cellulose acetate dot blotting of GAGs                                                                          
Cellulose acetate sheets were marked with a grid of 1cm
2
 squares using a pencil. Multiple 
applications of each fraction were applied to the membrane using a pipette. The acetate sheet 
was dried thoroughly between applications in an oven at 75
0
C for 5 minutes each. Following 
the final drying the sheet was stained using a solution of 0.5% Azure A stain for 10-20 
seconds, then de-stained in tap water until a good contrast between stained dots and 
background was achieved. 
 
2.11 Gel-filtration (TSK G2000 SW column) 
The TSK column was equilibrated in normal saline overnight prior the experiment. 20 µl of 
the filtered oligosaccharides obtained from each heparinase enzyme samples (shell fish and 
commercial HS/ Heparin) were injected via 20µl sample loop into the equilibrated column at 
a flow rate 250 µl/ml for 180 minutes and the elutes were monitored at 232 nm.  
 
2.12 Disaccharide analysis of GAG chain by strong anion-exchange high   
  Performance liquid chromatography (SAX-HPLC) 
Samples from enzymes digestion assay were applied to a Pro-Pac PA-1 SAX-HPLC 
column (4.6 x 25cm) pre-equilibrated in water adjusted to pH 3.5 with HCl at a flow rate 1 
ml/min. The disaccharides were resolved using a linear gradient of 0 -3M NaCl in deionised 
water, pH 3.5 for 70 min at flow rate of 1ml/min. Elutes were monitored for UV absorbance 





2.13 Determination of cells viability (MTT assay). 
The breast cancer cell MDA468 and MDANQ01, and human lymphoblastic and 
erythrocytic cell line (Molt-4 and K562) were grown in RPMI 1640 medium supplemented 
with 1 % L-glutamine, 1 % of 100 Units/ml penicillin and  0.1 mg/ml streptomycin and 10% 
inactivated FCS. While the ovarian cell line HeLa and fibroblast cell line 3T3 were grown in 
DMEM medium supplemented with 20 % inactivated FCS, 1 % L- glutamine, 1 % of 100 
units/ml penicillin & 0.1 mg/ml streptomycin. All cell lines were maintained in a humidified 
incubator with an atmosphere of 95% air and 5% CO2 at 37°C.   
Cell viability was determined by the MTT  
(3-(4,5dimethylthiazol2-yl)-2,5 diphenyltetrazolium bromide) test method. Cells were 
cultured overnight in 96-well plates (2.0 x 10 
4
 cells/ well) containing 100 µl medium prior to 
treatment with crude GAG extract, commercial GAGs and cisplatinum  at 37°C. A pilot study 
was conducted to choose the dose range used for this experiment. This was followed by 
addition of 100 µl of fresh medium containing various concentrations of GAGs (10-100 
µg/ml) or cisplatinum (0.35-25mM/ml) into each well, and incubated for another 96 hrs. The 
metabolic activity of each well was determined by the (MTT) assay and compared to those of 
untreated cells. At the end of the incubation period, 50µl of MTT solution (5 mg/ml in PBS) 
was added to each well and incubated for three hours at 37
0
C. After incubation the 
supernatants were carefully aspirated, then 200 μl of DMSO was added to each well and the 
plates agitated to dissolve the crystal product. Cell viability was determined based on 
mitochondrial conversion of 3[4,5-dimethylthiazol-2-yl]  2,5-diphenyltetrazolium bromide 
(MTT) to formazan. The amount of MTT converted to formazan is indicative of the number 
of viable cells.  
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The plates were gently agitated until the colour reaction was uniform and the 
absorbance was measured at 570 nm using a multi-well plate reader, Sigma Plot 2000 
software was used for data analysis. The cell viability effects from exposure of cells to each 
concentration of  crude whelk GAGs, commercial GAGs and cisplatinum were analysed as  
percentages of the control cell absorbance, which  were  obtained  from  control  wells  plated  
in  RPMI,1%  L- glutamate  and 10% FCS media. The average cell survival obtained from 
triplicate determinations at each concentration was plotted as a dose response curve. The 50% 
inhibition concentration (IC50) of the active substances was determined as the lowest 
concentration which reduced cell growth by 50 % in treated compared to untreated cells.  
 
2.14 Flow Cytometry Analyses of DNA Content (Cell cycle analysis). 
Cells were seeded into 25-cm plastic sterile culture flasks, and incubated for 24 hours 
prior to treatment with different concentrations of crude and purified GAGs samples. Cells 
were harvested at different time intervals (8-48 hours), centrifuged at 1500 rpm for 5 minutes, 
washed three times with phosphate buffer saline (PBS) and fixed in ice cold 70% (v/v) 
ethanol for 30 minutes. Before analysis, cells were centrifuged to remove ethanol and washed 
with PBS three times. Cells were then incubated at room temperature with 50 µl of 
Ribonuclease A (RNase) (50mg/ml) and finally stained with a solution containing 50 g/ml 
propidium iodide (PI) for 30 min in the dark. The stained samples were analysed with Partec 
flow cytometer. The cell cycle distribution was evaluated on DNA plots by Partec cyflow 





2.15 Annexin V-FITC apoptosis detection 
Cells were seeded into sterile 6 well plates at 5 x 10
5
 cells/ml, and incubated with or 
without GAG extracts at 37
0
C. Cells were harvested at different time intervals (8-48 hours), 
centrifuged at 1500 rpm for 5 minutes, washed twice with cold PBS and resuspended in 1x 
binding buffer (0.1M HEPES, 1.4 M NaCl and 25 mM CaCl2) at a concentration of 1 x 10
6
 
cells/ml. Cells (100 µl) were transferred into 5 ml culture tubes and stained with Annexin V 
FITC (5 µl) and PI (10 µl). The stained cells were gently vortexed and then incubated in the 
dark for 15 minutes at room temperature. 400 µl of 1 x binding buffer was added to each tube 
prior to analysis using a BD flow cytometer. 
 
2.16 DAPI fluorescent microscopy for apoptosis detection 
Cells were seeded into sterile 8 well plates at 5 x 10
5
 cells/ml, and incubated with or 
without GAG samples at 37
0
C. Cells were harvested at different time intervals (8-48 hours). 
The harvested cells were washed twice with cold PBS followed by 1x binding buffer (0.1M 
HEPES, 1.4 M NaCl and 25 mM CaCl2). The cells were immediately stained with DAPI and 
incubated in the dark for 10 minutes before finally being rinsed with binding buffer. The 
stained cells were viewed under the highest lens objective and the images obtained were 







2.17 Statistical analysis 
All of the results represent the mean ± SEM from triplicate experiments performed in 
a parallel manner unless otherwise indicated. Statistical comparisons between groups were 
made using one-way ANOVA followed by Student’s t-test, and significant differences were 















































3.0 Biological evaluation of cockle derived GAG mixtures 
3.1 Effects of cockle derived GAG mixtures on MDA468 breast cancer cell growth  
  (MTT assay results) 
 The effects of crude cockle GAG mixtures on MDA468 breast cancer cell 
proliferation were measured using the MTT assay. Cells were exposed to different 
concentrations of crude cockle GAGs (10-100 μg/ml) for 96 hours. Crude cockle GAG 
treatment had no growth inhibitory effect on the cell proliferation of MDA468 cell line 
(Figure.3.1A). Other commercial sourced GAGs (HS and CS) derived from bovine sources 
were tested along with crude cockle GAG on this cell line and none demonsrated any growth 
inhibitory effect on MDA468 breast cancer cell, as illustrated in Figure 3.1B. However, 
cisplatin, a standard anticancer drug did show growth inhibitory effects on MDA468 cell 
proliferation and this serve as a positive growth inhibitory control for all subsequent MTT 
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Figure 3.1: MTT cell viability assay for MDA468 cells after treatment with cockle     
  derived and commercially sourced GAG chains. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) Cockle GAGs and cisplatin as a positive inhibitory control, (B) Commercial 
and cockle GAGs with cisplatin as a positive control. Each value is presented as the mean SEM of three 
independent determinations. The bars in each chart are presented as relative values in comparison to untreated 
cells. 
Abbreviations: *-Significant (p≤0.05): **-Highly significant (p≤0.01)  
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3.2 Effects of Cockle derived GAG mixtures on the MDANQ01 breast cancer cell 
 In order to further examine any possible anti-cancer activity of cockle derived GAGs 
may have on breast cancer, the crude cockle GAG extracts was also exposed to another breast 
cancer cell (MDANQ01) using the MTT assay. Similarly, the crude cockle GAG did not 
show any growth inhibitory effect on MDANQ01 breast cancer cell proliferation (Figure 
3.2A). Moreover, MDANQ01 cells treated with the commercial GAGs (HS and CS) also 
showed no growth inhibitory effect (Figure 3.2B). However, cisplatin standard anti-cancer 
drug did exhibits growth inhibitory effects on MDANQ01 cell after the same period of 
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Figure 3.2: MTT cell viability assay for MDANQ01 cells after treatment with cockle 
  derived and commercially sourced GAG chains. 
 Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) Cockle GAGs and cisplatin as a positive inhibitory control, (B) Commercial 
and cockle GAGs with cisplatin as a positive control. Each value is presented as the mean SEM of three 
independent determinations. The bars in each chart are presented as relative values in comparison to untreated 








3.3 Effect of crude cockle GAG mixture on human lymphoblastic leukaemia  
   (MOLT-4) cell proliferation in vitro                                                                                   
 Despite the lack of anticancer activity seen with the breast cancer cell lines, the crude 
cockle GAGs was also tested on other cancer cell lines. The effects of crude cockle GAGs on 
cancer cell proliferation using a lymphoblastic leukaemia cell line (MOLT-4) showed much 
more promise. This cell line was similarly exposed to different concentrations of crude cockle 
GAGs (10-100 μg/ml) for 96 hours using an MTT assay.  
 Crude cockle GAGs decreased significantly the proliferation of MOLT-4 cell 
(p<0.001) in a dose dependent manner with a recorded IC50 of 16µg/ml (Figure 3.3A). 
According to the standard criteria set by the National Cancer Institute (Chen et al, 1988; 
Geran et al, 1972), crude extracts having IC50 values of less than 20 µg/ml are considered 
active against the tested cancer cell lines and this recommendation categorised this crude 
extract as a potential anti-leukaemia drug.  
The ability of the crude extract to inhibit cell proliferation of leukaemia cell lines was 
also compared favourably with the anti-proliferative effect of the DNA damaged anti-cancer 
drug (cisplatinum) (Figure 3.3A). These results show the potential of cockle derived GAGs as 
a future anti-leukaemia drug. 
 Almost as interesting as the anticancer activity of the cockle derived GAG was the 
complete lack of anticancer activity with the commercial GAGs (HS and CS) on the MOLT-4 
cell line  
(Figure 3.3B). These results suggest for the first time that GAGs chains may have selective 
anticancer activity against some cancer cell lines and that this based on their animal origin 
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Figure 3.3: MTT cell viability assay for MOLT-4 lymphoblastic leukaemia cells after 
  treatment with cockle derived and commercially sourced GAG chains. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) Cockle GAGs and Cisplatin as a positive inhibitory control (B) Commercial 
GAGs and Cisplatin as a positive control. Each value is presented as the mean SEM of three independent 
determinations. The bars in each chart are presented as relative values in comparison to untreated cells. 
Abbreviations: *-Significant (p≤0.05) **-Highly significant (p≤0.01). 






3.4 Effects of crude cockle GAG extracts on the growth of K562 erythroleukaemia 
     cells in vitro. 
 In order to investigate fully the selective activity of crude cockle GAGs against some 
cancer cells, its effects on cell proliferation of erythroleukaemia cell line (K562) was also 
measured using MTT assay. Crude cockle GAGs were shown to decrease proliferation of 
K562 cells in a dose –dependent manner with a recorded IC50 of 52 µg/ml [Figure 3.4 (A)]. 
Similarly, the growth inhibitory activity of the cockle GAG extract on K562 leukaemia cell 
line was also comparable to the growth inhibitory effect of the DNA damaged anti-cancer 
drug (cisplatin) (Figure3.4A). These results suggest that the cockle GAG extract has 
comparative activity with the standard anti-cancer drug (cisplatin) to treat this leukaemia cell 
line. Again all commercial GAGs (HS and CS) tested along with the crude extract showed no 














Figure 3.4: Concentration-dependent effect of Cockle GAG extracts on K562  
 erythroleukaemia cell viability. 
Cells were incubated with various concentrations of cockle GAGs extracts for 96 hours after which time cell 
viability was measured using an MTT assay (A) cockle GAGs and Cisplatin as a positive inhibitory control, (B) 
commercial and cockle GAGs with cisplatin as a positive control. Each value is presented as the mean SEM of 
three independent determinations. The bars in each chart are presented as relative values in comparison to 
untreated cells. 
Abbreviations: *-Significant (p≤0.05): **-Highly significant (p≤0.01). 
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3.5 Effect of cockle GAG mixtures on 3T3 normal fibroblast cell line 
 The cockle derived GAGs have demonstrated a degree of selective activity against 
some cancer cells in vitro. Selectivity is one of the positive characteristics of any potent anti-
cancer drug for future development. For this to be fully established, selective activity of crude 
cockle GAGs extracts was tested on the standard, non cancerous, 3T3-fibroblast cell line. 
Interestingly, the crude extract did not show any growth inhibitory effect on the 3T3 cells as 
shown in Figure 3.5. This result suggests that this extract may be highly selective against the 
leukemic cell lines; however this needs to be established with a much wider range of normal 









































Figure 3.5: MTT cell viability assay for normal fibroblast (3T3) cells after treatment 
   with cockle GAGs. 
Cells were incubated with various concentrations of cockle GAGs for 96 hours after which time cell viability 
was measured using MTT assay and cisplatin was used as a positive inhibitory control. Each value is presented 
as the mean SEM of three independent determinations. The bars in each chart are presented as relative values in 










3.6 Cell cycle analysis of the MOLT-4 cell line after treatment with cockle GAG  
     extracts                                                                                 
 Our preliminary studies have highlighted that cockle derived GAGs induces cell death 
in leukaemia cell lines including MOLT-4 cell line; However, the mechanism of this 
anticancer activity was initially unknown. Therefore, the mechanism of cell death induced by 
crude cockle GAGs treatment on leukaemia cell using MOLT-4 cell line was examined by 
subjecting treated and untreated cells to cell cycle analysis by flow cytometry. A pilot study 
was conducted to choose the dose used for this experiment. Results obtained from this study 
demonstrated marked disruptive effects on MOLT-4 DNA composition following a brief (16-
24 hours) treatment with the high concentration (50 µg/ml) of the crude extract [Figure 3.6 (i) 
A-C]. The dose was chosen based on the result obtained from pilot study. 
Significant MOLT-4 cell cycle arrest at G1phase with crude cockle GAGs was 
observed after 16 hours incubations using 50μg/ml with concomitant cell arrest at both G1 
and G2/M-phase at 24 hours incubations. 16 hours incubations of the cell with 50μg/ml crude 
cockle GAGs increased the G1 phase population by 13 % and 20 % at 24 hours. 24 hours 
incubations also increased the cell population at G2/M-phase by 15 %. Crude cockle GAGs 
decreased the S- phase population by 13 % at 16 hours and 35 % at 24 hours. The observed 
effect of the extract on the cell cycle of MOLT-4 cells were statistically significant (p< 0.05) 
at 16 hours and highly significant (p<0.01) at 24 hours; when compared the corresponding 
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Figure 3.6 (i): Cell cycle analysis of MOLT-4 lymphoblastic leukaemia cell line  
  following treatment with 50µg/ml of cockle GAG extracts. 
MOLT-4 cell were stained with PI stain and subjected to cell cycle analysis by flow cytometry. (A) Charts 
showed averages of three independent experiments after treatment with or without crude cockle GAGs. (B) 
Flow cytometry of MOLT-4 cells after 16 and 24 hours incubation without GAGs. (C) Flow cytometry 
histogram of MOLT-4 cells after 16 and 24 hours incubation with 50 µg/ml crude cockle GAGs. 




















To investigate whether the deleterious effect of the crude extract on MOLT-4 cell was 
dose-dependent, we also examined its effect on DNA composition of MOLT-4 cell line 
following treatment with lower concentration (20µg/ml) of the crude extract, using cell cycle 
analysis by flow cytometry. Results obtained showed time-dependent marked disruptive 
effects similar to that obtained for the higher concentration (50µg/ml) of the crude extract on 
MOLT-4 cell cycle [Figure 3.7 (ii) A-C]. The DNA disruptive effect was assessed between 8 
and 48 hours time intervals using lower concentrations (20µg/ml) of the crude extract. 
Significant MOLT-4 cell cycle arrest at G1 and G2/M-phase with concomitant cell reduction 
at S-phase was also observed at 16 and 24 hours following cockle GAG mixture treatment 
(20μg/ml).  
Additionally, 16 hours incubations of the cell with 20μg/ml crude cockle GAGs 
increased the G1 phase population by 4 % and 21 % at 24 hours. 24 hours incubations also 
increased the cell population at G2/M-phase by 6 and 11 % respectively [Figure 3.6 (ii) A-C]. 
Low concentration of crude cockle GAGs decreased the S- phase population by 10 % at 16 
hours and 32 % at 24 hours. The observed effect of the extract on the MOLT-4 cell cycle 
were statistically significant (p< 0.05) when comparing the corresponding values of the test 
samples with the control. There was no noticeable effect observed at 8 and 48 hours 










Cell cycle arrest caused by cockle treatment on MOLT-4 leukemia cell line 
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Figure 3.6 (ii): Cell cycle analysis of MOLT-4 lymphoblastic leukemia cell line following 
   treatment with low concentration (20µg/ml) of cockle GAG extract. 
MOLT-4 cell were stained with PI stain and subjected to cell cycle analysis by flow cytometry (A). Charts 
showed averages of three independent experiments after treatment with or without crude cockle GAGs. (B) 
Flow cytometry of MOLT-4 cells after 16 hours incubations with or without crude cockle GAGs. (C) Flow 
cytometry of MOLT-4 cells after 24 hours incubation with or without crude cockle GAGs. 




















3.7 Annexin V-FITC Apoptosis Assay of the MOLT-4 Lymphoblastic leukemia cell line 
 following treatment with crude cockle GAG  
The role of apoptosis in the anticancer effects seen with the cockle GAG extracts was studied 
using the Annexin V apoptotic assay induced by crude cockle GAG on the MOLT-4 
leukemia cell line. We incubated different concentrations obtained from a pilot study (20 & 
50 µg/ml) of the crude cockle extract with the MOLT-4 cells at different time intervals (8-48 
hours). Both treated and untreated cells were stained with both PI and annexin V-FITC stains 
and analysed by flow cytometry. The results obtained demonstrate that the numbers of early 
apoptotic cells increased significantly at both 16 (p≤0.01) and 24 (p≤0.01) hours time points 
following incubation with cockle GAGs when compared with the corresponding values of the 
control group. At 16 hours post-treatment, the proportion of early apoptotic cells in the cockle 
GAG treated cells reached 4.36%, which was significantly higher (p<0.05) than the control 
group (0.68%) [Figure 3.7(A-C)]. At 24 hours post treatment, the proportion of early 
apoptotic cells increased from 0.48% (control) to 6.95% (cockle GAG). This finding suggests 
that the anticancer effects seen with crude cockle GAGs on the leukaemia cell line is, in part, 
linked to time-dependent apoptosis. 
However, there was no noticeable apoptotic effect observed at 8 and 48 hours for both 
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Figure 3.7: Detection of Apoptotic MOLT-4 cells treated with cockle GAG‘s extracts by 
 Annexin V Staining. 
MOLT-4 cells were treated with cockle crude GAGs for 16 and 24 hours and then stained using Annexin V-
FITC and PI provided in the Annexin V-FITC Apoptosis Detection Kit (see materials and methods). The 
combination of Annexin V-FITC and PI allows for the distinction between early apoptotic cells (annexin V-
FITC positive), late apoptotic and/or necrotic cells (Annexin V-FITC and PI positive), necrotic (PI stained 
positive) and viable cells (unstained). (A) MOLT-4 cell treated with or without cockle GAGs for 16 and 24 
hours respectively. (B) MOLT-4 cell treated with or without cockle GAGs for 16 hours. (C) MOLT-4 cells 
treated with or without cockle GAGs for 24 hours. 
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Biological assay results for whelk GAG 














3.8 Effect of crude whelk GAG extracts on the growth of the MDANQ01 breast  
                                                   cancer cell line 
The proliferation of MDANQ01 breast cancer cells was found to be inhibited strongly by 
crude whelk GAG extracts with a recorded IC50 of 25.14 µg/ml (Figure 3.8A). The observed 
inhibitory effect of whelk GAGs on this cell line compared favourably with cisplatin (a 
DNA-damaging agent) anticancer drug (Figure 3.8A-B). The results obtained are in stark 
contrast to the activites seen with cockle GAG extracts on this breast cancer cell line. This 
may indicate the presence of unique structural differences between the GAG chain present in 
the whelk and cockle samples. Again, the commercial GAG samples of HS and CS failed to 
show any appreciable anticancer effects (Figure 3.8B). These findings are unique and identify 
whelk derived GAG chains as potential treatments for breast cancer. The selective nature of 
this activity between whelk and cockle GAGs is also a fascinating new discovery with huge 
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Figure 3.8: MTT cell viability assay for MDANQ01 cells after treatment with Whelk 
  extract and commercial GAGs.                                                                               
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) whelk extract GAGs with Cisplatin as a positive inhibitory control, (B) 
commercial GAGs with cisplatin as a positive control. Each value is presented as the mean SEM of three 
independent determinations. The bars in each chart are presented as relative values in comparison to untreated 
cells. 
Abbreviations: * Significant (p≤0.05): **-Highly significant (p≤0.01) 
    ** 





3.9 Effect of crude whelk GAG extracts on the growth of MDA468 breast cancer 
 cells  
 The proliferation of MDA468 breast cancer cell was similarly inhibited, in a dose 
dependent, by crude whelk GAGs with a recorded IC50 of 70.94 µg/ml (Figure 3.9A). In 
contrast, the whelk GAGs had a more profound anticancer activity with the MDANQ01 cell 
line. Again the activity was dose-dependent with an IC50 of 25.14µg/ml (Figure 3.8A). These 
results suggest that the MDANQ01 cell line is more sensitive to whelk GAGs treatment than 
MDA468 cells. The observed inhibitory effect of whelk GAGs on this cell line also compared 
favourably with cisplatin (a DNA-damaging agent) anti-cancer agent at a concentration range 
between 1-25 µM with a recorded IC50 of 0.88 µM (Figure 3.9A-B). Once again, the 
commercial GAGs (HS and CS) (Figure 3.9B), did not have growth inhibitory effect on this 
cell line but rather serve as a growth catalyst for this cell line.  
 These results suggest that the whelk derived GAG’s possesses a unique activity 
against the growth of breast cancer cells and shows great potential for the treatment of this 
disease. Indeed the differences in IC50 values for the two breast cancer cell lines suggests that 
the whelk derived GAG’s could be selective to certain cell types and this selectivity may well 
be important in targeting the effects of these molecules towards tumour cells.                              
Further studies to establish the effects of these GAG’s on other tumour and normal cell lines 
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Figure 3.9: Concentration-dependent effect of whelk GAG extracts on MDA468 breast 
  cancer cell viability. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) Whelk crude GAGs with Cisplatin as a positive inhibitory control, (B) 
Commercial and crude whelk GAGs with cisplatin as a positive control. Each value is presented as the mean 
SEM of three independent determinations. The bars in each chart are presented as relative values in comparison 
to untreated cells.  
Abreviation: * Significant (p≤0.05): ** Highly significant (p≤0.01) 
* 








3.10 Effect of crude whelk GAG extracts on the growth of K562 and MOLT-4  
   leukaemia cells lines (K562 and MOLT-4)  
 Further investigation of anticancer effects of crude whelk GAG was performed using 
two different cancer cell lines (MOLT-4 and K562). The results obtained from this study 
confirm the whelk derived GAGs anticancer activities. The anti-proliferative activities of 
these polysaccharides are dose-dependent on both leukaemia cell lines with the best activity 
seen against K562 cell line (Figure 3.10B). Suprisingly, the growth inhibitory activities of the 
crude whelk was more pronounced on erythroleukaemia cell line (K562) than MDANQ01 
breast cancer cell. The recorded IC50 for crude whelk GAG exctract on k562 leukemia cell 
was 14µg/ml. Contrarily, the crude whelk GAG extracts inhibited the growth of MOLT-4 
leukaemia cell proliferation in a concentration-dependent manner with arecorded IC50 of 
41.11µg/ml and the lowest concentration (10µg/ml) of the extract did not show any growth 
inhibitory effect on lymphoblastic leukaemia cell (MOLT-4) Figure 3.10A).  
 The anti-proliferative activities of the crude whelk GAG extracts on the two 
leukaemia cell lines compare favourably with the cisplatin positive control and the low IC50 
observed for K562 suggests the crude whelk GAG extracts would show promise as the basis 
for an anti-leukemia drug, based on the recommendation of the standard National Cancer 
Institute criteria. More importantly, the different anticancer activities display by the crude 
whelk GAG extracts on these two cell lines also suggests that the whelk derived GAG’s 
could be selective for certain cell types and this selectivity may well be important in targeting 
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Figure 3.10: MTT cell viability assay for MOLT-4 and K562 leukaemia cells after  
  treatment with whelk GAG extracts  
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) MOLT-4 leukaemia cells treated with crude whelk GAGs withcisplatin as a 
positive inhibitory control, (B) K562 leukaemia cell line treated with crude whelk GAGs and cisplatin as a 
positive control. Each value is presented as the mean SEM of three independent determinations. The bars in 
each chart are presented as relative values in comparison to untreated cells. 
 Abbreviations- *-Significant (p≤0.05): **-Highly significant (p≤0.01) 
** ** 
 
**  **  ** ** **  **  ** ** 




3.11 Effect of crude whelk GAG extracts on the growth of HeLa Cervical cells        
 The anticancer activity of whelk GAG mixture was also tested on the standard HeLa 
cell line as this cell line is particularly susceptible to induction of apoptosis. The result shows 
that crude whelk GAG mixture strongly inhibited the growth of the HeLa ovarian cell line 
and its anticancer effects were more pronounced than on all other cancer cells investigated so 
far in this study, with a typically recorded IC50 of 12μg/ml. Moreover, it is clear that the anti-
cancer activities of this whelk GAG mixure are greater than that observed for cisplatin anti-
cancer drug (Figure 3.11A-B). 
 Once again all commercial GAGs tested along with whelk crude GAGs did not 
demonstrate any inhibitory effect on the HeLa cells proliferation: suggesting that the 
inhibitory effect may be a unique feature of the GAG’s derived from whelks. This result also 
suggests that this polysaccharide’s anti-cancer activity is stronger than cisplatinum anti-
cencer drug. In addition, the data suggests that the whelk derived GAG’s could be more 
selective to this cell types than other cells tested and this selectivity may well be important in 
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Figure 3.11: MTT cell viability assay for HeLa cervical cell after treatment with whelk 
   GAG extracts   
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay with cisplatin as a positive inhibitory control. Each value is presented as the 
mean SEM of three independent determinations. The bars in each chart are presented as relative values in 
comparison to untreated cells. 













3.12 Effect of crude whelk GAG mixtures on the growth of normal fibroblast cells 
     (3T3)  
 The effects of crude whelk GAGs on growth of normal fibroblast cells (3T3) was 
measured using MTT colorimetric assay. Cells were exposed to different concentrations of 
the crude whelk GAGs for 96 hours. Crude whelk GAG extracts did not show any growth 
inhibitory effect on 3T3 cell proliferation (Figure 3.12). Moreover, the effects of crude whelk 
GAGs on 3T3 cells compare favourably with the results obtained for commercial GAGs. 
These results suggest that whelk derived GAG’s is selective against cancer cell types and at 
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Figure 3.12: MTT cell viability assay of normal fibroblast 3T3 cells after treatment with 
  whelk GAGs extracts. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay. Each value is presented as the mean SEM of three independent determinations. 








3.13 Effect of Heparinase I, II, & III enzymes on anti-proliferative activity of whelk 
 GAG extracts using MDA468 and MDANQ01 breast cancer cell lines. 
 The crude whelk GAG extract was depolymerised with Heparinase I, II&III enzymes 
to break the long linear chain polymer to smaller oligosaccharides chains, this has previously 
been shown to destroy any GAG related biological activities. The oligosaccharide product 
was then incubated with the two breast cancer cell lines (MDANQ01 and MDA 468) for 96 
hours, as described under materials and methods. The results obtained showed a dramatic 
reduction in the growth inhibitory effects of whelk GAG extracts on both breast cancer cell 
lines (Figure 3.13A-B). These results suggest that the anticancer activities of these novel 
GAG extracts appears to be connected to the intact linear polysaccharide chains that were 
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Figure 3.13: MTT cell viability assay for MDANQ01 and MDA468 breast cancer cells 
   after treatment with heparinase depolymerised whelk GAG extracts. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time  cell viability was 
measured using an MTT assay (A) MDA468 cells after treatment with whelk GAG Heparinase I-III enzyme 
digest with cisplatin as a positive inhibitory control, (B) MDANQ01 cells treated with whelk GAG Heparinase 
I-III enzyme digest  with cisplatin as a positive inhibitory control. Each value is presented as the mean SEM of 
three independent determinations. The bars in each chart are presented as relative values in comparison to 
untreated cells.  
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3.14 Cell cycle analysis of MDANQ01 cells after treatment with crude whelk GAG 
      extracts 
Flow cytometry was used to investigate the effects of the whelk GAG extracts on the 
progression of the cell cycle. Cells exposed to either 20ug/ml or 50ug/ml whelks GAG’s 
showed perturbation of MDANQ01 cell’s cycle after 24-72 hours exposure to the crude 
extract. 
 Whelk GAGs induced cell cycle arrest of MDANQ01 cells at both S and G2M phases 
was observed as shown in Figure 3.14A-C. This brought about a significant accumulation of 
cells at S and G2/M phases leading to the subsequent reduction of number of cells in G1 
phase. 24 hours treatment of MDANQ01 cells with 50µg/ml whelk GAGs caused a marginal 
increased in the number of cells at G2/M-phase from 26.97% ± 6.28 (control) to 29.16% ± 
0.1) (50 µg/ml wk). At 48 h the cell population at S-phase (Figure 3.14A-C) increased from 
20.48% ±8.19 (control) to 26.76% ±2.26 (50 µg/ml whelk). Similarly lower concentrations of 
whelk GAGs disrupted MDANQ01 cell cycle progression at both S and G2/M.The longest 
incubation time (72 hours) with low doses of the crude GAGs (Figure 3.14A-C) significantly 
altered the cell cycle by inducing a more than two fold increase in the percentage of cell 
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Figure 3.14: Cell cycle analysis of MDANQ01 breast cancer cell line following treatment 
  with crude whelk GAG extract. 
MDANQ01 breast cancer cells were treated with PI stain and subjected to cell cycle analysis by flow cytometry 
(A). Charts showed averages of three independent experiments after treatment with or without crude whelk 
GAGs. (B) Flow cytometry of MDANQ01 cells after 24 hours incubations with or without crude whelk GAGs. 
(C) Flow cytometry of MDANQ01 breast cancer cells after 48 hours incubation with or without crude whelk 
GAGs and (D) Flow cytometry of MDANQ01 breast cancer cells after 72 hours incubation with or without 
crude whelk GAGs. 



















3.15       Cell cycle analysis of MDA468 breast cancer cell lines after treatment with 
 crude whelk GAG extracts  
Whelk GAGs treatment also caused significant cell cycle disruptions in the MDA468 
breast cancer cell line in a similar manner to that observed in the MDANQ01 cells. Cell cycle 
disruptions were observed at both S and G2/M phases (see Figure 3.15A-C). Higher 
concentrations of whelk GAGs (50µg/ml) also induced a time-dependent DNA disruptive 
effect on MDA468 cells as shown in Figure 3.15A-B. A short hour (48 hours) incubation of 
the crude whelk GAG extracts with MDA468 cells induced cell accumulation at G2/M; 
however, these differences were not statistically significant (p>0.05) when compared with the 
corresponding values of the control.  
The longer 72 hours incubations of the cells with high doses of crude GAGs 
significantly altered the cell cycle by inducing more than a two-fold increase in the 
percentage of cell population at the S-phase (p<0.02). Crude whelk GAG extracts increased 
cell population at G2/M-phase from 24 ± 4.8 % (control) to 31 ± 3.4% (50µg/ml whelk) after 
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Figure 3.15: Cell cycle analysis of MDA468 breast cancer cell line following treatment 
   with crude whelk GAG extract. 
MDA468 breast cancer cells were stained with PI stain and subjected to cell cycle analysis by flow cytometry 
(A). Charts showed averages of three independent experiments after treatment with or without crude whelk 
GAGs (B) Flow cytometry of MDA468 breast cancer cells after 48 hours incubation with or without crude 
whelk GAGs and (C) Flow cytometry of MDA468 breast cancer cells after 72 hours incubation with or without 
crude whelk GAGs. 
















3.16 Effects of crude whelk GAG mixtures on the induction of apoptosis in MDA468 
    breast cancer cells 
Previous investigations revealed that whelk GAGs induced cell death in MDA468 
breast cancer cells; however, the mechanism of cell death induced by this crude 
polysaccharide was not yet known. An Annexin V-FITC Apoptosis Detection Kit was used in 
order to elucidate the mechanism of cell death induced by whelk GAG extracts. The two cell 
lines were incubated with varying concentrations of the whelk GAGs at different time 
intervals and the apoptosis determination was carried out as described under the materials and 
methods section. The results reveal that high concentration (50µg/ml) of the whelk GAG  
extract appears to have caused the breast cancer cells death by inducing apoptosis (late 
apoptosis) in proportion to the rate of cell death caused by the crude extract on the cells 
Figure 3.16A-C). 
 Whelk GAG extracts (50 µg/ml) increased the percentage of cells stained positive for 
both Annexin V-FITC and PI after 24 hours treatment from 16.48 (control) to 28.40 
(50µg/ml). 48-hour incubations with the whelk GAGs also slightly increased the number of 
cells stained with annexin V-FITC from 1.64 % (control) to 2.4 % (50µg/ml). However there 
were signs of substantial cell lysis at this time point. Moreover, the number of cells stained 
positive for both Annexin V-FITC and PI increased marginally from 8.2 % (control) to 12.89 
% (50µg/ml). However, lower concentration (20µg/ml) of the whelk GAG extract did not 
show any apoptotic effect on MDA468 cell line: both 8 and 72 hours incubations of the cells 
with the crude extract did not show any noticeable apoptotic effect on the two cell lines 
(results not shown).  
In addition to the late apoptotic effect of the extract on MDA468 breast cancer cell, 
there was a false apoptotic effect observed in the control cells 24 hours after incubation, 
148 
 
likely caused by trypsinisation of the cells after incubation. In order to eliminate this false 
apoptotic effect, both the treated and untreated cells were stained with DAPI and viewed 
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Figure 3.16: Detection of Apoptotic MDA468 breast cancer cells treated with crude   
whelk GAG extracts by Annexin V Staining. 
MDA468 breast cancer cells were treated with crude whelk GAGs for 24 and 48 hours and then stained using 
Annexin V-FITC and PI provided in the Annexin V-FITC Apoptosis Detection Kit (see materials and methods). 
The combination of Annexin V-FITC and PI allows for the distinction between early apoptotic cells (annexin V-
FITC positive), late apoptotic and/or necrotic cells (Annexin V-FITC and PI positive), necrotic (PI stained 
positive) and viable cells (unstained). (A) MDA468 cell treated with or without crude whelk GAGs for 24 and 
48 hours respectively. (B) MDA468 cell treated with or without crude whelk GAGs for 24 hours. (C) MDA468 
cell treated with or without crude whelk GAGs for 48 hours. 


















3.17 Flow cytometry and Annexin V-FITC apoptosis detection of MDANQ01 cells 
   following incubation with whelk GAG extracts  
Whelk GAGs induced cell death in MDANQ01 breast cancer cells; however, the 
mechanism of cell death induced by this crude GAG required further study. In order to 
elucidate the mechanism of cell death induced by crude whelk GAGs, Annexin V-FITC 
Apoptosis Detection Kit was utilised (see materials and methods). High concentration 
(50µg/ml) of crude whelk GAGs induced time-dependent apoptosis on MDANQ01 cells 
(Figure 3.17A-C). 24-hour incubation of the crude whelk GAG extracts with the cells, 
increased the number of cells stained with annexin V-FITC from 1.02 % (control) to 2.84 % 
(50 µg/ml) and the number of cells stained with both Annexin V-FITC and PI was also 
increased from 7.07 % (control) to 15.16 % (50 µg/ml).  
Similarly, 48-hour incubation of the whelk GAG extract also induces apoptosis on 
MDANQ01 cells but the apoptotic effect was slightly reduced than the observations made at 
24 hours. At 48 hours, the number of cells stained with annexin V-FITC increased from 
2.99% (control) to 5.92 (50µg/ml) and those cells stained with both Annexin V-FITC and PI 
also increased from 9.28 % (control) to 13.66 % (50µg/ml). However, lower concentration 
(20µg/ml) of the crude extract did not show any apoptotic effect on this cell line.  Both 8 and 
72 hours incubations of the cells with the crude extract did not show any noticeable apoptotic 
effect on MDANQ01 cell line (results not shown). 
Similarly, a false apoptotic effect was observed in the control cells, which may be 
caused by the trypsinisation’s step draw back of the cells after incubation. In order to rule out 
this false apoptotic effect, both the treated and untreated cells were also stained with DAPI 
and viewed under the fluorescent microscope, as described under the materials and methods. 
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Figure 3.17: Detection of Apoptotic MDANQ01 breast cancer cells treated with crude   
whelk GAG extracts by Annexin V Staining. 
MDANQ01 breast cancer cells were treated with crude whelk GAGs for 24 and 48 hours and then stained using 
Annexin V-FITC and PI provided in the Annexin V-FITC Apoptosis Detection Kit (see materials and methods). 
The combination of Annexin V-FITC and PI allows for the distinction between early apoptotic cells (annexin V-
FITC positive), late apoptotic and/or necrotic cells (Annexin V-FITC and PI positive), necrotic (PI stained 
positive) and viable cells (unstained). (A) MDANQ01 cell treated with or without crude whelk GAGs for 24 and 
48 hours respectively. (B) MDANQ01 cell treated with or without crude whelk GAGs for 24 hours. (C) 
MDANQ01 cell treated with or without crude whelk GAGs for 48 hours. 



















3.18 Assessment of apoptosis using DAPI flourescent microscopy following treatment 
 of MDA468 breast cancer cell with Crude whelk GAG extracts 
To confirm whether the anti-proliferative effect of whelk GAG extracts on MDA468 
breast cancer cell line was due to apoptosis; cells were incubated with or without crude whelk 
GAGs, stained with DAPI stain and the cells morphology examined under a fluorescent 
microscope. MDA468 cells were treated with 50 μg/ml of crude whelk GAGs or negative 
control (FCS media) for 24 and 48 hours and subsequently analysed by DAPI staining. 
Control cells incubated with media and without crude whelk GAGs showed no signs of 
apoptosis or oncosis and exhibited brightly fluorescing round, blue-stained nuclei (Figure 
3.18A-B). In contrast, those cells treated with crude whelk GAGs for 24 and 48 hours showed 
a number of cells with condensed and fragmented nuclei, an indication of apoptosis (Figure 
3.18A-B). 
Trypsinisation, which is known to cause membrane damage, is one of the major steps 
involved in annexin V-FITC apoptosis detection assay. It may be responsible for some false 
anexin V-FITC positive staining observed in the untreated group. The above result obtained 
from DAPI stain confirms this hypothesis and shows clearly that the control group showed no 
induction of any apoptosis. This result also confirms that crude whelk GAG extracts induces 
apoptosis on MDA468 breast cancer cell. Therefore, the combined results of apoptosis 
detections by annexin V-FITC and DAPI stains suggest that the breast cancer cell death 
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Figure 3.18: Detection of apoptotic MDA468 cells by DAPI fluorescent microscopy  
  following treatment with crude whelk GAG extracts. 
MDA468 cells treated with crude whelk GAGs were stained and morphology of apoptotic cell nuclei was 
observed by DAPI staining using a fluorescence microscope. Nuclei were stained with DAPI (blue). Images 
were photographed at the same exposure time under a x40 objective with Hamatsu 1394 ORCA-285 camera. 
(A) MDA468 cells treated with or without crude whelk for 24 hours. (B) MDA468 cells treated with or without 




3.19 Assessment of apoptosis using DAPI flourescent microscopy following treatment 
 of MDANQ01 breast cancer cell with Crude whelk GAG  
  
 Similarly, to confirm whether the reduced cell growth observed in MDANQ01 cell 
line treated with crude whelk GAGs was due to apoptosis as revealed by annexin V-FITC 
apoptosis detection.  MDANQ01 cells treated with or without 50μg/ml of crude whelk GAGs 
for 24 and 48 hours were stained with DAPI and cell morphology examined under fluorescent 
microscope. Control cells incubated with media without crude whelk GAGs showed no signs 
of apoptosis or oncosis and exhibited brightly fluorescing round, blue-stained nuclei (Figure 
3.19A-B). However, the treated cells showed a numbers of cells with condensed and 
fragmented nuclei, an indicator of apoptosis (Figure 3.19A-B). 
Furthermore, this result confirms that crude whelk GAG extracts induce apoptosis on 
MDANQ01 cells. Therefore, the combined results of apoptosis detections by annexin V-
FITC and DAPI staining suggest that the anti-proliferative activity of the crude whelk GAGs 





























Figure 3.19: Detection of apoptotic MDANQ01 cells treated with crude whelk GAG  
  mixtures by DAPI fluorescent microscopy. 
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Figure 3.19: Detection of apoptotic MDANQ01 cell treated with crude whelk GAG  
  mixtures by DAPI fluorescent microscopy 
MDANQ01 cells treated with crude whelk GAGs were stained with DAPI and morphology of apoptotic cell 
nuclei was observed by DAPI staining using a fluorescence microscope. Nuclei were stained with DAPI (blue). 
Images were photographed at the same exposure time under a x40 objective with Hamatsu 1394 ORCA-285 
camera. (A) MDANQ01 cells treated with or without crude whelk for 24 hours. (B) MDANQ01 cells treated 



















3.20 Assessment of apoptosis using annexin V-FITC apoptosis detection following  
  treatment of HeLa cells with crude whelk GAG extracts  
Preliminary studies reveal that crude whelk GAGs cause cell death in HeLa cells but 
the mechanism of this cell death is not yet known. This study was performed to elucidate the 
mechanism of cell death induced by crude whelk GAGs on HeLa ovarian cells using an 
Annexin V-FITC Apoptosis Detection Kit. HeLa cells are one of the most susceptible cells to 
apoptosis, as demonstrated and confirmed in this sudy. The apoptotic effects of whelk GAGs 
were more pronounced and better established with this cell line than that seen in either the 
leukaemia or breast cancer cell lines. 24-hour incubation of the crude whelk extracts with 
HeLa cells induce almost 50% apoptosis (late apoptosis) with an additional 10% early 
apoptosis detected and this differences were highly significant (p=0.000) when compared 
with the corresponding values of the control. Moreover, a number of cell deaths were caused 
by necrosis, as illustrated in (Figure 3.20A-C). Additionally, 48-hour incubation of the crude 
whelk GAGs with HeLa cells also induced almost 70% late apoptosis and almost 10% early 
apoptosis, with a few cells (< 10%) affected by necrosis (Figure 3.20A-C). Small amounts of 
positive apoptosis and necrosis were observed in the untreated control cells. This was easily 
resolved by fluorescent microscopy and DAPI staining, which reveals no false positive for 
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Figure 3.20: Detection of Apoptosis in HeLa cells by Annexin V Staining following     
treatment with whelk GAG extracts. 
HeLa cells were treated with crude whelk GAGs for 24 and 48 hours and then stained using Annexin V-FITC 
and PI provided in the Annexin V-FITC Apoptosis Detection Kit. The combination of Annexin V-FITC and PI 
allows for the distinction between early apoptotic cells (annexin V-FITC positive), late apoptotic and/or necrotic 
cells (Annexin V-FITC and PI positive), necrotic (PI stained positive) and viable cells (unstained). (A) HeLa 
cell treated with or without crude whelk GAGs for 24 and 48 hours respectively. (B) HeLa cell treated with or 
without crude whelk GAGs for 24 hours. (C) HeLa cells treated with or without crude whelk GAGs for 48 hours 
Abbreviations: *-Significant (p≤0.05) 
 
 
3.21 Assessment of apoptosis using DAPI flourescent microscopy following treatment 
of HeLa cells with whelk GAGs  
Apoptotic effects of crude whelk GAGs on HeLa cervical cells were confirmed as 
follows: Cells treated with 50μg/ml of crude whelk GAGs or negative control (FCS media) 
for 24 and 48 hours were stained with DAPI and viewed under fluorescent micrope. Control 
cells incubated in ordinary FCS media without crude whelk GAGs exhibited no signs of 
apoptosis and exhibited brightly fluorescing round, blue-stained nuclei (Figure 3.21A-B). In 
contrast, cells treated with whelk GAG extracts  showed a number of cells with condensed 
and fragmented nuclei; a clear  indication of apoptosis induction (Figure 3.21A-B). This 
result confirms that whelk GAG extracts induce apoptosis with the HeLa cells. Both the 
DAPI and annexin V-FITC results suggest that cell growth inhibitory activity of whelk GAGs 
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Figure 3.21: Detection of apoptotic HeLa cells by DAPI fluorescent microscopy  
  following treatment with whelk GAG  
HeLa cells, treated with crude whelk GAGs, were stained with DAPI and the morphology of apoptotic cell 
nuclei was observed by DAPI staining using a fluorescence microscope. Nuclei were stained with DAPI (blue). 
Images were photographed at the same exposure time under a x40 objective with Hamatsu 1394 ORCA-285 
camera. (A) HeLa cells treated with or without crude whelk for 24 hours. (B) HeLa cells treated with or without 

















3.22 Fractionation of whelk GAG extracts by ion-exchange chromatography 
Crude whelk GAG extracts were next subjected to ion-exchange chromatography in 
order to identify the biologically active component. Ion-exchange chromatography is used 
routinely to separate GAG mixtures into their respective GAG family members; for example, 
HS, CS and DS. Six major peaks were identified, when the whelk GAG extracts were 
subjected to ion-exchange separation; each peak was believed to contain different GAGs 
family members (Figure 3.22). Peaks were designated, A-F, in order of increased elution time 
(table 1). In some preparations fraction D was absent; however, the remainders of the 
fractions were consistently present. When assayed in the MTT assay against both breast 










Figure 3.22: Ion-exchange chromatography elution profile for whelk GAG extracts. 
Samples were applied to a DEAE-Sephadex ion-exchange column and resolved using a linear 0-3 M NaCl 
gradient in 50mM sodium phosphate buffer pH 7.0 at a flow rate of 1ml/min for 100 min. Fractions were 
collected and the absorbance monitored at a wavelength of 254nm. Fractions were pooled as indicated, desalted 
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A 27-37 HS-like 19.90 27-37 0.9-1.24 
B 39-47 CS/DS-like 13.50 39-47 1.26-1.62 
C 49-62 CS/DS-like 18.00 49-62 1.63-2.1 
D 65-73 Unknown 16.00 65-73 2.14-2.5 
E 75-88 HS-like 23.30 75-88 2.56-2.9 
F 89-94 Unknown 9.30 89-94 2.91-3.0 
 
Samples were applied to a DEAE-Sephadex ion-exchange column and resolved by a linear 0-3 M NaCl gradient 
in 50mM sodium phosphate buffer pH 7.0 at a flow rate of 1ml/min for 100 min. Fractions were collected and 
the absorbance monitored at wavelengths of 254nm. Fractions were pooled as indicated, desalted and 
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Note: Also included in this section was proliferative effect of depolymerised whelk GAG on 























Biological activities of purified whelk  











3.23 Effect of purified whelk fraction E on the growth of MDANQ01 breast cancer 
      cells  
Fraction E samples showed significant (p<0.05) growth inhibitory effects on 
MDANQ01 breast cancer cells proliferation (Figure 3.23A) after 96 hours incubation as 
described under materials and methods section. The growth inhibitory effects of fraction E on 
MDANQ01 was similar to that observed for crude whelk GAGs extracts but the recorded 
IC50 (41.89 μg/ml) was higher than what was recorded for crude whelk GAGs (25.14 μg/ml). 
However, the growth inhibitory effect of fraction E was more pronounced with higher 
concentrations (50-100 μg/ml) than the lower concentrations (10-30 μg/ml). 
In addition to the above result, other purified whelk fractions (A,B,C,& F) and 
commercial GAGs were also tested along with fraction E. Interestingly none of them showed 
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Figure 3.23: MTT cell viability assay for MDANQ01 breast cancer cells after treatment 
  with GAG mixtures and purified whelk fraction E. 
Cells were incubated with various concentrations of GAGs for 96 hours after which time cell viability was 
measured using an MTT assay (A) MDANQ01 breast cancer cell line treated with crude whelk’s purified 
fractions and commercial GAGs (B) MDANQ01 breast cancer cells treated with fraction E and crude whelk 
GAGs. Each value is presented as the mean SEM of three independent determinations. The bars in each chart 
are presented as relative values in comparison to untreated cells. 
Abbreviations: *-Significant (p≤0.05): **-Highly significant 
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3.24 Effect of purified whelk fraction E on MDA468 breast cancer cell proliferation  
Fractions E also showed dose-dependent growth inhibitory effects on MDA468 breast 
cancer cell line (Figure 3.24A) after 96 hours treatment (see materials and methods section). 
Its growth inhibitory effect on MDA468 compares favourably to the effect of the crude whelk 
GAG extracts with a lower recorded IC50 of 45.98μg/ml against an IC50 of 70.96 μg/ml 
recorded for crude whelk GAGs. Similarly, higher concentrations (50-100 μg/ml) of fraction 
E show more effective growth inhibitory activity against MDA468 than their lower 
concentrations (10-30 μg/ml) counterpart (Figure 3.24A). 
However, other purified whelk fractions (A, B, C & F) and commercial GAGs did not reveal 
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 Figure 3.24: Concentration-dependent effect of purified whelk GAG fraction E on  
  MDA468 breast cancer cell viability. 
Cells were incubated with various concentrations of cockle GAGs for 96 hours after which time cell viability 
was measured using an MTT assay (A) Cells treated with commercial GAGs and whelk’s purified fractions (B) 
Cells treated with fraction E and crude whelk GAG extracts. Each value is presented as the mean SEM of three 
independent determinations. The bars in each chart are presented as relative values in comparison to untreated 
cells. 
Abbreviations: **- Highly significant (p≤0.01) 







3.25 Cell cycle analysis of the MDANQ01 breast cancer cell line after treatment with  
 purified whelk fraction E 
   Whelk fraction E induced cell cycle arrest on MDANQ01 cells at both S and G2/M 
phases as shown in Figure 3.25A-C. It caused significant accumulations of cells at S and 
G2/M phases, leading to the subsequent reduction in the overall number of cells in G1 phase. 
After 48 hours treatment with 50µg/ml whelk fraction E, the percentage of cell population at 
S-phase increased from 20.48 % (control) to 25.06 % (50 µg/ml fraction E). At 72 hours, the 
cell population at G2/M-phase increased from 21.27 % (control) to 38.46 % (Figure 3.25A-C) 
 This result suggests that purified fraction E partly elicits its anti-proliferative activity 
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Figure 3.25: Cell cycle analysis of MDANQ01 breast cancer cell line following treatment 
  with purified whelk fraction E. 
MDANQ01 breast cancer cells were stained with PI stain and subjected to cell cycle analysis by flow cytometry 
(A). Charts showed averages of three independent experiments after treatment with or without purified whelk 
fraction E (B) Flow cytometry of MDANQ01 breast cancer cells after 48 hours incubation with or without 
purified whelk fraction E and (C) Flow cytometry of MDANQ01 breast cancer cells after 72 hours incubation 
with or without purified whelk fraction E. 
Abbreviations: *- Significant (p≤0.05) 
 
3.26   Cell cycle analysis of the MDA468 cell line after treatment with Purified whelk 
    fraction E  
Cells exposed to 50ug/ml whelks fraction E showed perturbation of MDA468 cell’s 
cycle after 24-72 hours exposure to the purified extract. 
Whelk fraction E induced mild cell cycle arrest of MDA468 cells at both S and G2/M phases 
as shown in Figure 3.26A-C. After 24 hours treatment with 50µg/ml whelk fraction E, 
MDA468 cells population at S-phase increased from 21.94% (control) to 29.19% (50 µg/ml 
fraction E). 72 hours incubation of the cell with purified fraction E also increased the cell 
population at G2/M from 25.75% (control) to 35.75% (50 µg/ml fraction E). However, 48-
hour incubation of the purified fraction E with MDA468 cell did not have any effect on the 
cell cycle. 
           The purified fraction E showed consistent DNA disruptive effect on both breast cancer 
cell lines and these results suggest that the purified fraction E induces growth inhibitory 
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Figure 3.26: Cell cycle analysis of MDA468 breast cancer cell line following treatment 
   with purified whelk fraction E.  
MDA468 breast cancer cells were stained with PI stain and subjected to cell cycle analysis by flow cytometry 
(A). Charts showed averages of three independent experiments after treatment with or without purified whelk 
fraction E (B) Flow cytometry of MDANQ01 breast cancer cells after 24 hours incubation with or without 
purified whelk fraction E and (C) Flow cytometry of MDANQ01 breast cancer cells after 72 hours incubation 
with or without purified whelk fraction E. 
Abbreviations: *- Significant (p≤0.05) 
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3.27 Purified whelk fraction E induces mild apoptosis and necrosis on MDANQ01 
 breast cancer cells (revised Annexin V-FITC apoptosis detection assay results). 
High concentration (100µg/ml) of purified whelk fraction E induces mild apoptosis 
and necrosis on MDANQ01 cell (Figure 3.28 (A-B). 24-hour incubation of the purified 
fraction with the cells increased the number of cells stained with Annexin V-FITC from 1.02 
% (control) to 2.01 % (100µg/ml). The number of cells stained with both Annexin V-FITC 
and PI also increased from 7.07 % (control) to 9.3 % (100µg/ml). In addition, this extract 
induces mild necrosis on MDANQ01 cells: the cell stained with PI increased from 6.47 % 
(control) to 7.56 % (100µg/ml).  
However, lower concentration (20-50µg/ml) of the purified fraction did not yield any 
apoptotic effect on this cell line: both 8 and 72-hour incubations of the cells with the purified 



















Figure 3.27: Detection of Apoptotic MDANQ01 breast cancer cells treated with purified 
whelk fraction E by Annexin V Staining. 
MDANQ01 cells were treated with purified whelk fraction E for 24 hours and then stained using Annexin V-
FITC and PI provided in the Annexin V-FITC Apoptosis Detection Kit (see materials and methods). The 
combination of Annexin V-FITC and PI allows for the distinction between early apoptotic cells (annexin V-
FITC positive), late apoptotic and/or necrotic cells (Annexin V-FITC and PI positive), necrotic (PI stained 
6t66positive) and viable cells (unstained). (A) MDANQ01 cell treated with or without purified whelk fraction E 
24 hours. (B) Flow cytometry of MDANQ01 treated with or without purified whelk fraction E for 24 hours. 
24 hours  Untreated     Treated 
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3.28 Annexin V-FITC apoptosis assay of the MDA468 breast cancer cell line following 
 treatment with purified whelk fraction E  
Purified fraction E induces time-dependent apoptosis on MDA468 cells (Figure 
3.28A-C). 24 hours incubations of purified fraction E with the cells increased the number of 
cells stained with both Annexin V-FITC and PI from 16.48 % (control) to 20.96 % 
(50µg/ml). Similarly, 48-hour incubations of the purified fraction E also induce late apoptosis 
on MDANQ01 cells but the apoptotic effect was more pronounced than that observed at 24 
hours. At 48 hours, the number of cells stained with Annexin V-FITC and PI increased from 
8.2 % (control) to 14.16 % (50µg/ml). In addition to the apoptotic effect of the purified 
fraction on MDA468 cells, there was also an increase in the number of cells stained with PI; 
an indication of necrosis. At 48 hours, the number of cells stained with PI increased from 4.0 
% (control) to 7.4 % (50µg/ml).  
However, other concentrations (20 and 100µg/ml) of the purified fraction did not 
show any apoptotic effect on this cell line: both 8 and 72-hour incubations of the cells with 
the crude extract did not show any noticeable apoptotic effect on the MDA468 cell line 
(results not shown) presumable due to the extent of cell death seen in the higher doses. 
The observed apoptotic and necrotic effect of the purified fraction E on both breast cancer 
cells suggest the possible growth inhibition of these cells proliferation was caused by 
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Figure 3.28: Detection of time-dependent Apoptotic MDA468 breast cancer cells treated 
with purified whelk fraction E by Annexin V Staining. 
MDA468 cells were treated with purified whelk fraction E for 24 and 48 hours and then stained using Annexin 
V-FITC and PI provided in the Annexin V-FITC Apoptosis Detection Kit (see materials and methods). The 
combination of Annexin V-FITC and PI allows for the distinction between early apoptotic cells (annexin V-
FITC positive), late apoptotic and/or necrotic cells (Annexin V-FITC and PI positive), necrotic (PI stained 
positive) and viable cells (unstained). (A) MDA468 cells treated with or without purified whelk fraction E for 
24 and 48 hours. (B) Flow cytometry of MDA468 treated with or without purified whelk fraction E for 24 hours 

















Table 4: Summary of biological effects of fraction E 
 MDA468 breast 
cancer cell line 
MDANQ01 breast 
cancer cell line 
3T3 normal 
fibroblast cell line 
Proliferatve assay Inhibited cell growth Inhibited cell growth Supported cell 
growth 
IC50 45.98µg/ml 41.89µg/ml - 
Cell cycle arrest Induced cell cycle 
arrest at both S and 
G2/M phase 
Induced cell cycle 
































Characterisation and purification results  













3.29 Assignment of unsaturated CS dissacharides from cockle GAG extracts. 
                        In order to ascertain the presence of CS/DS-like disaccharides in crude cockle 
GAG extracts, samples were degraded by chondroitinase-ABC lyase, and the unsaturated 
disaccharides produced were resolved by SAX-HPLC. The major disaccharides produced 
were non and mono-sulfated Δ UA 1 → 3GalNAc, Δ UA 1 → 3GalNAc6S and Δ UA 1 → 
3GalNAc4S (Table 5). Commercial CS was analysed along side with samples for qualitative, 
and standardisation purposes and the digestion was monitored at 232 nm to assess when 
completion had occurred (Figure 3.29) 
The elution profiles for crude cockle GAG extracts were compared with the reference 
chromatogram and they showed that the crude cockle GAG extracts contains both CS\ DS 
(Figure not shown.). 
The first peak (I) with retention time 16 minutes is assigned to non-sulfated 
disaccharide (ΔDi-0S) composed ΔUA→3GalNAc. The second peak (II) with retention time 
19 minutes is assigned to mono-sulfated disaccharide (ΔDi-6S) composed of 
ΔUA→3GalNAc (6S). The third peak (III) with retention time 20 minutes is assigned to 
mono-sulfated disaccharide (ΔDi-4S) composed of ΔUA→3GalNAc (4S). The percentage 
compositions of each disaccharide peak from ABC lyase digested cockle GAG samples using 
the peak area were 60%, 20% and 20% respectively. Other unidentified peaks were also 
eluted along with the disaccharides which may suggest partial digestion or resistance to the 





Table 5: Disaccharides compositions of CS/DS-like glycans found in cockle GAG 
mixtures 
Disaccharides Cockle GAG mixtures 
disaccharide 
compositions in % 
Commercial CS 
GAG disaccharide 





Δ UA-GalNac 60 Not detected 16 
Δ UA-GalNac (6S) 20 27 19 
Δ UA-GalNac (4S) 20 73 20 
Δ UA (2S)-GalNac Not detected Not detected  
Δ UA-GalNac (4S,6S) Not detected Not detected  
Δ UA (2S)-GalNac (6S) Not detected Not detected  
Δ UA2S-GalNac4S Not detected Not detected  
 
The percentage compositions of each disaccharides peak was calculated by using peak area 











Figure 3.29: Kinectic of chondroitinase ABC enzyme degradation of commercial CS.  
Commercial CS was dissolved in enzyme buffer and 30µl of the enzyme was added. Digestion was measured 














3.30 Assignment of unsaturated HS dissacharides from cockle GAG extracts                              
 In order to examine the HS disaccharide compositions of crude cockle GAG extracts, 
smples were digested with heparinases 1, 11 & 111 enzymes. The resulting oligosaccharides 
were applied to a Pro-Pac PA-1 SAX-HPLC column (see materials and methods section for 
details). The number of peaks generated from crude cockle GAG extracts was compared to 
HS disaccharide standards obtained from complete digestion of commercial HS GAGs. The 
results obtained from this analysis, revealed that the invertebrate glycosaminoglycan yields 
mainly, the non- sulfated disaccharides ∆UA (1→4) GlcNAc (I) with retention time (Rt) 16 
minutes (Table 6). Both N-sulfated ∆UA (1→4) GlcNS disaccharide and 6- O-sulfated ∆UA 
(1→4) GlcNAc6S disaccharides were also detected (18 and 5% respectively).  
It is notewhorthy, that the two unsaturated disaccharides (∆UA (1→4) GlcNS6S and 
∆UA2S (1→4) GlcNS) peaks were also present in cockle HS but the percentage composition 
of each was less than one. Additionally, the mono-sulfated ∆UA2S (1→4) GlcNAc, the rare 
disulfated disaccharide (∆UA2S (1→4) GlcNAc6S) and the trisulfated disaccharide (∆UA2S 
(1→4) GlcNS6S) were completely absent in crude cockle HS-GAG and this form the major 
difference between the crude and the commercial GAG mixture. 
Furthermore, to confirm whether cockle GAGs contain low sulfated HS-like 
disaccharides, a portion of the crude extract was also digested with heparinise III enzyme and 
the resulting oligosaccharides resolved by SAX-HPLC revealed that the main disaccharides 
composition in cockle GAGs is non-sulfated ∆UA (1→4) GlcNAc disaccharide. Similarly, 
both N-sulfated ∆UA (1→4) GlcNS and 6- O-sulfated ∆UA (1→4) GlcNAc6S disaccharides 
peaks were also detected. However, the other three disaccharides (∆UA (1→4) GlcNS, ∆UA 
(1→4) GlcNS6S and ∆UA2S (1→4) GlcNS) peaks were completely absent in cockle HS-like 
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GAGs, in contrast to what was observed for the commercial HS digested with heparinise III 
(result not shown). 
 These results suggest that cockle mixture contain low sulfated HS-like GAGs and the 
disaccharides composition analysis also suggests that this mollusc HS-like GAG contain non-

















Table 6: HS Disaccharides compositions from heparinase digest of cockle GAG extracts 






∆UA (1→4) GlcNAc 75  55.00 
∆UA (1→4) GlcNS 18 18.00 
∆UA (1→4) GlcNAc6S 5.0 5.0 
∆UA2S (1→4) GlcNAc Not detected 6.0 
∆UA (1→4) GlcNS6S <1.0 2.0 
∆UA2S (1→4) GlcNS <1.0 7.0 
∆UA2S (1→4) GlcNAc6S Not detected <1.0 
∆UA2S (1→4) GlcNS6S Not detected 6.0 
 
The percentage compositions of each disaccharides peak was calculated using peak area 









3.31 Gel Filtration analysis (TSK 2000PW) of heparinase degraded cockle GAG 
 extracts  
A pilot study was conducted in order to ascertain the minimum amount of enzymes 
and time required to digest completely 1mg commercial HS and 1mg of crude cockle GAGs. 
Digestion was monitored by observing changes in the gel-filtration profile of the sample 
(result not shown). The digestion appeared complete after additions of 30mU of Heparinase I, 
II and III and incubation for a 48-hour period at 37 
0
C. Further addition of enzyme and 
incubation for a further 24 hours caused degradation of the disaccharides into smaller units 
(monosaccharide) (results not shown). 
 After 48 hours’ incubation of either crude or commercial HS GAGs with Heparinase 
I, II and III enzymes, a 50 μl of the digested sample was applied to TSK 2000PW column and 
the eluted profile was monitored at 232 nm for 180 minutes. The elution profiles obtained for 
both comercial HS and crude cockle GAGs confirmed a complete digestion of both samples 
as shown in Figure 3.30 (A-B). This result confirms the SAX-HPLC finding presented in the 
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Figure 3.30: Analytical TSK2000PW gel-filtration profiles of HS/Heparin and crude 
  cockle GAGs after complete digestion with Heparinase I, II and III  
  enzymes 
50 µg of the enzymes GAGs digest by the Heparinase I, II and III enzymes were chromatographed on a 
TSK2000PW analytical gel-filtration column (30 x 0.75 cm) and the elution was monitored at 232 nm for 180 
minutes. (A) Elution profile for commercial HS/Heparin standard digested in Heparinase I, II, and III. (B) 
Elution profile for crude cockle GAGs digested in Heparinase I, II, and III. (C) Elution profile for HS/Heparin 














3.32 Superose 12 size exclusion chromatography analysis of intact cockle extracts  
     GAG chains                                                                      
Cockle GAG extracts were analysed for size using a superose 12 size exclusion column. 
GAG content of the fractions collected from this column was determind by cellulose acetate 
dot blotting assay. This showed that fractions 1-14 & 28-40 did not contain any GAGs 
(Figure 3.31), however fractions 15-27 showed distinct binding of azure A stain to the 
sulfated GAG components present in these fractions. The intensity of the stain is relatively 
proportional to the concentrations of GAGs present in each fraction i.e. the more GAGs in the 
fraction, the deeper the stain. Quatitative analysis of GAGs compositions in crude cockle 
GAG extracts was determind by densitometry analysis; the result shows two major GAGs 
containing peaks were eluted from the Superose 12 column. The larger molecular weight 
species [fractions 15- 20 (A)] were eluted first, followed by the smaller polysaccharide 








Figure 3.31: Superose 12 size exclusion chromatography and cellulose acetate dot  
  blotting result for crude cockle GAG mixture 
(A) Cellulose acetate dot blotting assay result for crude cockle GAG mixture (B) Densitometry and scan 
analysis of cellulose acetate dot blotting: each peak represents GAG with relative size based on their structural 
composition and ionic contents (SO3 and COO
-
) 
11 12 13 14 15 16 17 18 19 20 
21 22 23 24 25 26 27 28 29 30 





3.33 PAGE analysis of crude cockle GAG extracts and commercial GAGs after 
 enzymatic depolymerisation. 
 The crude cockle GAG extracts and commercial GAGs treated separately with 
heparinase (I, II, and III) and ABC lyase enzymes were analysed using PAGE. The results are 
presented in Figure 3.32. 
All intact GAG samples show slow moving and very diffuse and unresoved bands [(Figure 
3.32 (2, 3, 5 and 8)], indicating a heterogeneous mixture of GAG chains. Conversely, all the 
enzyme-treated samples demonstrated faster-moving bands; thus indicating shorter chain 
oligosaccharides due to degredation of chains by the enzymes [(Figure 3.32 (1, 4, 6 and 7)]. 
These results confirmed the presence of both CS/DS-like and HS-like oligosaccharides in the 










Figure 3.32: PAGE analysis of enzymatic depolymerised GAGs. 
All the commercial GAGs and crude cockle GAG mixture were incubated with heparinase (I,II, and III) and 
ABC lyase enzymes separately for 48 hours and approximately 20 μl of the degraded sample was applied to 
each lane. (1) Crude cockle GAG extracts digested with ABC lyase enzyme. (2) Intact crude cockle GAG 
extracts. (3) Intact crude cockle GAG extracts. (4) Crude cockle GAG extracts digested with Heparinase I,II, 
and III enzymes. (5) Intact HS commercial GAG (6) HS-GAG sample digested with Heparinase I, II, and III 
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3.34 Assignment of unsaturated CS dissacharides for whelk GAG extract  
Whelk GAG extracts was digested with the enzyme chondroitinase ABC lyase in 
order to determine the presence of CS/DS-like GAGs. The digestions were monitored 


































Figure 3.33: Kinetic of chondroitinase ABC enzyme degradation of GAGs 
Commercial CS and whelk GAGs was each dissolved in enzyme buffer and 30µl of the enzyme was added to 
each dissolved sample. Digestion was measured continuously by the change in absorbance at 232 nm on a 
spectrophotometer. (A) Commercial CS in chondroitinase ABC enzyme (B) Crude whelk GAG in 









 The elution profile for crude whelk GAG extracts, compared with the reference 
chromatogram, showed that the crude whelk GAG extracts contain both CS/DS-like 
disaccharides (Table 7). The percentage composition of each disaccharide peak was 
calculated and data recorded in table 4. The main disaccharides peaks, as resolved by SAX-
HPLC, are mono-sulfated disaccharide (ΔDi-6S) composed of ΔUA→3GalNAc (6S) and 
(ΔDi-4S) composed of ΔUA→3GalNAc (4S). These two peaks compared favourably, by 
retention time, with the commercial CS disaccharides peaks. However, there are other broad 
peaks eluted along with the disaccharides, which may indicate partial digestions or resistance 















Table 7: Disaccharides compositions of CS/DS-like glycans found in whelk GAG  
     extracts 
Disaccharides Whelk GAG composition ( 
%) 
Commercial CS 
composition ( %) 
Δ UA-GalNac Not detected Not detected 
Δ UA-GalNac (6S) 55 73 
Δ UA-GalNac (4S) 45 27 
Δ UA (2S)-GalNac Not detected Not detected 
Δ UA-GalNac (4S,6S) Not detected Not detected 
Δ UA (2S)-GalNac (6S) Not detected Not detected 
Δ UA2S-GalNac4S Not detected Not detected 
 
The percentage compositions of each disaccharides peak was calculated using peak area 








3.35: PAGE analysis of crude whelk GAG extracts and commercial GAGs after 
 enzymatic depolymerisation. 
The crude whelk GAG extracts and commercial GAGs were treated separately with 
heparinases I, II and III and with ABC lyase enzymes and analysed using PAGE. The results 
are presented in Figure 3.34. 
All the intact GAG samples show a very diffuse bimolecular weight band [(Figure 3.34 (2, 3, 
5 and 8)], indicating a long linear polymer chain with hetergenous populations. Conversely, 
all the enzyme treated samples showed faster moving less intensely stained bands indicating 
shorter chain oligosaccharides as products of enzymatic digestion, these differences can be 
used to determine the specific presence of GAG subfamilies based on the enzymatic 
specificities of the enzymes [Figure 3.34 (1,4,6 and 7)]. 
 These results confirmed the presence of both CS/DS-like and HS-like 














Figure 3.34: PAGE analysis of enzymatic depolymerised GAGs. 
All the commercial GAGs and crude whelk GAG extracts were incubated with heparinase (I, II, and III) and 
ABC lyase enzymes separately for 48 hours and approximately 20 μl of the degraded sample was applied to 
each lane. (1) Crude whelk GAG extracts digested with Heparinase I, II,and III enzymes. (2) Intact crude whelk 
GAG extracts. (3) Intact HS commercial GAG. (4) HS commercial GAG digested with Heparinase I,II, and III 
enzymes. (5) Intact whelk GAG extracts (6) Whelk GAG extracts mixture digested with ABC lyase enzyme. (7) 
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3.36 Superose-12 size exclusion chromatography of crude whelk GAG Extracts.                  
 The results obtained show that crude whelk GAG extracts contain five main peaks 
with varying sizes, by UV monitoring and GAG binding dot blot assay.The void volume of 
the column (V0) was calculated as being at fraction 14, as shown in Figure 3.35, with 
fractions (15-32) contains varying concentrations of GAGs within the five peaks eluted. The 
qualitative analyses of the five GAG peaks were performed using densiometry of the stained 
dot blot. Each peak represents different populations of GAG chains eluting according to their 
















Figure 3.35: Superose 12 size exclusion chromatography and cellulose acetate dot   
     blotting assay of crude whelk GAG extract. 
(A) Cellulose acetate dot blotting assay result for crude whelk GAG mixture (B) Densitometry and scan analysis 
of cellulose acetate dot blotting.  
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Characterisation of purified whelk  












3.37 Assignment of unsaturated CS dissacharides from purified whelk GAG fractions  
In order to ascertain which of the whelk GAG peaks obtained from the ion exchange 
column contain CS/DS-like GAGs, samples were digested with chondroitinase-ABC lyase. 
The resulting oligosaccharides products were analysed by SAX-HPLC. Only two fractions (B 
and C) from the ion exchange column (Table 8) were sensitive to depolymerisation by 
chondroitinase ABC lyase, the other three peaks (A, E & F) were resistant to the action of 
this enzyme. The depolymerised whelk GAG peaks B and C produced two major peaks 
which were identified as Δ UA-GalNac6S and ΔUA-GalNac4S. The oligosaccharides peaks 
were identified by comparing their elution positions with those of standard oligosaccharides 
obtained from commercial CS GAGs.  
 The SAX-HPLC separation of the unsaturated oligoccharides produced by the action 
of chondroitinase-ABC on purified whelk fraction B produced three major disaccharide 
peaks, assigned to unsaturated non-sulfated Δ UA-GalNac (di-0S), mono-sulfated Δ UA-
GalNac6S (Di-6S) and ΔUA-GalNac4S (DI-4S). From the peak areas, it could be calculated 
that these three disaccharides contain 55% Δ UA-GalNac, 35% Δ UA-GalNac6S and 10 % 
ΔUA-GalNac4S of the total disaccharide composition (Table 8). Other unidentified peaks 
were also eluted with the oligosaccharides which may be an indication of contamination or 
imcomplete digestion of the polymer. 
 Simlarly, SAX-HPLC result of depolymerised peak C demonstrated two major 
disaccharides peaks with similar elution profiles to the commercial CS disaccharides (Table 
5). The first peak was assigned the mono-sulfated disaccharide Δ UA-GalNac6S (ΔDi6S). 
Also from the peak areas, it could be calculated that these two disaccharides contain 22% Δ  
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UA-GalNac (6S) and 78 % Δ UA-GalNac (4S). Other unidentified peaks were also eluted 
along with the disaccharides which may suggest contamination or resistance to 
chondroitinase-ABC enzyme. 
Fractions A, F and the biologically active fraction E were found to be resistant to chondroitin 
ABC lyase treatment and did not produce any degredation peaks. Further investigation of the 
biologically active fraction E was obviously required in order to confirm the nature of the 
















Table 8: Disaccharides compositions of CS/DS-like GAGs present in ion-exchange  
 purified whelk peaks B and C 
Disaccharides Whelk fraction B 
disaccharide 
composition ( %) 





composition ( %) 
Δ UA-GalNac 55 Not detected Not detected 
Δ UA-GalNac (6S) 35 22 23 
Δ UA-GalNac (4S) 10 78 77 
Δ UA (2S)-GalNac Not detected Not detected Not detected 
Δ UA-GalNac (4S,6S) Not detected Not detected Not detected 
 
The percentage composition of each disaccharides peak was calculated using peak area 









3.38 Heparinase I-III enzymatic treatments and disaccharide analysis by SAX-HPLC 
of the active whelk fraction E 
To further elucidate the HS-like disaccharides in ion-exchange purified whelk GAG peak 
(fraction E), the pooled biologically active fraction E was digested with Heparinase I, II, and 
III enzymes. The resulting oligosaccharides were resolved by SAX-HPLC and showed six 
confirmed HS disaccharide peaks with some minor contamination from other unidentified 
peaks. The major disaccharides peak from the heparinase digested fraction E was assigned to 
non- sulfated HS disaccharide ∆UA- GlcNAc, which comprised 60 % of the total 
disaccharide composition of fraction E (Table 9). The N-sulfated disaccharide ∆UA -GlcNS 
was also present with a percentage composition of 29%. The 6- O-sulfated ∆UA -GlcNAc6S 
disaccharide has a percentage composition of 2% of the total disaccharides composition. The 
forth peak was assigned to the unsaturated ∆UA-GlcNS (6S) disaccharide with a percentage 
composition of  7 %. The fifth peak was assigned to the rare di-sulfated ∆UA (2S)-GlcNAc6S 
disaccharide with a very low composition of less than 1%. The tri-sulfated disaccharides 
∆UA (2S) (1→4) GlcNS (6S) was also present in this polysaccharide but the percentage 
composition was very low (1%). Interestingly, the 2-O-sulfated ∆UA (2S)-GlcNAc and ∆UA 
(2S)-GlcNS disaccharides were completely absent from this polymer and this form the major 
difference between this novel and the commercial HSGAGs disaccharides. However the 
disaccharide analysis couldn’t rule out the presence of disaccharides not normally seen in HS 
that might account for the different activities observed with Whelk derived GAGs and 
commercial HS. 
Fraction E was also digested with heparinases I, II, and III individually, to identify the 
specific enzyme or enzymes responsible for the depolymerisation of whelk fraction E. 
Enzymatic activities were monitored by following the increase in UV absorbance at 232 nm 
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with time and the resulting oligosaccharide were applied to SAX-HPLC column and resolved 
using a NaCl gradient.  Heparinase I and II showed limited ability to degrade the fraction E 
GAGs. In contrast, heparinise III demonstrated significant activity against this polysaccharide 
(Table 10). This result suggests that whelk fraction E contains a significant proportion of low 


















Table 9: Disaccharides compositions of HS-like GAGs found in purified whelk fraction 
  E. 






∆UA (1→4) GlcNAc 60  55.00 
∆UA (1→4) GlcNS 29 18.00 
∆UA (1→4) GlcNAc6S 2 5.0 
∆UA2S (1→4) GlcNAc Not detected 6.0 
∆UA (1→4) GlcNS6S 7 2.0 
∆UA2S (1→4) GlcNS Not detected 7.0 
∆UA2S (1→4) GlcNAc6S <1 <1.0 
∆UA2S (1→4) GlcNS6S 1 6.0 
 
The percentage composition of each disaccharides peak was calculated using peak area 







Table 10: Disaccharides compositions of HS-like GAGs found in purified whelk fraction 
  E depolymerised by heparinase III lyase. 
HS disaccharides Whelk fraction E  
disaccharide composition  
(%) 
Commercial HS  
disaccharide compositions  
(%) 
∆UA (1→4) GlcNAc 75.00  59.00 
∆UA (1→4) GlcNS 16.00 22.00 
∆UA (1→4) GlcNAc6S 1.00 4.00 
∆UA2S (1→4) GlcNAc Not detected 7.00 
∆UA (1→4) GlcNS6S 8.00 2.00 
∆UA2S (1→4) GlcNS Not detected 6.00 
∆UA2S (1→4) GlcNAc6S Not detected Not detected 









3.39 HPLC Gel Filtration analysis of whelk fraction E after heparinase degradation         
 The digestion of the purified whelk fraction E was monitored through changes in the 
gel-filtration profile of the sample (result not shown). The digestions appeared complete after 
additions of 30mU of Heparinase I, II and III, followed by continuous incubation for 48 hour 
period at 37 
0
C. After 48 hours’ incubation of purified whelk fraction E or HS/heparin GAG 
with heparinase I, II and III enzymes, a 50μl of the digested sample was applied to TSK 
2000PW column and the eluted profile was monitored at 232 nm for 180 minutes. The elution 
profiles obtained for both HS/Heparin and purified whelk fraction E confirm complete 
digestion of both samples as shown in Figure 3.36 (A-B). This result confirms the SAX-
HPLC result described in the previous section and the single broad peak obtained 
corresponds to HS disaccharides (dp
2
). 
However, heparin digested with Heparinase I enzyme for 48 hours shows a number of 
oligosaccharide peaks in addition to the usual disaccharide peak; an indication of incomplete 
degradation of the commercial GAGs. The peaks corresponding to the various 
oligosaccharides are also labelled appropriately in Figure 3.36 (C). Both SAX-HPLC and 












































































Figure 3.36: Analytical TSK2000PW gel-filtration profiles of HS/heparin and purified 
whelk fraction E after complete digestion with Heparinase I, II and III enzymes. 
50 µg of the enzymes GAGs digest by the Heparinase I,II and III enzymes were chromatographed on a 
TSK2000PW analytical gel-filtration column (30 x 0.75 cm) and the elution was monitored at 232 nm for 180 
minutes. (A) Elution profile for commercial HS/Heparin standard digested in Heparinase I,II, and III. (B) 
Elution profile for purified whelk fraction E digested in Heparinase I, II, and III. (C) Elution profile for 














3.40 PAGE analysis of purified whelk fractions and commercial GAGs after  
   enzymatic depolymerisation. 
The purified whelk GAG extracts and commercial GAGs were digested individually 
and with a mixture of Heparinases I, II, and III enzymes. Similarly, these polysaccharide 
fractions were also digested individually with ABC chondroitinase enzyme. The resulting 
oligosaccharides from each enzyme digestion were analysed using PAGE (Figure 3.37). 
All the intact GAG samples show a very intense and diffuse banding pattern [(Figure 3.37 (2, 
3, 5 and 8)] indicating a heterogeneous mixture of polymer chains, a unique characteristic of 
GAGs polymers.  
Conversely, all the sensitive enzyme-treated samples show less intensely staining 
bands and faster mobilities, suggesting breakdown into shorter chain oligosaccharides 
[(Figure 3.37 (1,4,6 and 7)]. 
This result confirmed the presence of both CS/DS and HS-like oligosaccharides in the crude 







Figure 3.37: PAGE analyses of enzymatic depolymerised whelk derived and   
  commercial GAGs. 
All the commercial GAGs and crude purified whelk fractions were incubated with heparinase (I,II, and III) and 
ABC lyase enzymes separately for 48 hours.(1) Intact fraction C dissolved in enzyme buffer. (2) Purified 
fraction C digested with chondroitinase-ABC lyase. (3) CS commercial GAG digested with chondroitinase-ABC 
lyase.intact HS commercial GAG. (4) Intact CS commercial GAG dissolved in enzyme buffer (5) Intact purified 
whelk fraction E dissolved in enzyme buffer. (6) Purified fraction E digested with Heparinase I, II and III. (7) 
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3.41 Superose-12 size exclusion chromatography of purified whelk fraction E 
The results obtained from these analyses revealed that purified whelk fraction E 
contain sulfated GAGs, as illustrated in Figure 3.38 since azure A binds to GAGs in this 
fraction.The GAG content/overall sulfate content in each fraction is proportional to the 
intensity of staining. Scanning densitometry analysis of the cellulose acetate dot blotting 
assay shows that fraction E contains one major and high molecular weigh GAG componant, 
this corresponds to the largest peak seen in the superpose-12 seperation of the un-fractionated 
crude GAG extract (Figure 3.35). It also contains a minor peak corresponding to one of the 



















Figure 3.38 Superose-12 size exclusion chromatography and cellulose acetate dot  
  blotting assay for purified fraction E GAG mixtures 
(A) Cellulose acetate dot blotting assay result for purified fraction E (B) Scanning densitometry analysis of 
cellulose acetate dot blots: each peak represents GAG with relative size based on their structural composition 




























4.1  Outline of the major findings 
The results of this study provide significant insight into the pharmacological properties of 
whelk and cockle derived GAGs in different cancer cells, including breast, cervical and 
leukaemia cell lines. A summary of the main findings are indicated below: 
 Whelk GAGs inhibit the growth of negative eastrogen receptor (ER-ve) breast cancer 
cell in vitro (MDA468 and MDANQ01) 
 Whelk GAGs also inhibit the proliferation of cervical cancer cell (HeLa) in vitro  
 They  also inhibits the growth of both erythroleukaemia (K562) and lymphoblastic 
(MOLT-4) leukaemia cell in vitro 
 Whelk GAGs cause cell cycle arrests in both leukaemia and breast cancer cell  
 Whelk GAGs induce apoptosis in both cervical and leukaemia cell  
 Whelk GAGs contain both CS/DS and HS-like GAGs 
 Fraction E obtained by ion-exchange chromatography of whelk GAG extracts showed 
selective anti-cancer activity against breast cancer cell lines. 
 Fraction E caused cell cycle arrest and initiated apoptosis in breast cancer cell lines 
 Cockle  derived GAGs showed selective anti-cancer activity against both 
erytholeukaemia and lymphoblastic leukaemia cells 
 Cockle GAGs brought about cell cycle arrest on lymphoblastic leukaemia cells 
 Cockle GAGs induced apoptosis on lymphoblastic leukemia cells 
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4.2    Selective anti-cancer activity of cockle GAGs against leukemia cell lines 
Previous studies have revealed the anti-cancer activities of some GAG-like 
compounds, for example, low molecular weight heparin, HS mimetics and some modified 
CS/DS compounds (Afratis et al 2012 : Babara et al 2012 : Neha et al 2010 : Mellor et al 
2007). No studies have linked therapeutic activity of mollusc derived GAGs to anti-cancer 
activity in breast and leukemic cancer cells. GAG extracts isolated from cockle molluscs had 
a significant growth inhibitory effect (p<0.001) on erythrocytic leukemic cells (K562) and 
lymphoblastic leukemic cell (MOLT-4) (fig.3.3A and 3.4A). The recorded IC50 for the two 
cell lines were 16 (MOLT-4 cell line) and 50 (K562 cell line) µg/ml respectively. According 
to the standard criteria set by the National Cancer Institute (Chen et al, 1988; Geran et al, 
1972), crude natural product extracts possessing an IC50 of less than 20 μg/ml are considered 
active against appropriate cancer cell lines.  
Cockle GAGs extracts revealed a recorded IC50 of less than 20 μg/ml in MOLT-4 cell 
proliferation assay and this according to the National Cancer Institute categorise it as an 
active anti-leukemic cancer drug. Interstingly, this GAG mixture was non-toxic to a normal 
fibroblast cell line (3T3); a cell line that is frequently used as the model for the cytotoxicity 
testing in normal cells.  Similarly, high concentration of cockle GAG extracts did not show 
any effect on cell proliferation of MDA468 and MDANQ01 breast cancer cells (fig.3.1A & 
B). In this regard, the cytotoxicity of this novel GAG was highly selective against K562 and 
MOLT-4 leukemic cell type and non-toxic to normal cells. It would be interesting to 
determine the exact biochemical nature of this selectivity and if time had allowed a LC 
MS/MS proteomic and pathway analysis examination would have been attempted before and 





4.3 Evidence of broader and stronger anti-cancer activity of whelk GAGs extracts 
Globally, breast cancer is currently one of the leading causes of death and the most 
commonly diagnosed cancer in women aged below 39 years. Among women aged 35-39 in 
the UK, around 1,350 cases of breast cancer are diagnosed each year (Breast cancer 1975-
2010). Estrogen receptor negative (ER
-ve
) breast cancers are tumours with a distinct natural 
history, treatment response, and prognostic profile (Wang and Lin 2008). ER
-ve
 breast cancers 
make up 25%–30% of all breast cancers, and their clinical course tends to be more aggressive 
than that of estrogen receptor positive (ER
+ve
) breast cancers (Wang and Lin 2008). Patients 
with ER
-ve
 breast cancer generally have shorter disease-free survival and overall survival 
times (Wang and Lin 2008). Most patients with ER
-ve
 tumours do not benefit from anti-
hormonal therapy, and are also disadvantaged because of the resistance issues associated with 
many anti-cancer therapies (Wang and Lin 2008). Conventional breast cancer treatment 
involves surgery that may be coupled with radiation, chemotherapy and systemic adjuvant 
therapy (Koo et al, 2008).  
The approach of modulating tumour progression with drugs that inhibit growth of 
tumours is one of the new concepts in adjuvant chemotherapy when used alone or in 
combination with classic anti-tumour drugs (Basappa et al, 2012). Currently, there is great 
interest in the search for new anti-cancer drugs that can improve patient responses to cancer 
treatment and reduce the number of deaths, while minimizing the side effects. Certain types 
of GAG chain have been reported to be potentially useful in cancer therapy and are predicted 
to have minimal side effects (Basappa et al, 2012).  
Our data, which shows selective activity amongst tumour cell lines and normal tissue, 




The presence of GAGs in both vertebrates and invertebrates has been attributed to 
many physiological and biological roles including carcinogenesis and angiogenesis through 
its interaction with some growth factors and their receptors (Gomes et al, 2010). Yamada and 
others have reported the isolation of all groups of GAGs including sulfated and non-sulfated 
from many animals including molluscs (Yamada et al, 2007: Nader et al, 1983: Cassaro and 
Dietrich, 1977). 
The whelk GAG extracts demonstrated unique anti-cancer activity against many 
cancer cells including Estrogen receptor (ER)-negative breast cancer in vitro. It is an 
extremely important observation for possible intervention in the hard to treat cancers. In 
contrast to the observed selective anti-cancer activity of cockle GAG extracts against certain 
cancer cells, whelk GAG extracts, was cytotoxic to all cancer cell lines tested in this work. 
This GAG extracts demonstrated significant (p<0.001) growth inhibitory effects on both 
MDA468 and MDANQ01 breast cancer cell with recorded IC50 70.96 and 25.14 µg/ml 
respectively. The growth inhibitory effect of this novel GAG on the two breast cancer cell 
lines tested were shown to be dose-dependent and MDANQ01was more sensitive to the 
GAG’s treatment than MDA468.  
These results suggests a possible synergy between the reductase enzyme that is 
present in MDANQ01 and whelk GAG mixture which may have made the cell line more 
susceptible to growth inhibitory effects of whelk GAG mixture. It is very likely that other 
gene difference play a role in the observed selectivity and only a detailed 
proteomic/transcriptomics and pathway analysis may resolve this. The growth inhibitory 
activity of whelk GAG mixture was comparable to the effect of cisplatin anti-cancer drug on 
the two cancer cell lines (Figure 3.9A and 3.10A). 
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However, the results obtained earlier for similar GAGs extracted from another 
shellfish (cockle GAG) did not show any inhibitory effect on the proliferation of these breast 
cancer cells; thereby suggesting that the inhibitory effect may be a unique fine structural 
feature of the GAGs derived from whelks. In addition, the non-toxic activity of all other 
commercial GAGs (HS/Heparin and CS/DS) tested along side whelk GAG mixtures on the 
two breast cancer cell lines suggest that the whelk GAG contains some unique structural 
features not seen in the commercial GAG samples. These structural features may be a unique 
pharmacological feature that makes whelk derived GAGs a potential candidate as the basis 
for a future anti-cancer drug.  
Furthermore, whelk GAG Extracts were also cytotoxic to erythrocytic (K562) and 
lymphoblastic (MOLT-4) leukemic cells (Figure 3.11A&B). The cytotoxic activity of whelk 
GAG mixture was more pronounced on both cervical (Hela) and erythrocytic leukemic cells  
with recorded IC50 of 10.47 and 12.57 µg/ml respectively (Figure 3.11 and 3.12). However, a 
higher IC50 of 49.11 µg/ml was recorded for lymphoblastic leukemia cell but this GAG 
extract did not show any noticeable cytotoxic activity against normal fibroblast cell (3T3), an 
indication of selective activity against cancer cell growth. Indeed the differences in IC50 
values for the five different cancer cell lines suggests that the whelk GAG mixtures could be 
selective to certain cell types and this selectivity may well be important in targeting the 
effects of these molecules towards tumour cells.  
Additionally, in breast cancer, changes in GAG and proteoglycan expression on the 
cell surface and in the ECM allow tumour cells to proliferate, gain the ability to invade 
surrounding tissues, metastasize to distant organs and induce angiogenesis (Koo et al, 2008). 
Therefore, a novel exogenous GAG (like the whelk GAG extracts) with unique structural 
composition may modulate this effect in various ways (see later discussion), which may 
ultimately leads to growth inhibition observed in this study. The whelk GAG extracts may act 
227 
 
in several ways: by activating (agonists) or inactivating (antagonists) protein-based receptors, 
competing with endogenous GAGs and/or inhibiting GAG biosynthesis etc. (Ghandi and 
Mancera, 2010). 
 This result is also consistent with the findings of Linhardt and others who have 
identified some new classes of GAG chain-based molecules (neoglycans, low molecular 
weight heparin, ultra low molecular weight heparin, HS mimicking compound and heparin 
mimicking compound)  with anticancer activity ( Lindhardt 2011: Xu et al 2011:Zhou et al 
2011) . Whelk GAG extracts show comparative anti-cancer activities to this class of GAG 
chain-based molecules with similar IC50. However, native CS and unfractionated heparin did 
not inhibit cell death in all the cancer cells tested along with the GAG chain drugs: 
commercial GAGs likewise did not have any growth inhibitory effect on any of the cancer 
cells tested in this study (Afratis et al 2012: Linhardt and Liu 2012:  Borsig et al 2011:  Neha 
et al 2010: Pumphrey et al 2002) 
 
 4.4    Selective anti-cancer activity of whelk bioactive fraction E against breast cancer 
  cell. 
It has been reported previously that understanding the fine structure and specific 
biological roles of GAGs may lead to the development of novel therapeutic approaches 
(Afratis et al, 2012). In order to study the fine structure of the whelk GAG mixtures, the 
crude extract was purified by ion-exchange chromatography and the resulting fractions were 
tested on some cancer cell lines (Figure 3.23 and 3.24). All the fractions eluted were non-
toxic to breast cancer cell except fraction E. Fraction E was found to be cytotoxic to both 
MDA468 and MDANQ01 with recorded IC50 value of 45.98 and 41.89µg/ml respectively. 
The cytotoxic effect of fraction E on both cancer cell lines was dose-dependent and similar to 
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the crude extracts. In contrast to the crude extract, fraction E was non-toxic to other cancer 
cell lines such as HeLa, K562, MOLT-4 and normal fibroblast (3T3) cell.  
These  results suggests that this fraction E was selective against breast cancer cells, 
mirroring that results seen for the original crude whelk GAG mixtures and may possess a 
unique structure that inhibits the growth of breast cancer cell lines tested in this study (see 
later discussion). The results  with fraction E suggests that this fraction is the bioactive 
component responsible for the anti-cancer activity of whelk GAG extracts, at least those seen 
with the breast cancer cell lines. Further understanding the exact structural features seen in 
this particular fraction may open a new therapeutic approach to cancer therapy.  
 
 
4.5 Molecular mechanism of action of cockle GAG extracts on leukaemia cell lines 
 Recently, cell cycle analysis has been used to identify a molecular target for new anti-
cancer drugs (Basappa et al, 2012: Dawson et al, 2008: Marks 2007 and Tiligada et al, 2002). 
Cellular proliferation is mediated primarily by cell cycle which consists of four distinct 
sequential phases (G0/G1, S, G2, M).They are controlled by cellular signalling regulatory 
mechanisms involving a family of proteins that have variable level of expression according to 
the stage of the cell cycle (van den Heuvel 2005: Jack and Weinberg, 1996).  
 Perturbations in cell cycle regulation are reported as one of the most common features 
of the transformed cell (Weinstein, 1996), which could be associated with gain of function for 
uncontrolled growth due to enhanced expression of growth-factor-receptor autocrine loop 
(Earp et al, 1995). Several therapeutic agents including some anti-cancer drugs, such as 
DNA-damaging drugs, microtubule inhibitors, anti-metabolites, and topoisomerase inhibitors, 
take advantage of disruption in normal cell cycle regulation to target checkpoint controls and 
ultimately induce growth arrest or apoptosis of tumourogenic cells. 
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 Leukemia cell are known to be very sensitive to any chemotherapeutic agents/drug 
that either disrupt the cell cycle or cause apoptosis (Askoy et al 2008). Some of these 
chemotherapeutic agents cause leukemia cell death through usual DNA disruption, while 
others cause cell death by programmed cell death (apoptosis); a key player in the balance 
between cell replication and cell death (Feng et al 2007). Many chemotherapeutic agents are 
effective on the cells that are in the S phase of the cell cycle (Askoy et al 2008). However, 
other chemotherapeutic agents such as artemisinin mainly arrests the cell cycle in the G1 
phase, while paclitaxel and lycorine were shown to arrest the cell cycle in the G2/M phase 
and induce apoptosis by increasing the activation of caspase-8, caspase-9, or caspase-3 
(Pezuto et al 1997). Similarly, an increase in the percentage of cells in the G2/M phase upon 
treatment with sulforaphane was observed in HT29 human colon cancer cells as well as in 
Jurkat T-leukemia (Singh et al 2004). Cisplatin also cause cell cycle arrest at both the G1/S 
and G2/M checkpoints (Roberts and Thompson, 1979). 
  In the present study, cockle GAG extracts caused time-dependent disruption in 
lymphoblastic leukaemia cell cycle regulations, resulting in G1 and G2/M-phase arrest with a 
concomitant marked reduction of cells at S-phase. This result is consistent with the cell cycle 
arrest cause by many other chemotherapeutic agents listed above which is primarily cause by 
the accumulation of the chemotherapeutic agent. The ultimate effects might mediate DNA 
strand breaks, which can cause the failure of DNA repair and subsequent arrest of the cell 
cycle during the G1 and G2/M-phase. This result is also similar to the actions of other 
chemotherapeutic agents which commonly intervene at multiple points in the cell cycle. 
 These drugs have been reported to have diverse mechanisms of action and exhibit 
specificity in terms of the stage of the cell cycle in which they have activity (Johnson and 
Walker, 1999). This type of checkpoint arrest (G1 and G2/M) is common to some DNA 
damage anti-cancer drugs like cisplatin and is one of the most established chemotherapeutic 
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approaches in cancer treatment (Roberts and Thompson, 1979). Zhan et al.reported the 
mechanisms of actions of cisplatin cell cycle arrest at G1 phase is mediated by p53, which 
induces an increase in p21, resulting in inhibition of cyclin/cdk2 and cyclin/cdk4 complexes 
and hypophosphorylation of Rb (Zhan et al, 1993).The G2/M checkpoint induced by DNA 
damage can occur by either p53-dependent or –independent mechanisms (Zhan et al, 1993). 
Both p21 and phosphorylation of cdk1 is required for entry into M and can participate in the 
DNA damage G2/M checkpoint. 
 Fan and his co-worker also reported that tumour cells in which p53 is inactive can 
bypass the G1/S checkpoint and exhibit increased sensitivity to DNA-damaging agents such 
as cisplatin (Fan et al, 1997) as a result of failure to arrest and repair their damaged DNA.                             
These researches indicated that chemotherapeutic agent causes cell cycle arrest at both G1 
and G2/M phase of the cell cycle similar to what was observed in the present study. 
Therefore the G1 and G2/M cell cycle arrest cause by cockle GAG mixture on leukemia 
cell may predictably has a similar mechanism of actions described by Zhan and Fan above. 
Unfortunately, the cell cycle regulators (cyclins and cdk’s) that control G1 and G2/M 
check points were not done during this project work and this may perhaps provide a better 
explanation for the mechanism of cell cycle arrest caused by cockle GAG extracts. This 
finding indicates that the cell growth inhibitory effect of cockle GAG extracts on leukaemia 
cells is due, in part, to its cell cycle arrest. The mechanism underlying the cell cycle arrest 
effect of cockle GAG mixtures remains unclear and this can easily be resolved by 
investigating the cell cycle regulators that control the transition of cell at G1, G1/S (CDK2 , 
CDK4, cyclin E and D and CDKI’s) and G2/M (CDK1, cyclin A and B) phase using western 
blotting  analysis. 
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4.6  Molecular mechanism of action of whelk GAG extracts on breast cancer cell 
 The perturbation of normal cell cycle controls, which is the hallmark of cancer, 
provides numerous opportunities for targeting checkpoint controls to develop new therapeutic 
strategies for this disease. Such strategies include induction of checkpoint arrest and arrest of 
proliferating cells at various stages of the cell cycle, which may sensitize them to treatment 
with other therapeutic agents such as radiation, and targeting of therapies towards specific 
regulatory components of the cell cycle (Johnson and Walker 1999). 
  Matsui et al reported S-phase arrest caused by methotrexate and 5-fluorouracil, a 
known DNA-damaging agent that inhibit DNA synthesis (Matsui et al, 1996). Lowel et al 
also reported that tumour cells in which p53 is inactive, DNA damage induced by these drugs 
goes undetected, and cells progress to G2 and subsequently undergo apoptosis (Lowel et al, 
1993). Heparin GAG has shown antihypertensive, anti-inflammatory, anticoagulant in 
different human cells including vascular smooth muscle cells (VSMC) (Leverand Page 2002). 
Castellot and other groups demonstrated the antiproliferative activity of heparin on VSMC, 
hepatoma and ovarian epithelial cell (Patel et al 2002: Fedarko et al 1989: Castllot et al 
1985). It is generally accepted that heparin and heparin like GAGs including HS biological 
activities is linked to their structure (SAR). However, Wright and other research groups 
suggested the antiproliferative effect of heparin on VSMC was due to its ability to bind 
VSMC surface receptor, accumulation within the cell and cell cycle arrest at both G0/G1 and 
S phase (Reily et al 1996: Wright et al 1985). Scarffe et al, similarly reported an increase in 
the percentage of cells in the G2/M phase upon treatment with sulforaphane in HT29 human 
colon cancer cells as well as in Jurkat T-leukemia (Scarffe et al 1980). 
 Askoy et al in his recent in vitro work reported antiproliferative effect of heparin on 
lymphoblast. They demonstrated that heparin induces cell cycle arrest of lymphoblast at both 
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G2/M and S phase in a dose and time dependent manner. Hence, suggested that the 
antiproliferative effect of heparin on lymphoblast was mediated by cell cycle arrest at both 
G2M and S phases, and the prolonged effect of the cell cycle arrest could play a role in cell 
progression and proliferation (Aksoy et al 2008). These researches indicated that 
chemotherapeutic agents including heparin GAG elicit their antiproliferative effect partly by 
inducing cell cycle arrests at different stages of the cancer cell cycle. It is also shown that 
heparin GAG elicit its antiproliferative activity by binding to its receptor on the cell surface; 
accumulating within the cells and cell cycle arrests at different phases of the cell cycle. 
 In the present study, Whelk GAG extracts and the purified fraction E caused 
consistent perturbation in breast cancer cell cycle control, which ultimately resulted into cell 
cycle arrest at S and G2/M-phase. S-phase arrest is suggestive of cell inability to replicate, 
which could abrogate the progression of cell cycle to the mitotic stage, the penultimate event 
in the cell cycle. This GAG extracts and it’s purified fraction E induces cell cycle arrest of 
both MDANQ01 and MDA468 breast cancer in a dose and time dependent manner (Figure 
3.15-16 and 3.26&27). This result is consistent with the work of Aksoy et al on heparin GAG 
cell cycle arrest on lymphoblast.  
 Heparin is a well established GAG that is structurally similar to HS and both crude 
whelk and purified fraction E is a novel HS-like GAGs isolated from shellfish. The 
comparative effect of heparin, crude whelk and purified fraction E GAGs on cell cycle arrests 
may be structurally originated, however, it is difficult to conclude on this note unless a 
comprehensive structural elucidation of the crude and purified fraction E is done. 
Additionally, this result suggest that antiproliferative effects of both crude whelk and purified 
fraction E GAG was mediated by cell cycle arrest at both S and G2/M phase and the 
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accumulative effect of the cell cycle arrests could play a role in the cell cycle progression and 
cell proliferation. 
  
4.7  Cockle GAG mixture inhibit proliferation of MOLT-4 leukaemia cell partly by 
 apoptosis 
 
  Apoptosis is another familiar molecular target for new anti-cancer drugs. Apoptosis 
detection is of great importance in cancer research because the balance between cell 
proliferation and apoptosis shifts towards cell proliferation in cancer cell lines. Cancer results 
from the imbalance between cell proliferation and apoptosis (Wesselborg et al 1999). 
Therefore there is an active search for the most efficient and safe anti-cancer treatments that 
induce apoptosis in immortal cancer cells (Coppola et al, 2008). 
  Cockle GAG extracts only induced marginal early apoptotic effect on MOLT-4 
leukaemia cell as shown in Figure 3.8. The apoptotic effect of cockle GAG extracts was 
noticeable between 24 and 48 hours post incubation. Apoptosis plays a major protective 
mechanism against cancer (Zhou et al 2004) and this result shows that cockle GAG extract 
can induce apoptosis on MOLT-4 cells. This finding is consistent with the apoptotic effects 
seen with chemically modified GAG chains and heparin on lymphoblast and other carcinoma 
as described by Erduran and other research groups (Erduran et al 2007: Erduran et al 2004: 
Pumphrey et al 2002: Li et al 2001: Erduran et al 1999:  Manaster et al 1996). Manaster and 
other research groups have earlier reported the apoptotic effect of heparin on various human 
cells including peripheral blood neutrophils, lymphoblasts and mononuclear cells. They also 
suggested that heparin apoptotic effect of lymphoblasts was via an extrinsic pathway of 
apoptosis (Erduran et al 2007: Eduron et al 2004: Erduron et al 1999: Manaster et al 1996). 
Pezuto et al also reported the apoptotic effect of paclitaxel and lycorine, (known 
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chemotherapeutic agents) and they demonstrated that the antiapoptotic effect of these drugs 
were due to increase activation of caspace-3, 8 and 9 (Pezuto et al 1997). Erduran et al in 
their work demonstrated that low dose of heparin (20 U/mL) causes apoptosis in the 
lymphoblast and this low concentration also cause a high expression of Fas and a low 
expression of Bcl protein-2 in the lymphoblast (Erduran et al 2004). This was contrary to the 
in vitro work of Manaster and coworkers who reported apoptotic effect of heparin at very 
high concentrations (50-200 U/mL) (Manaster et al 1996). In another recent in vitro study, 
caspace 3 and 8 activation levels were investigated and it was shown that heparin induce 
apoptosis of the lymphoblasts and activation of caspase-3 and -8 (Eduran et al., 2007)  
Li et al in their work reported that heparin induce apoptosis in human nasopharyngeal 
carcinoma cell (CNE2) and demonstrated the apoptotic effect of heparin on this cell may be 
probably regulated by increased expression of c-myc and the rates of bax/ bcl-2. They 
suggested heparin may function as an inducer of apoptosis in carcinoma cells (Li et al 2001).  
These researches indicated that low-dose heparin caused significant levels of apoptosis of 
lymphoblasts, and apoptosis was found to increase with increased heparin levels. 
 It is thus suggested that the growth inhibitory effect of cockle GAG extracts on leukaemia 
cells is due, in large part, to cell cycle arrest and apoptosis. The apoptotic effect of cockle 
GAG on leukemia cell is consistent with the apoptotic effect of low concentrations of heparin 
on the lymphoblast and the cell cycle arrest cause by cockle GAG may provide an insight to 







4.8 Crude and purified whelk GAG extracts inhibit cancer cell growth by apoptosis, 
    analysis by annexin V staining 
Apoptosis is characterised by cell shrinkage, condensation of the nuclear chromatin, 
and fragmentation of the nucleus and the apoptotic bodies (Hoffbrand, 1998: Kroemer et al, 
1997). The biochemical event that characterises apoptosis and appears to be related to the 
nuclear condensation and fragmentation is double-stranded cleavage of DNA 
internucleosomal sites (Koury, 1992: Arends et al, 1990). 
 Apoptosis is also characterised by membrane damaged, leading to a subsequent 
leakages of the phosphotidylserine into the outer menbranes layers and Annexin V is a 
recombinant phosphatidylserine-binding protein that binds strongly and specifically to 
phosphatidylserine residues. Only the apoptotic cells are expected to stain positive for 
annexin V-FITC at the early stage of apoptosis while the necrotic cells stain positive for PI. 
However, at late apoptosis stage, the damaged cells are expected to stain positive for both PI 
and annexin V-FITC stains because at late apoptosis, the cells can be killed via apoptotic or 
necrotic pathway and distinguishing between the two processes may be difficult. 
The work presented in this project has demonstrated that both crude and ion – 
exchange purified whelk GAG extracts can induce time-dependent apoptosis on certain 
cancer cell lines. Crude whelk GAG extracts induces time-dependent apoptosis on both breast 
cancer cells (MDA468 and MDANQ01) and cervical cell (HeLa) as shown in Figure 3.17, 
3.21 and 3.22. Interestingly, the apoptotic effect of crude whelk GAG mixture was more 
pronounced on cervical cell with apoptotic cell population of about 50-70%. Consistently, the 
purified fraction E induced mild but not statistically significant (P>0.05) late apoptosis and 
necrosis effect on both MDANQ01 and MDA468 cells with time-dependent increase in the 
number of late apoptotic cells in MDA468 cell. Concisely, DAPI Fluorescent microscopy 
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results also showed some cells with morphological changes that characterised late apoptosis 
(Figure 3.18 and 3.22).These results are consistent with the findings of Wengers and other 
researchers on low molecular weight GAGs and other GAGs mimetics. The work of Wengers 
and others showed that low molecular weight heparin elicit their anticancer activities on 
pancreatic cancer by apoptosis induction (Wenger et al 2009).  Erduran and others have also 
reported apoptotic effect of heparin on different human carcinoma and lymphoblast (see 
section 4.7). The difference in pharmacological activities of low molecular weight GAGs and 
the unmodified GAGs have been attributed to their enhanced bioavailability which facilitates 
their uptake into the cells (Lindhardt et al 2004).  
 Conclusively, the apoptotic effect of whelk GAG mixture on the two mammalian cells 
appears to be largely associated with cell cycle arrest, DNA fragmentation, and 
externalization of phosphatidylserine lipids. The cell cycle arrest cause by these GAG 
extracts and its purified fraction E can also provide a great insight into the molecular 
mechanism of action of apoptotic effect of crude whelk and purified fraction E. Conversely, it 
is worthwhile, to investigate the activation level of the apoptotic proteins (bcl-2 and bax) as 
well as caspase 3, 8 and 9. This will provide more insight into the molecular mechanism of 
apoptotic effects of this novel GAGs. 
 
 
4.9 PAGE and size exclusion analysis of cockle GAG mixture 
Size exclusion assay results shows that the crude cockle extracts contain different 




). Although the 
peaks from the gel filtration analysis  were not extensively studied in this present work, the 
densitometry analysis of the cellulose acetate dot blotting assay classified the fractions into 
two broad peak according to their sizes/charges. GAGs are negatively charged polymers 
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consist of repeating units of disaccharides containing one uronic acid or galactose and one N-
acetylglycosamine. The variation in charge may be very large since each disaccharide is more 
or less sulfated. The ionic bonding between cationic dyes (Azure A) and the negatively 
charged GAGs are generally thought to be proportional to the number of negative charges 
present on the GAG chain i.e. both sulfate and carboxyl groups (stone et al, 1994). The azure 
A dye was only bound to the sulfated polysaccharide because of the suitable arrangement of 
GAG ionic sites for interactions with the dye dimer but was not found to bind with other 
compounds including proteins (Samir and Kost 2000). Hence, the wells stained with azure A 
dye in the present work suggest the presence of GAGs with varying concentrations and 
different sulfation levels. Electrophoresis mobility of the cockle GAG samples on PAGE was 
visualized with azure A staining. 
 Additionally, slight variations in mobilities between the crude and depolymerised 
samples were also observed. Difference in electrophoretic mobility of the various intact GAG 
chains is an indication of distinctive structures present within these polysaccharides 
(Vijayabaskar and Somasundaram 2012). The GAG extracts isolated in this study was 
compared with commercial GAGs (HS, CS/DS) (Figure 3.34&3.36) to initially determine the 
typical chain lengths and general level of sulfation from the mollusc derived GAG samples. 
Dietrich and other researchers showed that sulfated polysaccharide had different 
electrophoretic mobilities for different buffer system, depending on the structure of the 
polysaccharide (Mariana and Barbara 1999: Dietrich et al 1989). PAGE analysis results 
supported the evidence that crude cockle extracts did indeed contain GAGs and the GAGs-
like compound isolated contained CS/DS and HS-like members of the GAG family. 
 However, the exact nature of the structural differences between typical commercially 
available porcine HS, CS, DS  and the mollusc derived GAGs remains to be determined. This 
will be critical in determining the exact nature of the biological activity of the mollusc 
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derived GAGs. it is assumed that there must be subtle structural differences in these GAG 
chains that do not appear in the commercially available GAGs which did not show any 
cellular toxicity on the cancer cell lines tested in this study. The bare minimum for 
investigating structual differences in GAG chains is to perform a disaccharide analysis where 
the GAG chains are chemically or enzymatically reduced to their constituant discaccharides 
and then individually quantified by strong ion-exchange chromatography. This data will at 
best only provide limited information on structure activity relationships attributed to these 
GAGs. It will take many years to determine the exact nature of the GAG binding sequences 
involved in these observed anti-cancer activities.  
 
 
4.10 SAX-HPLC and gel-filtration of cockle GAG extracts 
SAX-HPLC analysis of chondroitinase ABC lyase digest confirmed the presence of 
three major disaccharide components in the crude cockle GAG mixture. The non-sulfated 
disaccharide (ΔUA-GalAc) has the highest composition, in contrast to the commercial CS/DS 
in which this disaccharide was absent. The two most abundant CS/DS mono-sulfated 
disaccharides [ΔUA-GalNac (6S) and ΔUA-GalNac (4S)] were also present in in the same 
proportion in the crude GAG mixture, whereas the commercial CS were found to contain 
high level of ΔUA-GalNac (6S) and a low level of ΔUA-GalNac (4S) disaccharides. This 
unique structural composition formed the major difference between the crude cockle CS and 
the commercial CS GAGs.  
This result also suggests that this crude GAG extracts contains less sulfated CS-like 
GAGs: this slight structurer modification may in part contribute to it’s growth inhibitory 
effect on leukaemia cells. Predictably, the anti-tumour activity of this crude GAG extracts 
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may in part due to the unique structurer composition of its CS-like chain and the possible 
explanation for this bioactivivity may be linked to the suggestion of Asimakopoulou and 
coworkers in his comprehensive review on biological Role of Chondroitin Sulfate in Cancer 
and Chondroitin-based Anticancer Agents. He suggested that the important roles play by this 
GAG molecule in cancer biology may be attributed to their involvement in various 
interactions with tumour cells and other effective molecules, such as growth factors and also 
affects several signaling pathways (Asimakopoulou et al, 2008). He also stressed the need for 
proper understanding of the biological role of CS in cancer, tumour angiogenesis and 
invasion. This suggestion has favoured the development of novel drugs which target the 
tumour cells and the interactions with other effective molecules of the ECM or the cell 
surface (Asimakopoulou et al, 2008).  
Similarly, Kozlowski and other groups have reported an isolation of dermatan sulfates 
from S. plicata and P. Nigra. This DS was found to contain the same disaccharide core 
structure [α-L-IdoA(2SO4)-1→3β-D-GalNAc]n, but sulfated at carbon 4 or 6 of the GalNAc 
residues, respectively (Kozlowski and Pavao, 2011: Kozlowski et al., 2011). Both ascidian 
dermatan sulfates regardless of the position of sulfation on the N-acetylgalactosamine 
drastically attenuate metastasis of both MC-38 colon carcinoma and B16-BL6 melanoma 
cells, and the infiltration of inflammatory cells in a thioglycollate peritonitis mouse model 
(Kozlowski and Pavao, 2011; Kozlowski et al., 2011). 
 Pumphrey and co-workers has also reported similar role of a novel modified CS 
molecule (neoglycans) on cancer cells. This molecule was found to reduce cell viability by 
induction of apoptosis of myeloma and cancer cells in vitro. Pumphrey in his work also 
reported that, EDAC-modified CS reduced or abolished tumour growth, when injected 
directly into breast tumours growing in nude mice (Asimakopoulou et al, 2008: Borsig et al, 
2007: Pumphrey et al, 2002). 
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Several studies have reported the role of CS in promoting tumour growth and 
mediating events that enhance tumour invasion and metastasis effects that can be abolished 
by chemically modified CS, or the use of CS with altered sulfation patterns (Asimakopoulou 
et al, 2008: Borsig et al, 2007: Pumphrey et al, 2002). Some of these studies have proved the 
potential use of modified CS as a potent anti-cancer agent. Although the cockle derived CS 
chains appear to have an unusual disaccharide composition in comparison to commercial 
porcine CS, we cannot confirm absolutely that the link between these differences and the 
anticancer activities seen in this study. 
Moreover, differences in HS structure have already been implicated in this study as 
being linked to the cockle GAG extracts anti-cancer activities. Structural studies of cockle 
GAG extracts also implicated HS in the biological activity seen on cancer cells. Quantitative 
and qualitative analysis of HS oligosaccharides mapping was performed by depolymerising 
cockle GAG extracts with a mixture of Heparinase I, II and III and then analysing the 
resulting unsaturated oligosaccharides by SAX-HPLC chromatography. The most important 
differences seen  between the commercial HS GAGs and cockle extracted HS-like GAG 
chains is the absence of ∆UA (2S)-GlcNAc, disulfated ∆UA(2S)-GlcNAc(6S) and the  tri-
sulfated ∆UA(2S)-GlcNS(6S). A very low level of ∆UA-GlcNS (6S) and ∆UA (2S)-GlcNS 
was also observed in the crude GAG mixture. 
 Thus, these result suggests that cockle GAG mixture contain low sulfated HS-like 
GAG with low 2 O sulfate group because of the absence of trisulfated ∆UA2S (1→4) 
GlcNS6S and disulfated ∆UA2S (1→4) GlcNAc6S disaccharides. PAGE analysis and TSK 
gel-filtration results confirmed the presence of HS-like disaccharides in the heparinase 
digested cockle GAG extracts.  
 This is an extremely unusual disaccharide compositional analysis for HS. Many 
studies have reported the isolation of HS-like GAGs with various disaccharides compositions 
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from different molluscs. Dietrich and coworkers in their work isolated highly sulfated HS-
like GAGs from various molluscs, in contrast to the usual low sulfated HS-like GAGs that are 
usually isolated from molluscs (Volpi and Maccari 2005: Kim et al 1998: Dietrich et al 
1989). Vijayabaskar and other groups had previously reported an isolation of HS-like species 
from molluscs (Vijayabaskar and Somasundaram, 2012: Cesaretti et al, 2004: Jordan et al, 
1986 and Dietrich et al, 1985). Pejler et al also reported the isolation of HS-like GAGs 
containing a large amount of GlcN (3-O-sulfate) disaccharide from clam molluscs. This 
disaccharide unit is a unique marker for the antithrombin-binding region of heparin/HS 
disaccharide and it showed a similar antithrombin activity with unfractionated heparin (Pejler 
et al 1987). Chi and his co-workers in their work reported an isolation of HS with a unique 
structure, containing IdoA (2-O-sulfate)-GlcNAc as its major repeating disaccharides 
sequence (Acharan sulfate) from African giant snail (Chi et al 2006: Kim et al 2004). HS-like 
GAGs with unique disaccharide units composed of of non- sulfated, 2-O-sulfated or 3-O-
sulfated GlcA as well as 2-N-sulfated and/or 6-O-sulfated GlcN has also been isolated from 
the bivalve Nodipecten nodosus (Gomes et al 2010). Interestingly, none of the above HS-like 
GAGs has been shown to have any anticancer activity. 
 In addition, Dreyfuss and co-workers recently reported an isolation of heparin 
mimetics with low 2 O sulfate group (similar to what was observed in this study) from 
shrimp. This HS structural mimetics was shown to have anti inflammatory and anti 
angiogenesis activities. It was clearly shown that the biological activity of this heparinoid was 
due to its ability to interact with angiogenic growth factors such as FGF-2. He also linked the 
antiangiogenic effect of this novel GAG to the presence of low content of 2-O-sulfate groups 
in the shrimp heparin like GAG which in a similar manner to the 2-O-desulfated-heparin, 
could competitively inhibit the interaction between growth factors and cell surface HS 
proteoglycans (Dreyfuss et al 2010). Unfortunately, Dreyfuss failed to investigate the 
242 
 
anticancer activity of this HS mimetics and this present study has critically investigated the 
anticancer activity of this unique HS-like GAG from cockle. The presence of low 2 O sulfate 
groups was also observed in the HS like GAG isolated from cockle GAG and this structural 
modification may explain the anticancer activity of this unique GAG. 
Furthermore, there was a decrease of the specific sulfatation in position 2 of the 
glucuronic acid unit with a strong increase of the disaccharides bearing non-sulfated 
glucuronic acid and glucosamine. This decrease may also in part contribute to the inhibitory 
effect of cockle GAG mixture on leukaemia cells due to important role of 2-O-sulfated IdoA 
in HS-binding to FGF-2 a known survival factor for leukaemia cells grown in culture (Liuzzo 
and Moscatelli 1996). Walker and others had earlier reported that structurally defined 
oligosaccharides from HS that are rich in IdoA (2S)-containing disaccharides bind strongly to 
FGF-2 and that the affinity for FGF-2 increases with oligosaccharide length and IdoA (2S) 
content (Walker et al, 1994: Ishihara et al, 1993: Maccarana et al, 1993: Habuchi et al, 1992 
and Turnball et al, 1992).  
The presence of 2-O-sulfated IdoA has also been reported to be required for the 
promotion of the growth-factor’s mitogenic activity. It is also noteworthy that extracted 
cockle HS-like GAGs might be competed with the endogenous HS GAGs in the binding of 
growth factors such as FGF-2 or blocking specific interactions of the cancer growth factors 
(e.g.FGFs) with their receptors resulting into cell growth inhibition. It has previously been 
shown that GAG-based drugs elicit their pharmacological effect in several ways: by 
activating (agonists) or inactivating (antagonists) protein-based receptors (e.g.FGF-2), 
competing with endogenous GAGs and/or inhibiting GAG biosynthesis (Gandhi et al., 2010).  
Intruingingly, there is evidently a role for FGF-2 in haematopoiesis and the K562 
leukaemia cell line has previously been shown to express HSPG’s that bind strongly to    
FGF-2, therefore, this may be involved in modulation of its biologic activities (Olwin and 
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Rapraeger, 1992 : Flaumenhaft et al, 1982). HS is also necessary for the long-term biologic 
activity of FGF-2, the presence of HSPGs in the K562 cell line could have significant effects 
on the ability of these cells to respond to FGF-2 by promoting the formation of the FGF-
2/HS/TK-receptor ternary signalling complex, hence promoting cell growth (Liuzzo and  
Moscatelli 1996).  
Structural variations between K562 HS and cockle GAG HS may impinge on the 
ability of FGF-2 to bind its TK cell surface receptors, thereby inhibiting cell proliferation and 
functions, thus, this may manifest itself partly in the anticancer activities seen with cockle 
GAGs on the K562 cell line. 
 Taken together, previous data discussed above and the results reported here strongly 
suggest that the novel GAGs isolated from cockle is capable of sequestering the growth 
factors, making them unavailable for the interaction with their receptors and thus inhibiting 
tumour cell proliferations. Thus, the pharmacological and biochemical properties of cockle 
GAG, such as anti cancer activity against leukemic cells with a very low IC50 point to this 
compound as a compelling drug candidate for treating cancer disease. 
  
 
4.11 Ion- exchange fractionation of crude whelk GAG mixture 
 The process of ion-exchange chromatography helped to enhance the activities of the 
crude whelk GAG extract by removing the unwanted salt contaminant from the GAG 
preparation (Saravanan et al, 2010). This partial purification of whelk GAG extracts has 
allowed  a better understanding of the structural compositions of  these whelk derived GAG 
chains. The ion-exchange chromatogram for crude whelk GAGs was shown in Figure 3.23. 
GAG chain sub-populations were eluted as a number of well defined peaks ranging from 0.9-
3.0M NaCl gradient. Although, the fractions were not studied extensively in this project , in 
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terms of this exact structural composition, we did however identify from the chromatagram  
the bioactive fraction E on DEAE column. This has proven to be very informative in 
determining the active GAG family member in the whelk GAG extracts. It also suggested 
that this fraction contained high charge density, high molecular weight and or high sulfated 
polysaccharide chains based on its late elution position in the NaCl gradient.  
 This speculation was confirmed by the superose-12 size exclusion result, which 
clearly showed fraction E to be comprises of  very high molecular weight polysaccharide 
chains (Figure. 3.42). Fraction E is similar in structural terms to the HS/ heparin-like fraction 
isolated from other molluscs (Andrade et al, 2013:Vijayabaskar and Somasundaram, 2012: 
Moses et al, 2002: Mariana and Barbara 1999). Although the anti-inflammatory, 
anticoagulant and anti-angiogenic potentials of these HS-like GAGs isolated from molluscs 
have been well documented, there is no information on their potential use as anti-cancer drug. 
However, Giulianna and others were concentrating solely on the anticoagulant activity of this 
fraction but failed to test the activity of this novel polysaccharide on cancer cells. 
 Interestingly, the result obtained in our study from the biological activity of this novel 
fraction showed its important role in cancer cell death and this is certainly encouraging as a 
platform for the future  development of the whelk GAGs as an anti-cancer drug. 
 
 
4.12   PAGE and size exclusion analysis of both crude and ion-exchange purified whelk 
  GAG extracts 
PAGE analysis of both crude and purified whelk extracts confirmed them to be GAG-
like in nature. The electrophoresis mobility of both the crude and ion- exchange purified 
fractions showed that they both contained different members of the GAGs family of 
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polysaccharides with different structural composition. Electrophoresis mobility of the sample 
on PAGE was visualized with azure A staining.  
There were notable differences in the electrophoretic mobility between intact samples 
and enzyme/chemically depolymerised GAG samples as the depolymerised samples contain 
smaller oligosaccharides that were capable of migrating faster than the crude sample. This 
gives us a rapid means of determining the prescence of individual GAG family members such 
as HS, CS and DS in extracts taken from mollusc tissue samples. The eletrophoretic mobility 
of the crude GAG extracts also showed difference in mobilites when compared with 
commercial porcine GAGs and this suggests a possible variation in both sulfate content and 
average chain length of GAGs derived from both sources (see next section for further details) 
Difference in electrophoretic mobility of the various GAGs is certainly an indication 
of distinctive structures within these mollusc derived polysaccharides in comparison to the 
porcine derived GAGs (HS,CS and DS) which showed no anti-cancer activities with the cell 
lines tested in this study (Figures 3.34&3.36). Dietrich et al and Mariana and Barbara showed 
that a sulfated polysaccharide had different electrophoretic mobility for different buffer 
system, depending on the structure of the polysaccharide. Overall PAGE analysis results 
supported the evidence that both crude and purified whelk GAG contain GAGs and the 
GAGs-like compound isolated were CS/DS and HS-like GAGs. 
Size exclusion assay results confirmed both crude and purified whelk fractions 





). Although the fractions obtained from the superose-12 gel filtration 
experiments were not extensively studied in the present work the densitometry analysis of 
cellulose acetate dot blotting assay confirmed the presence of strongly anionic 
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polysaccharides as a  result of Azure A dye binding, which could be classified into five broad 
peak according to their sizes.  
GAGs are negatively charged (cationic) polymers consist of repeating units of 
disaccharides containing one uronic acid or galactose and one N-acetylglycosamine. The 
variation in charge may be very large since each disaccharide is more or less sulfated and 
control of discaccharide composition is complex. The ionic bonding between charged dyes 
such as Azure A and the negatively charged GAGs are generally thought to be proportional to 
the number of negative charges present on the GAG chain, i.e., both sulfate and carboxyl 
groups (stone et al, 1994).  
The azure A dye was only bound to the sulfated polysaccharide because of the 
suitable arrangement of GAG ionic sites for interactions with the dye dimer but was not 
found to bind with other compounds including proteins (Samir and Kost 2001). Hence, the 
dots stained with azure A dye in the present project work suggest the presence of GAGs with 
varying concentration and different sulfation level seen in the crude GAG extracts. 
 
 
4.13 SAX-HPLC and gel-filtration of whelk GAGs 
The qualitative and quantitative analysis of chondroitinase ABC lyase depolymerised whelk 
GAG mixture shows two distinct peaks when resolved by ion-exchnge chromatography and 
their elution positions vary considerably from the commercial CS/DS GAGs 
oligosaccharides. The two fractions B and C derived from anion-exchange chromatographic 
analysis were the only two peaks from the ion exchange column that were sensitive to 
chondroitinase-ABC enzymes and the resulting oligosaccharides mixtures resolved by SAX-
HPLC shows that fraction B contain non-sulfated ΔUA-GalNac as its major disaccharides 
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peak and a low level of mono-sulfated ΔUA-GalNac(4S).This is significantly different to the 
dissacharide composistion analysis seen with the commercial CS/DS. The disaccharides 
composition of whelk fraction B is very similar to CS previously isolated from D. 
melanogaster (Toyoda et al., 2000). Many other studies have reported isolation of CS/DS 
with unique disaccharides compositions from invertebrates (Adamczyk et al 2010: Vilela-
Silva: Pavao et al 1998: Pavao et al 1995 ), however, the disaccharide compositions of these 
invertebrates CS/DS are slightly different from whelk fraction B CS in terms of sulfation 
pattern and level. 
 The whelk Fraction C peak matched the elution position of commercial CS/DS when 
applied to the ion-exchange column which suggested a more traditional discaccharide 
composition for this  whelk GAG sub-fraction. This prediction for the disaccharide 
composisition of whelk fraction C was confirmed by  chondroitinase ABC lyase digestion 
and the subsequent as resolved by SAX-HPLC showed two major disaccharides peaks eluted 
at the same time with similar elution pattern to the commercial CS GAGs. Furthermore, crude 
whelk GAG mixtures were also degraded by chondroitinase-ABC enzymes and the major 
disaccharides peaks shown were ΔUA-GalNac6S and ΔUA-GalNac4S disaccharides. The 
elution pattern and the retention time was also similar. It is notewhorthy that crude whelk 
GAG mixtures and its purified fractions B and C contain low sulfated CS/DS disaccharides. 
 The CS disaccharides compositions of  both crude and whelk fraction C is very 
similar to the CS isolated from Ascidians by Xu et al. This GAGs has been reported to have 
anti inflammatory activity, however, the author failed to investigate the anticancer activity of 
this unique GAGs (Xu et al 2011).  Although, most CS isolated from many invertebrates are 
more sulfated than whelk CS and they are structurally different in terms of sulfation level and 
pattern, hence, no anticancer activities has been reported for any of these GAGs (Adamczyk 
et al 2010: Vilela-Silva: Pavao et al 1998: Pavao et al 1995).  The structural differences 
248 
 
between other invertebrates CS and whelk CS, couple with the low sulfation composition of 
whelk CS may in part explain the anti cancer activity of this unique GAGs, more studies are 
needed to substantiate this speculation.  
 
 
 4.14 SAX-HPLC and gel-filtration of whelk bioactive fraction E 
 Qualitative analysis of HS/Heparin GAGs contained in the purified whelk fraction E 
was performed by depolymerisation with a mixture of heparinase’s I, II and III and with the 
resulting unsaturated oligosaccharides analysed by SAX-HPLC. The whelk derived GAG 
fraction E contains six oligosaccharides peaks in contrast to the commercial HS, which 
contained eight standard disaccharides peaks. The major peak was assigned to non-sulfated 
disaccharide ∆UA - GlcNAc. Other peaks were assigned to ∆UA-GlcNS, ∆UA-GlcNAc (6S), 
∆UA-GlcNS(6S), ∆UA(2S) (1→4) GlcNAc(6S) and ∆UA(2S) GlcNS(6S) disaccharides 
respectively. However, both ∆UA (2S)- GlcNAc and ∆UA(2S)GlcNS disaccharides were 
completely absent in this polymer and this is the major difference between the novel fraction 
E and the commercial GAGs.  
 Andrade et al in their recent work report an isolation of high sulfated HS/heparin 
GAG from the crab G. Cruentata mollusc. They demonstrated that the crab HS/heparin GAGs 
present intermediate structure between heparin and heparan sulfate. In addition, the crab 
heparin-like is rich in 2-O-sulfated glucuronic acid residues, possesses low levels of 
trisulfated disaccharides (∆UA (2S) GlcNS (6S) and lacks the defined pentasaccharide 
structure related to the antithrombin binding site (Andrade et al 2013). Brito et al in their 
work also isolated another HS/heparin from the shrimp. The shrimp contains mainly blocks 
of disulfated disaccharide units containing glucosamine N-sulfated/6-O-sulfated linked to 
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glucuronic acid [∆UA-GlcNS (6S)]. Sulfated regions consisting of glucosamine N-sulfated 
linked to iduronic acid 2-O-sulfated (∆UA (2S) GlcNS) are also present (Brito et al 2008). A 
recent work of Brito and co-workers also reported the isolation of another novel GAG with 
different HS/heparin like structure from shrimp head L. vannamei . The novel GAG from 
shrimp head possesses a high degree of N,6-sulfation and minor N-acetylation together with 
the high content of glucuronic acid and an absence of non-sulfated iduronic acid (Brito et al 
2014). 
 These researches show that HS/heparin with unique disaccharides entity are isolated 
from different molluscs and the presence of high percentage of non sulfated disaccharide∆UA 
- GlcNAc (60%) suggests that this GAG is more of HS like. The presence of disulfated 
disaccharide ∆UA-GlcNS(6S), ∆UA(2S) (1→4) GlcNAc(6S) in whelk Fraction E is 
consistent with the findings of Andrade and other research groups who have isolated these 
disaccharides from other mollusc. However, most of the GAGs isolated from GAG molluscs 
described by these researchers are more sulfated than whelk fraction E GAG.  
Moreover, the absence of both ∆UA (2S)- GlcNAc and ∆UA(2S)GlcNS discaccharides in 
whelk purified fraction E is extremely interesting as normally they would represent some of 
the major disaccharide species associated with HS derived from cells and tissues.  
 These major differences between whelk purified fraction E, commercial HS and other 
HS/heparin like GAGs from molluscs may explain the anticancer activity of this unique GAG 
extract. In addition, it is generally accepted that the binding of HS to FG-2 play a critical role 
in the biological activities of HS. This binding occurs through N-sulfated glucosamine and 2-
O sulfated iduronic acid and fraction E HS GAG contains low composition of this sulfation 
motif. This finding and complete absence of ∆UA (2S)- GlcNAc and ∆UA(2S)GlcNS 
disaccharides in whelk fraction E oligosaccharides composition may potentiate its 
antiproliferative activity on MDA468 and MDANQ01 breast cancer cells. The fraction E HS 
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is a structural heparin/HS, and thus it could interfere with the binding and cellular modulation 
of many proangiogenic growth factors. It may also predictably block the specific interaction 
with FGF to its tyrosine kinase receptor (Fearo et al 2007), thereby impede the dimerisation 
of the FGFR receptor and ultimately block signalling process that leads to proliferation.   
 Similarly, the tri sulfated disaccharide ∆UA2S (1→4) GlcNS6S composition was 
significantly low in the whelk fraction E HS–like GAGs (table 6). This result suggest that 
whelk fraction E contain low sulfated HS like due to the low composition of  the trisulfated 
disaccharides in contrasts with data obtained for heparin, where about 80% all of 
disaccharides are the ∆UA2S (1→4) GlcNS6S (Zhang et al 2009: Linhardt, 2009: Dietrichet 
al., 1998). This result is also consistent with the work of Andrade et al on shrimp GAG. 
Bivalve Anodonta anodonta (Andrade et al 2013). 
 TSK gel-filtration results also confirmed the presence of HS-like disaccharides (dp
2
) 
in fraction E GAG. This result corroborates the findings of Andrade and co-workers who had 
previously reported the isolation of HS-like disaccharides from different molluscs (Andrade 
et al, 2013:Vijayabaskar and Somasundaram 2012: Brito et al 2008: Moses et al, 2000: 
Mariana and Barbara 1999). Brito et al also report the isolation of HS GAG with low content 
of 2-O-sulfate groups in the shrimp heparinoid. They suggest that the anti-angiogenic effect 
of this GAG may be due to the presence of this unique disaccharide composition. Possibly 
this compound, like the 2-O-desulfated-heparin, could competitively inhibit the interaction 
between growth factors and cell surface HS proteoglycans (Brito 2008).  In contrast to this 
result, Volpi and co-workers reported the isolation of high sulfated HS/heparin like GAG 
from large fresh water mollusc Bivalve Anodonta anodonta (Volpi 2005). The heparin/HS 
from Anodonta Anodonta show a degree of sulfation similar to that of bovine mucosa heparin 
because of the presence of similar percentage composition of trisulfated ∆UA2S (1→4) 
GlcNS6S. It also contains a slight modification of other oligosaccharides and a significant 
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amount of disaccharides bearing the sulfation group at position 3 of the N-sulfoglucosamine -
6- sulfate. Its anticoagulant activity was also similar to that of bovine. 
  Other researchers have also reported an isolation of low sulfated HS that composed of 
blocks of low sulfated GlcNAc containing disaccharides and also highly sulfated Glc2S-
containing disaccharides (Yamada et al 2011) from molluscs. Chi et al also report the 
isolation of HS preparation with a unique structure from the giant African snail Achatina 
fulica and named acharan sulfate. The major repeating disaccharide sequence in acharan 
sulfate is IdoA (2-O-sulfate)-GlcNAc. Gomes et al in their recent work isolated a unique HS 
from the bivalve Nodipecten nodosus (Linnaeus 1758). The disaccharide units in the HS 
chain are composed of nonsulfated, 2-O-sulfated or 3-O-sulfated GlcA as well as 2-N-
sulfated and/or 6-O-sulfated GlcN, and the anticoagulant activity of the mollusk HS was 5-
fold lower than that of porcine heparin.  
 Interestingly, some of these HS-like GAGs isolated from other molluscs had 
anticoagulant activities similar to mammalian heparin GAGs (Andrade et al, 
2013:Vijayabaskar and Somasundaram 2012 and Moisés et al, 2000). However, none of these 
studies reported anti-cancer activity associated with any of these HS-like GAGs isolated from 
molluscs.  
  The results obtained so far show that fraction E contains HS-like GAG and this may 
in part be associated with its biological activities seen in the present work. Many studies have 
shown the anti proliferative effects of heparin GAG, low molecular weight heparin, ultra low 
molecular weight heparin and some HS mimetics on different cells including lymphoblast, 
VSMC and tumour cell (Erduran et al 2007: Erduran et al 2004:Patel et al 2002: Fedarko et al 
1989: Castllot et al 1985). Erduran and other research groups investigated the mechanism of 
antiproliferative effect of heparin. They reported the antiproliferative effect of heparin was 
due to apoptosis and cell cycle arrest (Aksoy et al 2008: Erduran et al 2007). Heparin is a 
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well established GAG with many therapeutic functions including antimetastatic and 
antiproliferative effects.The biological roles of this GAG is structurally related to its ability to 
bind growth factors including FGF-2 (Neha et al 2010). It is note worthy that the biological 
activities of HSGAGs are due in large part to its structural composition and thereby modulate 
the ability of many growth factors in their binding to their receptors. The present study 
demonstrated that whelk purified fraction E contain low sulfated HS-like GAG with complete 
absent of both ∆UA (2S)- GlcNAc and ∆UA(2S)GlcNS discaccharides. This unique 
structural composition of whelk novel GAG provide an insight into its antiproliferative 
activities against the breast cancer cells investigated in this study (see above discussion). The 
anti-cancer activity of whelk fraction E HS-like GAG is a new and unique finding in 
glycosaminoglycans study. 
It is well known that HS binds and modulates the activities of heparin-binding growth factors 
and their receptors, such as FGF’s which in turn control various aspects of tumour growth 
and angiogenesis (Dreyfuss et al, 2010). Binding of growth factors to its tyrosine kinase 
receptors causes dimerization and autophosphorylation/transphosphorylation of the receptors 
which in turn triggers activation of the cytosolic tyrosine kinase, which targets specific 
substrates for tyrosine phosphorylation. However, the purified whelk fraction E is structurally 
similar to HS GAGs and can selectively inhibit several growth factors or proteins involved in 
the above process and ultimately inhibit the tumour growth as observed in the present study. 
Early studies have shown that heparin inhibits the phosphorylation of numerous signaling 
pathways involved in proliferation and survival, such as mitogen activated protein kinase 
(MAPK), protein kinase C (PKC) and casein kinase II (CKII) (Ottlinger et al 1993:Pukac et 
al 1992: Castellot et al 1989 and Hathaway et al 1980). 
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 However the exact mode of action by which the whelk fraction E kills cancerous cells, at the 
GAG structural level and determination of the cellular pathways involved, needs further 
study. 
 We shouldn’t forget that heparinase degradation of both crude whelk and its purified 
fraction E GAG extracts showed abolition of the anti-cancer activities seen with both breast 
cancer cell lines in this study (Figures 3.13). Also complete degradation of fraction E by 
heparinase III lyase confirmed this purified fraction is HS-like: hence implicating HS as the 
contributor to the biological activities seen in this study. Further work needs to be undertaken 
to confirm that the anti-cancer activity seen with the whelk GAGs and the cancer cells lines is 















4.15 Overall summary 
 It is clear that the original aims and objectives of this study have been both met and 
suppassed. The study has demonstrated that both shellfish utilised contain GAG-like 
compounds, which were revealed experimentally to be CS/DS-like and HS-like GAGs. Anti-
cancer activity of GAGs from molluscs is reported for the first time in this study. Mollusc 
GAGs have always been evaluated for anticoagulants and anti-inflammatory activities due to 
the presence of HS/Heparin-like structure in its composition. The anti-cancer activities of 
both molluscs studied were shown to be specific to certain cancer cells and this can also be a 
tool in the future development of both mollusc GAGs into anti-cancer drugs. The low and 
different IC50 recorded for the two novel GAGs on certain cancer cell lines make these 
polysaccharide a candidate anti-cancer drugs to be developed in the future.  
 It is possible for the first time to study the mechanism of anti-tumour activity of both 
novel GAGs using annexin V-FITC, DAPI fluorescence microscopy and flow cytometry, in 
contrast to the conventional antiangiogenesis inhibiton, P-selectin inhibition and L-selectin 
inhibition analyses that are commonly used to assess anti tumour activity of GAGs related 
drugs. The problem encountered with the false positive apoptosis results observed with 
annexin V-FITC assay was finally resolved by DAPI fluorescence microscopy and this made 
the apoptotic data more concise and convincing. Fractionations of whelk GAGs have enabled 
new insight into the heterogeneity nature of both CS/DS and HS-like GAGs in this molluscs. 
Enzyme depolymerisations of the two crude polysaccharides confirm the presence of 
different GAGs (CS/DS-like and HS-like GAGs) in their tissue. SAX-HPLC analysis of the 
resulting oligosaccharides from the enzyme depolymerised samples gave insight into the 
structural heterogeneity of different CS/DS and HS-like GAGs in the two molluscs. The 
structural diversity of mollusc GAGs are reportedly even greater than that of vertebrate 
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GAGs (Andrade et al, 2013). The compositional analysis of both CS/DS and HS-like 
disaccharides of the two shellfish and the commercial GAGs performed for the purposes of 
this study provide insight into the sulfation level of each disaccharide in the total GAG 
compositions. This made the structure comparism easy and the differences between the novel 
and commercial GAGs were clearly seen. This study reveals that the biological activities of 
these two polysaccharides are due largely to the presence of GAG-like compounds within 
their composition. The depolymerised samples did not demonstrate any anti-cancer activities 
in any of the cancer cells tested. Similarly, the two novel polysaccharides are revealed as 
non-toxic to normal fibroblast cells; this will make it a better anti-cancer drug with a less 
toxic effect. Finally, at this juncture, it is difficult to reach a concrete conclusion on the 
mechanisms of apoptosis and cell cycle arrest, signaling pathways involved in tumour 
growth, and more detailed structural elucidations of the two novel polysaccharides; therefore, 
further research is required in this specific area. 
 
Limitation of this study 
This study was limited to isolation of GAGs from whelk and cockle from shell fish. 
Also the anticancer activities evaluated were limited to MDA468, MDANQ01, K562, 
MOLT-4, and HeLa cell lines. The cytotoxic effect of the two shell fish was only assessed on 
3T3 normal fibroblast cell line.  
 Characterisation of the major components of the novel GAGs extracted from the two shell 
fish was only done by conventional enzymatic and chemical method of analysis; the resulting 





There is need for more in-depth works on all aspect of this work, most importantly; 
The anticancer activities of the two novel GAGs need to be investigated on other cancer cell 
lines e.g MCF-7, T-47D, HL-60, MOLT-3. 
The anticancer activities should also be assessed on primary tumour cell  
In vivo study is also highly essential for the anticancer evaluation of these novel GAGs 
The cytotoxic effects can also be investigated on more normal, non cancerous cell line e.g. 
MCF-12, MCF-17, HUVEC and other normal epithelial cell lines. 
There is need to study the various signalling pathways involved in proliferation e.g MAPK, 
MEK, ERK. The effect of the novel GAGs on cell cycle regulators e.g cyclin A, B,D and E, 
CDKI,CDK2, CDK 4 e.t.c needs to be investigated. 
Apoptosis signalling pathway e.g. caspace 3, 8 and 9, bcl-2, bax e.t.c. should also be 
investigated before and after treatment with the novel GAGs. 
Structural and compositional analysis of the major biological components of the two novel 
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